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Abstract 
Despite extensive research efforts indicating statin-induced myopathy is an on-target 
effect mediated by HMG-CoA reductase inhibition, the underlying pathophysiology 
remains unknown. The purpose of this dissertation was to use transcriptomic and 
metabolomic profiling to identify mechanisms and biomarkers of statin-induced 
myopathy. Investigative studies were conducted with cerivastatin (0.5 and 1 mg/kg; 14 
days) in the rat because this species is predictive of the clinical response. Integration of 
transcriptomic and metabolomic profiles of skeletal muscles revealed alterations in 
cholesterol homeostasis and energy metabolism associated with myopathy in fast-twitch 
muscles, whereas slow-twitch muscles showed evidence of altered energy metabolism 
without myotoxicity. To further investigate these potential mechanisms of myopathy, a 
time course study was conducted with cerivastatin (1 mg/kg; 1, 6, 8, 10, and 14 days) in 
female rats which indicated that alterations in cholesterol homeostasis, and specifically 
upregulation of the 25-hydroxycholesterol pathway is likely mediated by pathology, 
removal of excess cholesterol and regeneration. This time course study also indicated an 
early and sustained transcriptional induction of pyruvate dehydrogenase kinase 4 in fast-
twitch muscles, suggesting a metabolic switch in energy metabolism which precedes 
induction of PGC-1α resulting in a more oxidative phenotype. However, evidence of 
myofibrillar protein degradation and myopathy ensued indicating impaired energy 
metabolism may be causally related to myopathy. In contrast, this transcriptional profile 
was not observed in slow-twitch muscles. Similar time course experiments were also 
conducted in primary fast-twitch myofibers. However, the in vivo findings were not 
always recapitulated in this model despite dose- and time-dependent cerivastatin-induced 
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toxicity which was prevented with mevalonate supplementation. Accordingly, the value 
and limitations of the in vitro model for investigating mechanisms of toxicity was 
demonstrated in this work. To identify biomarkers of myopathy, metabolomic profiling 
was conducted on urine from cerivastatin treated rats which revealed an increase in 1- 
and 3-methylhistidine (MH) with myopathy. These metabolites were most abundant in 
skeletal muscle and originated from the dipeptide anserine (1-MH) and myofibrillar 
proteins (3-MH: actin and myosin). Experimental paradigms resulting in myofibrillar 
protein catabolism indicated transcriptional induction of the muscle specific ubiquitin 
ligases (atrogin-1 and MuRF-1) were generally correlated with increased serum 3-MH. 
Furthermore, serum 3-MH was more sensitive than urine 3-MH, and traditional 
biomarkers of myopathy, including creatine kinase (CK) and aspartate aminotransferase 
(AST), suggesting it may be a useful preclinical biomarker of myopathy in non-fasted 
rats. In contrast, urine 3-MH provides an advantage over CK and AST as it detects 
skeletal muscle atrophy and hypertrophy. Collectively, this dissertation represents a body 
of work demonstrating the utility of transcriptomic and metabolomic profiling in 
identifying potential mechanisms and biomarkers of statin-induced myopathy. 
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Chapter 1 
 
 
Introduction 
 
 
1.1. Historical perspective: HMG-CoA reductase, cholesterol and 
coronary heart disease  
High serum cholesterol is a condition associated with atherosclerosis and coronary heart 
disease (CHD), the most common cause of mortality in developed countries (Vaklavas et 
al., 2009). A variety of risk factors have been identified for CHD including tobacco 
smoking, high blood pressure, obesity, sedentary lifestyle and age (Dent, 2010). 
However, low-density lipoprotein cholesterol (LDL-C) is one of the most important risk 
factors for developing atherosclerosis, and the 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase inhibitors, otherwise known as statins, represent a class of drugs 
used to modulate LDL-C levels by competitively inhibiting the rate-limiting step in 
cholesterol biosynthesis (Figure 1.1) (Coresh and Kwiterovich, 1996; Fielding and 
Fielding, 1996; Goldstein and Brown, 1990; Knopp et al., 1994; Vaklavas et al., 2009). 
The causal relationship between high cholesterol and CHD was initially proposed over 50 
years ago and since that time numerous studies have confirmed that lowering LDL-C in 
patients with hypercholesterolemia can reduce the incidence of CHD (Anderson et al., 
1987; Castelli et al., 1986; Keys, 1997; Pekkanen et al., 1990; Shepherd et al., 1995; 
Scandinavian Simvastatin Survival Study Group, 1994; Stamler et al., 1986). In 2005, 
over 150 million prescriptions were written for statins making this therapeutic class the 
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world‟s most widely prescribed class of drugs with sales in the billions of dollars 
(Bhardwaj and Chalasani, 2007; Buettner and Lecker, 2008; Fernandez et al., 2011; Kidd 
et al., 2006; Law and Rudnicka, 2006). Based on recent findings, the patient population 
indicated to receive long-term statins is likely to expand as it was confirmed that statin 
treatment causes a significant reduction of cardiovascular events in patients without pre-
existing hypercholesterolemia and statin therapy in children with familial 
hypercholesterolemia might prevent atherosclerosis in adolescence (Alegret and 
Silvestre, 2006; Rodenburg et al., 2007). Although statin therapy targets reduction in 
LDL-C some studies have also shown a marginal reduction in triglyceride levels and 
increased anti-atherogenic high-density lipoproteins (HDL) (Ginsberg et al., 1987; Vega 
et al., 1998; Bakker-Arkema et al., 1996; Grundy, 1998; Brown et al., 1998; Brown and 
Goldstein, 1986, 2004). 
 
1.2. HMG-CoA reductase structure, function and regulation 
HMG-CoA reductase is highly conserved across species and is composed of a single 
polypeptide (887-888 amino acids depending on species) which is separated into 
hydrophobic membrane and hydrophilic catalytic domains (Figure 1.2; DeBose-Boyd, 
2008). The membrane domain consists of three functional portions. Specifically, the N-
terminal membrane domain is comprised of 339 amino acids in the endoplasmic 
reticulum, with eight membrane spanning segments, and the linker region which connects 
to the soluble 548 amino acid C-terminal domain which represents the catalytic portion of 
HMG-CoA reductase (Figure 1.2; DeBose-Boyd, 2008; Istvan and Deisenhofer, 2000; 
Istvan et al., 2000). This protein is composed of two monomers in a dimer and two 
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dimers in a tetramer which catalyzes the 4-electron oxidoreduction of HMG-CoA into 
CoA and mevalonate with oxidation of two molecules of NADPH (Figures 1.1 and 1.2; 
Friesen and Rodwell, 2004). The HMG-like moieties of statins occupy the HMG-binding 
pocket in the active site of the enzyme through hydrogen bonding and ion pairing 
resulting in a conformational change preventing it from achieving its functional structure 
(Alegret and Silvestre, 2006). Although the tight binding is reversible the affinity of 
statins for the active site is in the nanomolar range whereas it is in the micromolar range 
for HMG-CoA (Alegret and Silvestre, 2006).  
 
HMG-CoA reductase is a highly regulated enzyme, subjected to diurnal variation, short 
and long term regulation as well as transcriptional and translational regulation (Clarke et 
al., 1984; Xu and Simoni, 2003). In the rat liver, HMG-CoA reductase mRNA and 
activity shows diurnal variation with the peak levels occurring during the daily 12 hour 
dark cycle and the nadir at the middle of the 12 hour light cycle (Clarke et al., 1984). 
Short-term regulation is mediated by phosphorylation and dephosphorylation by AMP 
activated kinase and protein phosphatase 2A, respectively (Gaussin et al., 1997; Hardie, 
1992). Long-term regulation involves modulation of HMG-CoA reductase protein level 
by several factors. Inhibition of HMG-CoA reductase leads to a reduction in mevalonate 
synthesis and sterol levels resulting in activation of the endoplasmic reticulum sterol 
regulatory element binding protein (SREBP) and HMG-CoA reductase through the 
intramembrane sequence called the sterol-sensing domain (SSD) (Figure 1.3; DeBose-
Boyd, 2008; Ikonen, 2008). SREBP cleavage-activating protein (SCAP) contains an SSD 
which binds and escorts SREBP proteins, which are membrane bound transcription 
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factors, from the ER to the Golgi by vesicle coated COPII proteins where they undergo 
two sequential preoteolytic cleavages including a serine protease (S1P) and a zinc 
metalloprotease (S2P) (Figure 1.3; Brown and Goldstein, 1997, 1999; Horton et al., 2002; 
Ikonen, 2008). Following proteolytic cleavage, these transcriptional factors translocate to 
the nucleus where they bind the sterol regulatory element (SRE) and induce expression of 
sterol-regulated genes including the LDL-C receptor and cholesterol metabolism genes 
with up to 200-fold induction of HMG-CoA reductase enzyme levels (Figure 1.3; Brown 
and Goldstein, 1997; Goldstein et al., 2006; Horton and Shimomura, 1999; Ikonen, 
2008). Consequently, hepatic inhibition of HMG-CoA reductase with statin therapy 
results in reduced cholesterol biosynthesis, decreased intracellular levels of cholesterol, 
upregulation of LDL-C surface receptors, and increased LDL-C uptake with a 
concomitant decrease in serum LDL-C (Goldstein and Brown, 1990).  
 
In sterol deprived cells, SCAP binds to SREBPs and is escorted from the ER to the Golgi 
where SREBPs are proteolytically processed to yield fragments that enter the nucleus and 
induce expression of sterol-regulated genes (Figure 1.3; Brown and Goldstein, 1999; 
Ikonen, 2008). In contrast, high intracellular cholesterol leads to fatty acid esterification 
and storage of these more hydrophobic sterols (Ikonen, 2008). Additionally, when ER 
membrane cholesterol levels increase the SCAP/SREBP complex fails to exit the ER, the 
proteolytic processing of SREBPs is abolished and the transcription of sterol-regulated 
genes is reduced (Ikonen, 2008). ER retention of SCAP/SREBP is mediated by sterol-
dependent binding to an insulin induced gene (INSIG), an ER resident protein which 
induces a conformational change (Figure 1.3; Yang et al., 2002; Ikonen, 2008). 
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Intracellular accumulation of lanosterol induces HMG-CoA reductase to bind INSIG, 
promoting ubiquitination and proteasomal degradation (Figure 1.3; Sever et al., 2003; 
Ikonen, 2008). Furthermore, intracellular accumulation of cholesterol results in 
enzymatic conversion to oxysterols, which are typically present in minor amounts 
(approximately 1:1000 compared to cholesterol) (Ikonen, 2008). Oxysterols, like 25-
hydroxycholesterol are more hydrophilic and play a role in cholesterol regulation, and at 
high levels they function as membrane solubilizers leading to reverse cholesterol 
transport from extrahepatic tissues and hepatic bile acid formation (Ikonen, 2008). 
Specifically, this regulation is mediated by cholesterol binding to SCAP and 25-
hydroxycholesterol binding to INSIG which promotes these chaperones to bind each 
other rendering a signal in SCAP which is not accessible to the COPII complex thereby 
preventing ER to Golgi vesicle transport (Figure 1.3; Ikonen, 2008). 
 
Mevastatin was the first compound in the class of HMG-CoA reductase inhibitors 
identified in 1976 following isolation from the fungus Penicillium citrinum and lovastatin 
was subsequently isolated from Aspergillus terreus and was the first statin approved by 
the Food and Drug Administration in 1987 (Figure 1.4; Endo et al., 1976, 1977; Endo and 
Kuroda, 1976, Tobert, 1987, 2003). Chemical modulation of fungal and microbial 
products led to the development and marketing of simvastatin in 1988 and pravastatin in 
1989, respectively (Figure 1.4; Tobert, 2003). Several compounds with completely 
different chemical structures were subsequently synthesized and approved for marketing 
including fluvastatin in 1994, atorvastatin in 1997, cerivastatin in 1998, rosuvastatin in 
2003 and pitavastatin 2003 (Figure 1.4; Alegret and Silvestre, 2006; Tolbert, 2003). The 
naturally occurring statins posses a common naphthalene ring and a β-hydroxylactone 
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structure along with different side chains. Mevastatin, lovastatin and simvastatin are 
considered prodrugs because they contain an inactive closed β-hydroxylactone ring which 
is activated by esterase in the liver to the open lactone form whereas the other statins are 
administered as the active acid form (Shitara and Sugiyama, 2006). Although the HMG-
CoA like moiety is common to all statins the synthetic compounds are structurally 
dissimilar and this contributes to unique physicochemical and pharmacokinetic properties 
(Figure 1.4) (Shitara and Sugiyama, 2006). Importantly, there are pharmacokinetic 
differences in absorption, distribution, metabolism and excretion which affects the safety 
of these compounds (Garcia et al., 2003; Shitara and Sugiyama, 2006).   
 
1.3. Pleiotropic effects of statins 
Statins have a variety of pleiotropic effects representing clinical benefits other than the 
pharmacological action of reducing LDL-C (Alegret and Silvestre, 2006). Mevalonate is 
the precursor for several biological intermediates, including isoprenoids farnesyl 
pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), and the pleiotropic 
effects are mediated by the ability of statins to inhibit the synthesis of these isoprenoid 
products (Figure 1.5; Alegret and Silvestre, 2006). Isoprenoids, including farnesyl and 
geranylgeranyl residues are covalently attached post-translationally to proteins involved 
with cellular signaling. This process, termed isoprenylation results in the addition of a 
hydrophobic isoprenoid moiety which permits anchoring of these prenylated proteins to 
cellular membranes and facilitates interactions with other membrane bound proteins 
(Grosshans et al., 2006; Leung et al., 2006; McTaggart et al., 2006). There are numerous 
prenylated compounds including ubiquinone, dolichol, Heme-a and nuclear lamins, 
however GTP-binding proteins, including Ras, Rho, Rab and Rac appear to be the most 
9 
 
important in mediating the pleiotropic effects of statins (Figure 1.5; Alegret and Silvestre, 
2006). GTPases cycle between a GDP-bound inactive and GTP-bound active state. In the 
GTP-bound state, these proteins activate a variety of effector proteins until GTP 
hydrolysis renders them inactive. To bind GTP, the GTPases must translocate from the 
cytoplasm to the plasma membrane and this process is dependent on isoprenylation and 
appropriate membrane attachment. GTPases are involved with a variety of cellular 
functions, including signaling, differentiation, proliferation, and cytoskeleton dynamics 
(Bellosta et al., 2000; Chan et al., 2003). Therefore, statin mediated depletion of 
isoprenoids has the potential to modulate a variety of cellular processes. Specifically, the 
pleiotropic effects of statins are mediated by several mechanisms including modulation of 
nitric oxide, inflammation, immunomodulation, coagulation and cell proliferation which 
stabilize atherosclerotic plaques, reduce platelet aggregation, improve endothelial 
function and reduce inflammation (Alegret and Silvestre, 2006; Bellosta et al., 2000; 
Buhaescu and Izzedine, 2007; Chan et al., 2003). In fact, the extensive therapeutic benefit 
of statins has led to these drugs being considered the “new aspirin” (Veillard and Mach, 
2002).   
 
1.4.  Adverse effects associated with statin therapy 
Statins are generally well tolerated and have a good safety profile. However, a variety of 
adverse effects have been observed in humans (Armitage, 2007). Hepatotoxicity, 
characterized by a non-asymptomatic elevation of liver enzymes, namely AST and ALT 
has been observed with an incidence of 1%, and usually occurs within 6 months of 
initiating statin therapy, and typically resolves with statin withdrawal or time (Bhardwaj 
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and Chalasani, 2007). Scattered case reports of peripheral neuropathy with statin 
treatment are rare and the risk is considered very low as this adverse effect has not been 
confirmed in randomized trials (Armitage, 2007). Gastrointestinal effects have also been 
reported with statin therapy but again the risk is considered minimal (Armitage, 2007). 
More recently, statin therapy has been associated with a modest increased risk of diabetes 
(Preiss and Sattar, 2012). However, the most commonly reported adverse effects of 
statins are various forms of myotoxicity ranging from myalgia to frank rhabdomyolysis 
(Table 1.1) (Buettner and Lecker, 2008; Rosenson et al., 2004; Sirvent et al., 2008).  
 
Statin-induced rhabdomyolysis is rare. However, clinical evidence indicates that myalgia 
may progress to life threatening rhabdomyolysis (Radcliffe and Campbell, 2008). First 
reported approximately 20 years ago, muscle-related complications did not receive 
significant attention until 2001 following the withdrawal of cerivastatin (Baycol®) from 
the market after more than 100 rhabdomyolysis-related deaths were associated with the 
drug (Thompson et al., 2003). Depending on the study, up to 20% of patients may 
experience statin-related muscle side effects which interfere with activities of daily living 
and this has contributed to the fact that fewer than 50% of statin users adhere to the 
therapy after 1 year (Buettner and Lecker, 2008). The incidence of statin myopathy in 
clinical practice is significantly greater than what was initially observed in randomized 
clinical trials evaluating statin efficacy (Fernandez et al., 2011; Kashani et al., 2006). 
There are several potential causes of this disparity including characteristics of patients in 
both groups as well as inconsistency in collection of adverse data (Buettner and Lecker, 
2008). Compared to typical patients, clinical trial participants were generally younger, 
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healthier and using fewer medications (Buettner and Lecker, 2008). Furthermore, up to 
half of all study participants screened were excluded because of various comorbities like 
renal or hepatic insufficiency, a history of muscular complaints, and patients already 
taking drugs which could increase systemic exposure of the statins (Fernandez et al., 
2011). Additionally, clinical trials with statins were designed to assess efficacy and 
adverse effects like rhabdomyolysis but not minor muscle discomfort which is often 
common in older patients (Fernandez et al., 2011). While clinical trials clearly 
demonstrated the therapeutic benefits of statin therapy these studies greatly 
underestimated the incidence of statin-induced myopathy which has been observed in 
clinical practice (Fernandez et al., 2011). In fact, the high incidence of adverse muscle 
effects, and the perceived risk of myopathy associated with these drugs, has limited the 
potential clinical benefit of statin therapy that otherwise could be achieved (Fernandez et 
al., 2011). Despite 20 years of use, both the etiology and mechanism of statin-induced 
rhabdomyolysis remain obscure. Therefore, elucidating the mechanism of myopathy may 
enable clinicians to fully harness the therapeutic potential of these drugs while 
minimizing the risk of this untoward effect. 
 
1.5. Rhabdomyolysis 
Rhabdomyolysis is the most severe form of myopathy and occurs in up to 0.5% of 
patients on statin therapy (Buettner and Lecker, 2008). Rhabdomyolysis is a life-
threatening syndrome first reported several thousand years ago by the Israelites following 
abundant consumption of quail which fed on hemlock during Spring migration (Billis et 
al., 1971; Rizzi et al., 1991; Rutecki et al., 1998). It is now recognized that eating quail 
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meat after they have consumed large amounts of hemlock causes rhabdomyolysis through 
a mechanism which may be directly related to the presence of toxic alkaloids including 
coniine in Hemlock which paralyzes muscles by blocking the nicotinic receptor on the 
post-synaptic membrane of the neuromuscular junction (Billis et al., 1971; Rizzi et al., 
1991; Rutecki et al., 1998). More recently, crush syndrome, characterized by crushing 
injury of skeletal muscle was reported during the 1908 Sicilian earthquake and in the 
German military medical literature during World War I in which soldiers were buried in 
trenches (Bywaters and Beall, 1941). Today, a variety of different causes have been 
associated with rhabdomyolysis including use of HMG-CoA reductase inhibitors, 
cyclosporine, fibrates, corticosteroids, alcohol, cocaine and amphetamines (Sauret et al., 
2002; Singh et al., 2005). Other significant causes of rhabdomyolysis include trauma (e.g. 
third degree burns, crush injury, electric shock), heat-related causes (e.g. heatstroke and 
malignant hyperthermia), ischemic limb injury and physical overexertion (e.g. marathon 
runners) (Sauret et al., 2002; Singh et al., 2005). Additionally, rhabdomyolysis has been 
associated with infections, inflammation, electrolyte imbalance, metabolic and 
endocrinologic causes and genetic disorders in lipid, carbohydrate and purine metabolism 
(Sauret et al., 2002; Singh et al., 2005). Importantly, the incidence of statin-induced 
myopathy is most prevalent in patients with underlying disorders associated with 
rhabdomyolysis including carnitine palmityl transferase, myophosphorylase and 
myoadenylate deficiencies (Phillips and Haas, 2008). Regardless of the mechanism of 
muscle injury, rhabdomyolysis is initiated by a pathologic cascade of events including 
leakage of extracellular calcium into the intracellular space, followed by a pathologic 
interaction with actin and myosin leading to overcontraction of the contractile apparatus, 
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and ultimately muscle destruction and fiber necrosis (Singh et al., 2005; Vanholder et al., 
2000). Muscle damage results in the leakage of large quantities of muscular cell 
constituents (e.g. potassium, phosphate, and myoglobin) into the circulation. These 
constituents are then filtered by the kidneys causing myoglobin to precipitate in the renal 
filtrate, and leading to renal tubular obstruction and damage, acute renal failure, 
multiorgan failure and death (Singh et al., 2005; Vanholder et al., 2000). The importance 
of rhabdomyolysis is not limited to the clinic as the incidence of skeletal muscle injury 
during the drug discovery process has become increasingly more prevalent in preclinical 
animals following investigative studies on new therapeutic targets (Scatena et al.., 2004; 
Vassallo et al., 2009). 
 
1.6. Muscle biology, physiology and biochemistry  
1.6.1. Skeletal muscle 
Skeletal muscle comprises approximately 40-55% of body mass in mammals and plays a 
vital role in posture, movement, heat production and more than 50% of over-all-whole 
body metabolism (Riechman et al., 2009; Zierath et al., 2004). Accordingly, skeletal 
muscle plays a major role impacting health and disease mediated by caloric, glucose, fat 
and cholesterol intake (Riechman et al., 2009). Specifically, skeletal muscle is the major 
site of glucose disposal and becomes insulin resistant with inactivity (Riechman et al., 
2009). In contrast, skeletal muscle contraction can directly stimulate growth and 
maintenance to prevent or treat the loss of muscle mass with various debilitating 
conditions associated with ageing and disease (Riechman et al., 2009). Skeletal muscle 
activity also contributes to cardiovascular health by accelerating metabolism, weight 
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control, increased vascularization, cholesterol regulation and anti-inflammatory effects 
(Riechman et al., 2009). 
 
Skeletal muscles are by volume the largest animal cell composed of post-mitotic 
myofibers (Guyton and Hall, 2006). Myofibers represent a unique cell type in that they 
are multinucleated, with more than 100 peripherally located nuclei per myofiber (Figure 
1.8; Bruusgaard et al., 2003; Newlands et al., 1998). Each of the nuclei is responsible for 
maintaining a defined area of the sarcoplasm and this has been described as the nuclear / 
cytoplasmic ratio (Gundersen and Bruusgaard, 2008). In fact, multinucleated skeletal 
muscle cells employ a unique mechanism of gene regulation. While all myonuclei are 
capable of transcription, the number of nuclei expressing a specific gene is a dynamic 
process, as the proportion of transcriptionally active nuclei decreases during fiber growth, 
with the frequency of active loci within these nuclei reflecting the degree of fiber 
differentiation (Newlands et al., 1998).  
 
Myofibers are established during embryogenesis by fusion of spindle-shaped myogenic 
stem cells known as myoblasts or satellite cells which form primary multinucleated 
myotubes (Figure 1.6; Gundersen and Bruusgaard, 2008; Yablonka-Reuveni et al., 2008). 
During postnatal development, myogenic cells proliferate, differentiate and fuse with the 
enlarging myofibers (Figure 1.6). In differentiated muscles, satellite cells reside beneath 
the basal lamina and are typically quiescent. However, following muscle damage, 
regeneration of the myofibers is initiated when myogenic stem cells proliferate into 
myotubes and repair the tissue by fusing with existing myofibers (Yablonka-Reuveni et 
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al., 2008). Accordingly, satellite cells are required throughout the life of a myofiber and 
specific regulation is needed to control quiescence, proliferation, differentiation and 
renewal. Satellite cell myogenesis depends on a highly orchestrated genetic program 
which controls transcription of specific genes in accordance with cell-cycle progression 
and differentiation (Figure 1.6; Yablonka-Reuveni et al., 2008). Myogenesis of satellite 
cells is regulated by a family of muscle-specific transcription factors known as muscle 
regulatory factors (MRF) (Figure 1.6). These muscle regulatory factors are expressed in a 
temporal ordered manner and include myogenic determination factor 1 (MyoD), 
myogenic factor 5 (Myf5), myogenin and myogenic regulatory factor 4 (MRF4) (Figure 
1.6). In normal mature muscle, satellite cells are mitotically quiescent but express a 
number of genes including paired-homeobox transcription factors (Pax3 and Pax7), 
CD34 and Myf5 which are considered molecular markers of this phenotype (Zammit et 
al., 2006). When satellite cells are activated, identified as the proliferative stage, they 
rapidly initiate MyoD expression, undergo CD34 isoform switch and continue expressing 
Pax7 and Myf5 while proliferating to produce myoblasts (Zammit et al., 2006). The onset 
of early myogenic differentiation is marked by myogenin expression along with other 
regulatory and structural genes associated with differentiated skeletal muscle cells 
(Zammit et al., 2006). As they elongate, myoblasts align with each other, guided in this 
by mutual membrane recognition followed by cell fusion and formation of long striated 
multinucleated myotubes which differentiate into mature myofibers (Mermelstein et al., 
2007). 
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Regulation of skeletal muscle regeneration following damage is also dependent on the 
immune response. Following acute skeletal muscle injury, neutrophils are recruited and 
increase in number within 2 hours and typically peak in concentration between 6 and 24 
hours post-injury and then decline rapidly (Tidball and Villalta, 2010). Following 
neutrophil invasion, phagocytic macrophages are recruited reaching peak levels about 24 
hours post-injury and continue to increase in concentration for about 2 days post-injury 
and then begin to decrease in number (Tidball and Villalta, 2010). A population of 
nonphagocytic macrophages invades the muscle and peaks in concentration at about 4 
days post-injury and remain elevated for several days (Tidball and Villalta, 2010). 
Coincident with the invasion of myeloid cells in skeletal muscle following acute injury 
the myogenic cells transition through the regeneration process described above (Figure 
1.7). In fact, in vitro and in vivo studies have demonstrated that factors released by the 
monocyte/macrophage lineage promote satellite cell proliferation and differentiation 
(Tidball and Villalta, 2010).  
 
Initiation of the inflammatory response occurs in injured skeletal muscle within a few 
hours and is believed to occur via membrane damage and release of stored 
chemoattractants. Several candidate proteins have been identified, including desmin 
which activates the complement system, chemokines (CXCL1 and CXCL5) and 
interleukin-6 which recruit neutrophils and mediate the Th1 inflammatory response 
(Tidball and Villalta, 2010). Additional chemokines, including CCL3, CCL4, CCL2 are 
also highly expressed following muscle injury suggesting these small molecules play an 
important role in the inflammatory and regeneration response (Tidball and Villalta, 
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2010). As with other tissues, damaged skeletal muscle responds with an innate immune 
response driven by Th1 cytokines including interferon-γ and TNF-α which promotes 
activation of macrophages to an M1 phenotype, which express the CD68
+
 (ED1) marker, 
and propagates a pro-inflammatory response (Tidball and Villalta, 2010). CD68
+
 is a 
receptor for oxidized-LDL and following ligand binding phagocytosis is activated by the 
M1 macrophages (Tidball and Villalta, 2010). Oxidized-LDL results from neutrophil 
release of myeloperoxidase which damages the skeletal muscle membrane and is 
considered an important step in regulating the process of tissue regeneration (Tidball and 
Villalta, 2010). M2 macrophages are activated by Th2 cytokines including interleukin-
4,10 and 13 as well as immune complexes and Toll-like receptors and attenuate the 
inflammatory process and promote tissue repair (Tidball and Villalta, 2010). The M2a 
and M2c macrophages express CD206 whereas M2c macrophages also express CD163. 
These CD antigens play an important function determining macrophage phenotype and 
regulating their specific activity (Tidball and Villalta, 2010). CD163 is a macrophage 
specific receptor for complexes of hemoglobin and haptoglobin, which following 
internalization and degradation, returns the extracellular levels to normal, thereby 
reducing additional cellular damage. This process inhibits the neutrophil and M1 
macrophage mediated extracellular formation of Fe
3+
 catalyzed free radicals (Tidball and 
Villalta, 2010). Furthermore, CD206 is a mannose receptor that binds and internalizes 
sugar moieties and myeloperoxidase present at high levels in damaged tissues and thus 
reduces inflammation and ongoing cytotoxicity (Tidball and Villalta, 2010). Although 
attenuation of the inflammatory response mediates skeletal muscle regeneration, 
inhibitors (e.g. non-steroidal anti-inflammatory drugs) of cycloxygenase-2 impair this 
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process by preventing metabolism of arachidonic acid necessary for prostaglandin 
synthesis which affects skeletal muscle proliferation, differentiation, fusion and muscle 
fiber growth (Tidball and Villalta, 2010). Accordingly, a very specific cascade of events 
in the inflammatory response is critical in skeletal muscle regeneration.  
 
Myofibers are densely packed with hundreds to thousands of myofibrils which represent 
more than 60% of total muscle proteins (Guyton and Hall, 2006; Munoz et al., 1994). 
Specifically, each myofibril contains about 1500 myosin (thick) filaments and 3000 actin 
(thin) filaments which are aligned adjacent to each other and responsible for muscle 
contraction (Figure 1.8). For illustrative purposes, a general overview of the skeletal 
muscle cell and function are described in Figure 1.9 and the histological appearance is 
shown in Figure 1.10. 
 
Energy required for muscle contraction is provided by ATP hydrolysis which is normally 
maintained by creatine kinase, adenylate kinase and myoadenylate deaminase. The 
concentration of ATP in muscles is approximately 4 mM and is sufficient to maintain full 
contraction for 1 to 2 seconds (Figure 1.11). The first source of energy that is used to 
reconstitute ATP is phosphocreatine, which carries a higher amount of free energy than 
ATP. However, the total amount of phosphocreatine in the muscle is also low, 
representing about 5-times as much as ATP. Therefore, the combined energy of ATP and 
phosphocreatine is sufficent to maintain maximal contraction for 5 to 8 seconds (Guyton 
and Hall, 2006). The second source of energy used to reconstitute ATP and 
phosphocreatine is glycolysis which utilizes glucose from stored muscle glycogen 
19 
 
(Guyton and Hall, 2006). The rapid degradation of glycogen to pyruvate and lactate 
liberates energy which is used to form ATP. Glycolysis is important because the reactions 
can occur in the absence of oxygen so muscle contraction can be maintained even when 
blood flow is diminished. Moreover, the glycolytic process is about 2.5-times more rapid 
than ATP generation from cellular oxidation of lipids (Guyton and Hall, 2006). However, 
because several end products accumulate in the muscle, glycolysis loses its ability to 
sustain maximum muscle contraction after about 1 minute (Guyton and Hall, 2006). The 
third source of energy is oxidative metabolism in which products of glycolysis as well as 
fatty acids and proteins are oxidized to liberate ATP (Guyton et al., 2006). More than 
95% of all energy used for sustained, long-term contraction is derived from this source.  
 
To meet the various functional needs, skeletal muscle is comprised of a heterogeneous 
spectrum of fiber types that differ in their contractile, metabolic and morphologic 
properties (Table 1.2; Guyton and Hall, 2006; Owczarek et al., 2005; Zierath et al., 
2004). Skeletal muscles were originally classified by color (red or white) and rate of 
contraction (slow or fast) in 1873 (Ranvier, 1873). At that time, skeletal muscles were 
classified based on the contraction speed which correlated with their morphology; fast-
twitch appeared white in color whereas slow-twitch fibers appeared red in color. 
However, it took another 53 years before the red color of skeletal muscle was found to be 
related to myoglobin content and capillary density (Needham, 1926). Between 1962 and 
1970, histochemical staining was developed which identified various myosin ATPase 
activities which generally correlated with the speed of contraction and fatigue properties 
and led to the functional classification of muscle fibers: slow-twitch oxidative (type I), 
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fast-twitch glycolytic oxidative (type IIA) and fast-twitch glycolytic (type IIB) (Pette et 
al., 1999). However, the relationship between fiber composition and athletic performance 
was not discovered until 1976 when endurance athletes were found to have a higher 
proportion of slow-twitch muscles and sprinters were found to contain predominately 
fast-twitch muscles (Costill et al., 1976). 
 
Currently, muscle fibers are classified with three different methods, including 
histochemical staining for myosin ATPase, myosin heavy chain isoforms by 
immunohistochemistry and biochemical differences in energy metabolism (Pette et al., 
1999; Scott et al., 2001). These methods led to the recent identification of an additional 
fast-twitch fiber called IID or IIX which is typically designated as IID(X), corresponding 
to the MHCIId(x) isoform (Pette et al., 1999). MHCIIb is very similar to MHCIId(x) and 
these isoforms have often been categorized together. However, humans only express 
MHCIId(x) whereas small mammals express both MHCIId(x) and MHCIIb (Scott et al., 
2001). Despite this species difference, the nomenclature for humans has not changed and 
MHCIIb is often used to represent MHCIId(x) (Pette et al., 1999; Scott et al., 2001). 
Together, these results indicate a total of four pure fiber types containing one MHC, 
including three fast (types IIA, IIB, IID(X) and one slow (type I) which correspond to 
MHCIIa, MHCIIb, MHCd(x) and MHCI. Additional studies have demonstrated the 
existence of hybrid fibers which contain two or more MHC isoforms and exhibit a 
heterogeneous phenotype (Pette et al., 1999; Scott et al., 2001). It should also be noted 
that myosin light chain, tropomyosin, α-actinin and troponin proteins have various 
isoforms which are expressed in a fiber specific manner (Scott et al., 2001). While these 
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proteins are not typically used for assessing muscle fiber types their expression can be 
confirmatory. Furthermore, it is important to mention that muscle fiber distribution varies 
between skeletal muscles within a species and between similar muscles of different 
species (Pette et al., 1999). Specifically, when comparing the same muscle across species 
the relative amount of MHCIIb is inversely related to the size of the animal (Pette et al., 
1999). In the mouse and rat, the psoas consists of predominately IIB fibers whereas in 
rabbits the same muscle contains a predominance of II(D)X fibers (Pette et al., 1999).  
 
Biochemical classification of skeletal muscle is also based on differences in energy 
metabolism and this approach leads to three different fiber types, including slow-twitch 
oxidative (SO), fast-twitch oxidative (FOG) and fast-twitch glycolytic (FG) (Table 1.2; 
Guyton and Hall, 2006; Owczarek et al., 2005; Zierath et al., 2004). Specifically, slow-
twitch oxidative muscle fibers are predominately involved with continuous activity 
requiring endurance (e.g. marathon running). To meet this long-term energy demand, this 
muscle type is more suited for the generation of aerobic energy, and as such contains 
more mitochondria compared to fast-twitch muscle fibers (Table 1.2; Guyton and Hall, 
2006; Zierath et al., 2004). Fast-twitch glycolytic fibers are used for phasic activity 
requiring maximal power during short periods of time (e.g. weightlifting). To achieve this 
short burst of energy requirement, these muscle fibers contain greater enzyme activity 
involved with rapidly releasing energy from phosphocreatine-creatine system, glycolysis 
and glycogen degradation compared to slow-twitch oxidative muscle fibers (Table 1.2; 
Guyton and Hall, 2006; Zierath et al., 2004). Furthermore, fast-twitch muscles have a 
significantly higher level of creatine phosphate (Pette et al., 1999). Fast-twitch oxidative 
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fibers have characteristics which are intermediate between the other two muscles (Table 
1.2). 
 
1.6.2. Cardiac and smooth muscle 
Although the emphasis of this dissertation is on cerivastatin-induced skeletal muscle 
toxicity it is important to note that cardiac and smooth muscle are functionally and 
morphologically unique. Each of these muscles have diverse phenotypic properties, 
functional roles and morphology which may contribute to differences in sensitivity and 
selectivity to drug-induced toxicity. Cardiac myofibers (cardiomyocytes) contain a single 
centrally located nucleus, are branched and interlock with adjacent myofibers through 
intercalated discs, which enable the heart to contract in a synchronous manner (Guyton 
and Hall, 2006). However, dysregulation of this synchronous cardiac cycle can damage 
the heart muscle thereby disrupting the synchronous waves resulting in random fiber 
contraction known as fibrillation, which can lead to cardiomyocyte death. Similar to 
slow-twitch muscles, the heart contains a rich supply of mitochondria which reflects its 
dependence on oxidative metabolism of fatty acids and to a lesser extent glucose for ATP 
(Guyton and Hall, 2006). Accordingly, drugs like isoproterenol specifically target the 
heart and slow-twitch muscles but not fast-twitch muscles (Ng et al., 2002). However, 
while cardiac muscle shares similarities with slow-twitch muscles, there are functional 
and morphological differences, and these properties likely contribute to the fact that some 
compounds like adriamycin selectively target the heart (Zhang et al., 2009). 
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Smooth muscle consists of single nucleated, spindle-shaped cells which contain no visual 
striations, representing the arrangement of actin and myosin in the sarcomere as well as 
the troponin complex involved with contraction. Although smooth muscle contraction is 
mediated by calcium ions and ATP major differences exist in the duration and quantity of 
energy required for contraction compared to striated muscles (Guyton and Hall, 2006). 
Specifically, skeletal muscle contraction is rapid whereas smooth muscle contraction is 
prolonged, lasting hours or days and this difference is attributed to the fact that 
significantly less energy is required to maintain contraction in smooth compared to 
skeletal muscle (Guyton and Hall, 2006). 
1.7. Skeletal muscle as a target organ of drug toxicity 
1.7.1. Fiber differences in skeletal muscle degeneration 
Numerous drugs have been shown to cause skeletal muscle toxicity, and in many cases 
these effects occur in a fiber specific manner (Owczarek et al., 2005; Sardao et al., 2008). 
Fibrates (PPAR-  agonists), -adrenergic agonists, chloroquine (used for malaria 
treatment) and bupivacaine (anaesthetic) preferentially cause a slow twitch myopathy (De 
Souza et al., 2006; Irwin et al., 2002; Ng et al., 2002; Velasco et al., 1995), whereas 
HMG-CoA reductase inhibitors and alcohol primarily target fast-twitch muscles (Adachi 
et al., 2003; Preedy et al., 2001; Westwood et al., 2005). Additionally, some compounds 
like glucocorticoids, adriamycin (cancer chemotherapeutic), carbofuran (pesticide), and 
pyridostigmine bromide (cholinesterase inhibitor) do not discriminate, causing toxicity in 
both fiber types (Braunstein and De Girolami, 1981; Dirks-Naylor and Griffiths, 2009; 
Doroshow et al., 1985; Hudson et al., 1985; Lee et al., 2005; Milatovic et al., 2005). In a 
similar manner, myopathy associated with several diseases, including diabetes, 
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sarcopenia, cachexia, sepsis and starvation predominately target fast-twitch muscle fibers 
(Gribmy, 1995; Lexell, 1995; Narici and Maffulli, 2010; Tomlinson and Irving, 1977). 
However, a more generalized skeletal muscle degeneration can also occur with strenuous 
exercise, inherited diseases (e.g. muscular dystrophy and metabolic myopathies) and 
myotonic dystrophy (Ashizawa and Sarkar, 2011; Vanholder et al., 2000). The 
mechanistic basis of fiber specific toxicity remains unknown but is believed to be 
associated with differences in contractile, metabolic and morphologic properties of the 
skeletal muscle (Vanholder et al., 2000). Specifically, the low oxidative capacity of fast 
glycolytic fibers has been proposed to predispose this fiber type to injury through 
depletion of high-energy phosphates (Gupta and Goad, 2000). Additionally, slow-twitch 
muscles contain higher levels of certain cytoskeletal proteins that may provide structural 
support for the sarcomeres and cell membrane which may help to maintain the integrity 
of these structures in the face of injury.  
 
In contrast to fiber specific degeneration, the specific fiber composition of skeletal 
muscle also contributes directly to the risk of developing various diseases. Specifically, 
individuals with a greater fast-twitch fiber composition are more likely to have chronic 
metabolic syndromes like insulin resistance, type 2 diabetes, obesity, and a blood lipid 
profile associated with an increased risk of cardiovascular diseases (Campbell et al., 
2001; Zierath et al., 2004). In contrast, having a greater proportion of slow-twitch muscle 
fibers increases insulin-stimulated glucose uptake and metabolism. However, with aging 
and physical inactivity, a slow- to fast-twitch fiber conversion occurs which increases the 
risks of metabolic diseases (Zierath et al., 2004).  
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1.7.2. Sex differences in skeletal muscle degeneration 
Skeletal muscle degeneration also occurs in a sex specific manner in humans, with 
females showing a greater sensitivity to HMG-CoA reductase inhibitors, fibromyalgia, 
temporomandibular disorder (masticatory muscle pain), and repetitive motion muscle 
disorders whereas men are more likely to develop sporadic inclusion body myositis (a 
muscle-specific autoimmune disease) (Bartels et al., 2009; Hart et al., 1998; Needham 
and Mastaglia, 2008; Warren and Fried, 2001). In contrast, the incidence of diseases like 
Duchene Muscular Dystrophy show no sex difference (Moser, 1984). The mechanistic 
basis for sex specific muscle degeneration is unclear. However, it is generally believed 
that sex hormones including testosterone and estradiol play an important role in 
modulating a variety of biochemical pathways affecting skeletal muscle energetics, 
metabolism, growth, maintenance of muscle mass and inflammation related to damaged 
tissue repair however the exact mechansims of action in skeletal muscle remain largely 
unknown (Sheffield-Moore and Urban, 2004; Tiidus et al., 2008). These broad effects are 
not surprising given that skeletal muscle is one of the most metabolically active tissues 
responsible for 75% of the insulin-induced glucose uptake in the body, has a large 
substrate storage capacity, and supplies precursors for glucose via gluconeogenesis and a 
repository of protein and amino acids (Barros and Gustafsson, 2011). Accordingly, the 
homeostatic balance of these biochemical pathways in skeletal muscle undergoes a 
continuous remodeling during growth, health, disease and ageing which is hormonally 
regulated in a sex-dependent manner (Sheffield-Moore and Urban, 2004).  
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Androgens like testosterone are converted to the bioactive metabolite dihydrotestosterone  
(DHT) by 5α-reductase or to estradiol by aromatase and target both reproductive and 
non-reproductive tissues such as skeletal muscle (Chen et al., 2005). In general, sex 
steroids are secreted by the ovary, testis and adrenal cortex. However, skeletal muscle is 
also capable of locally synthesizing sex steroid hormones from circulating testosterone, 
and acute exercise enhances the local bioactive androgen metabolism in skeletal muscle 
of both sexes (Aizawa et al., 2007, 2010). Given that skeletal muscle also contains both 
androgen and estrogen (ERα and ERβ) receptors these sex steroid hormones may exert an 
autocrine and/or paracrine action in skeletal muscle (Aizawa et al., 2007). In skeletal 
muscle, testosterone and DHT are known to promote protein synthesis, cell signaling, 
myoblast cell proliferation, glucose metabolism-related signaling, ATP production and 
reduce protein degradation (Haren et al., 2011; Pires-Oliveira et al., 2010; Yoshioka et 
al., 2006). Specifically, a net increase in protein anabolism is mediated in part by 
suppression of the skeletal muscle specific ubiquitin ligases atrogin-1 and MuRF-1 in the 
ubiquitin proteasome pathway which reduces myofibrillar protein degradation (Pires-
Oliveira et al., 2010; Sato et al., 2008; Ustunel et al., 2003; Zhao et al., 2008b). 
 
Most research on androgens has been directed towards hypogonadal men or those 
suffering wasting diseases causing profound skeletal muscle loss since these effects show 
a strong correlation with reduced circulating androgen levels (Sheffield-Moore and 
Urban, 2004). In hypogonadism patients, the therapeutic use of anabolic agents increases 
skeletal muscle mass and strength resulting from a net increase in muscle protein 
synthesis (Sheffield-Moore and Urban, 2004). Furthermore, testosterone does not affect 
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the relative proportions of fast- and slow-twitch myofibers in young and old men but 
rather increases the muscle fiber cross-sectional area and volume of both fiber types in a 
dose-dependent manner (Sinha-Hikim et al., 2002; 2006). Consistent with a role in 
energy metabolism, reduced serum testosterone levels in aging men correlates with an 
increased incidence of metabolic disorders like type 2 diabetes (Salehzadeh et al., 2011). 
Based on these effects, testosterone and selective androgen receptor modulators are being 
pursued as anabolic therapies for various catabolic skeletal muscle conditions like 
sarcopenia as frailty and old age are major public health problems which impact mobility 
and quality of life (Bhasin et al., 2006). Given the focus of this dissertation it is important 
to note that HMG-CoA reductase inhibition with statin therapy does not affect circulating 
levels of androgens in men (Hall et al., 2007). 
 
Similar to androgens, estradiol is considered an important regulator of metabolic 
homeostasis, including glucose and lipid metabolism (Foryst-Ludwig and Kintscher, 
2010). Although the exact mechanism is unclear, estradiol plays an important role in 
modulating glucose disposal in skeletal muscle through action on several proteins in the 
insulin signaling pathway (Barros and Gustafsson, 2011). Accordingly, physiological 
levels of estradiol are beneficial for insulin sensitivity and homeostatic metabolic 
regulation in skeletal muscle (Barros and Gustafsson, 2011; Livingstone and Collison, 
2002). In contrast, dysregulation of estradiol or the estrogen receptors (ERα and β), have 
specific metabolic actions in various tissues, including skeletal muscle. Specifically, 
these effects play a pivotal role in the development and progression of the metabolic 
syndrome, through modulation of carbohydrate and lipid metabolic homeostasis in 
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skeletal muscle (Barros and Gustafsson, 2011; Foryst-Ludwig and Kintscher, 2010; 
Ropero et al., 2008). Although the mechanism of these changes has yet to be completely 
elucidated, ERα along with the peroxisome proliferator-activated receptor γ coactivator 
1α (PGC1α) have been shown to coactivate pyruvate dehydrogenase kinase 4 and thus 
directly regulate glucose metabolism (Wende et al., 2005; Zhang et al., 2006).  
 
Estradiol also has a direct action on the hypothalamus mediated by ERα and β in which 
higher levels are associated with the estrus and menstrual cycles and pregnancy, and 
associated with reduced food intake. In contrast, ovarictomy, antiestrogen treatment and 
menopause result in increased food intake, body weight and abdominal fat accumulates 
which is mitigated with estradiol replacement (Barros and Gustafsson, 2011). Moreover, 
estradiol regulates peripheral feedback hormones that affect food consumption through 
actions on the central nervous system. Leptin, which is a potent catabolic hormone 
released by adipose cells reduces food intake and increases energy expenditure and it has 
been shown that estradiol modulates the leptin receptor and increases hypothalamic 
sensitivity to leptin, altering peripheral fat distribution (Barros and Gustafsson, 2011). 
Another important peptide (ghrelin) is produced in the stomach, regulated by estradiol 
and acts on growth hormone receptors which are potent stimulators of food intake 
through an unknown mechanism (Barros and Gustafsson, 2011). 
  
Given the biological effects of testosterone and estradiol it is not surprising that sex 
specific transcriptional regulation exists in skeletal muscle (Roth et al., 2002; Salehzadeh 
et al., 2011; Yoshioka et al., 2007). In fact, in vivo as well as in vitro studies have 
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demonstrated transcriptional differences related to cytoskeletal/contractile apparatus, 
mitochondrial processes, glucose, lipid, protein and amino acid metabolism (Yoshioka et 
al., 2007). However, the most abundant transcripts are similar in female and male rats 
indicating that the population of various fiber-types is not sex-dependent (Yoshioka et al., 
2007). Collectively, these data indicate that both testosterone and estradiol modulate 
skeletal muscle energy homeostasis and may be important mediators of sex-specific 
skeletal muscle toxicity. However, the role, if any, for these hormones in mediating 
statin-induced myopathy has yet to be investigated despite the observation that females 
are more sensitive than males.  
 
1.7.3. Adaptive characteristics of skeletal muscle to altered physiology 
and pathology 
Skeletal muscle demonstrates a remarkable plasticity which enables functional, 
morphological and metabolic adaptation to the ever changing physiological stimuli like 
exercise, environmental conditions and substrate availability as well as pathological 
conditions. In particular, weight lifting and aerobic exercise cause adaptations consisting 
of increased blood flow, increased muscle mass, satellite cell proliferation and evidence 
of new myofiber formation (Appell et al., 1988; McCormick and Thomas, 1992). These 
external stimuli activate various signaling pathways which modulate gene expression 
resulting in phenotypic changes in muscle fiber type, diameter, length and vascular 
supply. The fiber-type profile of different muscles is initially established during 
development and independent of neural influence. However, nerve activity plays a 
significant role in maintenance and modulation of the fiber phenotype during postnatal 
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development, in adults and during muscle regeneration (Schiaffino et al., 2007). Skeletal 
muscle fiber-type transformation occurs when either a slow- or fast-twitch fiber develops 
phenotypic properties of the other fiber type. Several independent signaling pathways 
including Ras/mitogen-activated protein kinase, NFAT, calcineurin, calcium/calmodulin-
dependent protein kinase IV, PPARs and the peroxisome proliferator γ coactivator (PGC-
1) are known to regulate this process (Schiaffino et al., 2007; Zierath et al., 2004).   
 
Skeletal muscle can also adapt to various physiological conditions by modulating mass. 
An increase in muscle mass is called hypertrophy whereas a decrease in muscle mass is 
called atrophy. The mass of skeletal muscle is governed by regulatory processes that 
modulate the rate of protein synthesis and degradation (Murton et al., 2008). These 
adaptations result in alteration in the mass and metabolic properties of the muscle fibers, 
with physiological capabilities that match the new functional demands. The 
multinucleated nature of skeletal muscle provides this tissue with a unique mechanism 
enabling it to adapt to such physiological changes. Specifically, each myonuclei regulates 
a local cytoplasmic domain in the vicinity of the nucleus, called the myonuclear domain 
(Gundersen and Bruusgaard, 2008). It is currently believed that regulation of muscle fiber 
mass during atrophy results in loss of nuclei by apoptosis whereas with hypertrophy new 
nuclei from muscle satellite cells fuse with the myofiber (Dupont-Versteegden, 2006; 
Gundersen and Brusgaard, 2008; Tews, 2005). In most cells, apoptosis leads to 
destruction of the nucleus and cell death however multinucleated muscle cells are able to 
harness this process to remodel the myofiber by eliminating specific myonuclei and 
reducing fiber size (Allen et al., 1999). It is unknown whether the number of nuclei is the 
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causative factor in regulating muscle mass or a consequence, but regardless the 
myonuclear domain is maintained during this processes (Allen et al., 1999; Gundersen 
and Bruusgaard, 2008).  
 
Muscle hypertrophy is associated with a net increase in protein synthesis, reduction in 
protein degradation or both resulting in increased number of contractile proteins, 
mitochondria, enzymes involved with energy metabolism and nuclei to maintain a 
constant ratio of nuclei to cytoplasmic volume (Boonyarom and Inui, 2006; Otto and 
Patel, 2010). Furthermore, and perhaps more importantly, an anabolic response in 
skeletal muscle is associated with increased muscle strength and function. Muscle 
hypertrophy results from a variety of factors including increased muscle activity 
associated with exercise and anabolic agents like testosterone, growth hormone (peptide 
released by hypothalamus) and -adrenergic agonists (e.g. epinephrine), as well as 
insulin, insulin-like growth factor-1 (IGF-1) and growth and differentiation factor 8 
(GDF8; myostatin) (Murton et al., 2008). However the anabolic actions of various 
hormones on skeletal muscle vary based on a variety of factors including age, sex, and 
duration of exposure (Sheffield-Moore and Urban, 2004). At the molecular level, skeletal 
muscle mass is controlled by two major signaling pathways that are regulated by either 
IGF-1 or myostatin. IGF-1 has a major effect on skeletal muscle size by increasing stem 
cell proliferation, protein synthesis, fusion of new myonuclei into myofibers, and 
myoblast differentiations (Figure 1.12). IGF-1 signals through the IGF-1 receptor via 
direct interaction with IGF-1 binding proteins and activation of several pathways with 
each culminating into different phenotypic changes in the muscle leading to an increase 
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and maintenance of muscle mass (Figure 1.12; Otto et al., 2010). Additionally, anabolic 
effects (e.g. testosterone) negatively regulate the myogenic atrophy pathways thereby 
maintaining existing skeletal muscle mass through prevention of muscle protein 
degradation and wasting (Otto and Patel, 2010). 
 
Myostatin is expressed specifically in developing and adult skeletal muscle and is 
regarded as a negative regulator of muscle mass (Lee, 2004). During development, 
myostatin expression limits the muscle size in concert with other factors that develop the 
limbs in relation to skeletal, vascular and ectodermal patterns of growth. In myogenic 
cells, myostatin downregulates expression of myogenic cell proliferation markers (Pax-3 
and Myf-5) and the muscle differentiation marker Myo-D (Rodino-Klapac et al., 2009). 
Targeted disruption of myostatin results in muscle hypertrophy and hyperplasia with 
muscle mass increases of up to 3-fold (Rodino-Klapac et al., 2009). Thus, myostatin 
modulates the number of muscle fibers that are ultimately formed by regulating 
proliferation and differentiation of myoblasts during development and second it regulates 
muscle fiber growth postnatally through hypertrophy and hyperplasia (Lee., 2004; Otto 
and Patel, 2010).  
 
 
Muscle atrophy is associated with a net increase in protein degradation resulting in 
reduction in number of contractile proteins, mitochondria, enzymes involved with energy 
metabolism and nuclei to maintain a constant ratio of nuclei to cytoplasmic volume 
(Boonyarom and Inui, 2006; Sandri, 2010). Induction of muscle atrophy is associated 
with a variety of conditions including neuromuscular diseases, diabetes mellitus, cancer 
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cachexia, disuse, immobilization, denervation, sarcopenia, wasting, fasting, starvation 
and drugs like glucocorticoids, and chloroquine (Murton et al., 2008). At the cellular 
level, the hallmark change associated with muscle atrophy is a reduction in the 
myofibrillar proteins resulting in dissolution of the sarcomeres (Boonyarom and Inui, 
2006). Although intracellular proteins are continuously hydrolyzed to their constituent 
amino acids and replaced by synthesis of new proteins, degradation occurs at widely 
differing rates, varying from minutes for some regulatory enzymes to weeks for 
myofibrillar proteins like actin and myosin (Lecker et al., 2006; Munoz et al., 1994). To 
ensure continual protein degradation is highly selective, cells contain several specific 
proteolytic systems maintained by complex regulatory mechanisms (Murton et al., 2008; 
Sandri, 2010).  
 
The cytosolic Ca
2+-
activated (ATP-independent) pathway consists of calpains which are 
cysteine proteases activated when cells are injured and cytosolic Ca
2+
 increases (Costelli 
et al., 2005). These proteases are thought to play an important role in tissue injury, 
necrosis and autolysis (Costelli et al., 2005; Lecker et al., 2006). Caspases are cytosolic 
proteases which cleave proteins after aspartic acid residues and are critical in destroying 
cell constituents during apoptosis (Lecker et al., 2006). Both the calpain and caspase 
pathways perform a limited proteolysis due to restricted specificity (Costelli et al., 2005). 
In contrast, two proteolytic systems; the autophagy-lysosome pathway and ubiqutin-
proteasome pathway (UPP) are responsible for degrading most proteins to their 
constituent amino acids during basal and catabolic-induced adaptive physiological 
responses (Sandri, 2010). These two pathways serve distinct yet coordinately regulated 
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functions through forkhead box protein O3 (FoxO3) transcriptional factor to preserve the 
appropriate composition and distribution of proteins and organelles in atrophying muscle 
which enables cells to respond to environmental and nutrient changes (Bursch et al., 
2008; Sandri, 2010; Zhao et al., 2008a). Additionally, these pathways are involved with 
diverse physiological responses such as biosynthesis, regulation of metabolism through 
elimination of specific enzymes, morphogenesis, cellular differentiation, tissue 
remodeling, aging, cellular defense, survival against injury, programmed cell death and 
ultimately as a fundamental survival strategy serving as a homeostatic mechanism at the 
subcellular level (Bursch et al., 2008).  
 
The autophagy-lysosome pathway constitutes a major adaptive survival response which 
degrades long-lived proteins and organelles whereas the UPP degrades myofibrillar and 
most soluble short-lived proteins (Sandri, 2010). In normal physiology, these pathways 
maintain homeostasis of skeletal muscle mass by tightly regulating protein degradation. 
During catabolic conditions, skeletal muscle is considered a protein reservoir which is 
mobilized by autophagy and the UPP to maintain gluconeogenesis in liver, to maintain 
protein synthesis, and to provide alternative energy substrates for preservation of critical 
organ function, including skeletal muscle (Figure 1.13) (Lecker et al., 2006; Rabinowitz 
and White, 2010; Sandri, 2010). Paradoxically, dysregulation representing inhibition or 
excessive skeletal muscle protein degradation can exacerbate other catabolic conditions 
and lead to pathogenic mechanisms, myofiber degeneration, morbidity and mortality 
(Masiero and Sandri, 2010; Motojima et al., 2002; Motojima and Seto, 2003; Nishida et 
al., 2009; Sandri, 2010).    
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In the autophagy pathway, double membrane vesicles or vacuoles engulf a portion of the 
cytoplasm including mitochondria, ribosomes, peroxisomes, ER, ribosomes, lipid 
droplets, cytosolic proteins, glycogen and protein aggregates that are released into the 
cytoplasm for reutilization in biosynthetic pathways (Figure 1.14) (Rabinowitz and 
White, 2010; Sandri, 2010). However, a massive quantity of autophagic vacuoles often 
forms before the manifestation of cell death and this is considered a hallmark reflecting 
the cells effort to survive a life-threatening insult (Bursch et al., 2008). These autophagic 
vacuoles or autophagosomes are delivered to lysosomes and the contents are degraded by 
the acidic proteases cathepsin B, D and H as well as other hydrolases. In the autophagy 
system, small ubiquitin-like molecules including LC3, GABARAP, GATE16 and Atg12 
are transferred from the conjugation system to membranes targeted for lysosomal 
degradation (Lecker et al., 2006; Sandri, 2010). Expression of the transcription factor 
FoxO3 is sufficient and required to activate the lysosomal-dependent protein degradation 
and this pathway is activated by the lack of insulin or essential amino acids (Lecker et al., 
2006; Sandri, 2010).  
 
A substantial body of evidence has accumulated implicating the UPP as the major 
regulator of myofibrillar protein degradation leading to skeletal muscle atrophy (Murton 
et al., 2008). However the UPP is unable to degrade intact myofibrils therefore initial 
disruption of the intact sarcomeric proteins is catalyzed by calpains and to a lesser extent 
caspases which targets proteins (nebulin, titin and desmin) involved in the correct 
assembly of the myofilaments to the sarcolemma (Costelli et al., 2005). Following 
calpain degradation of the sarcomere structure, the contractile proteins are released and 
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available for UPP protein degradation (Figure 1.15) (Costelli et al., 2005; Jackman and 
Kandarian, 2004; Murton et al., 2008). The UPP is an ATP dependent proteolytic system 
involving degradation of target proteins with substrates identified for degradation by the 
addition of ubiqutin (Ub) molecules. Ub is first bound to the Ub-activating enzyme (E1) 
via high-energy thioester bond. Ub is subsequently transferred to the Ub-conjugating 
enzyme (E2) and then conjugated to the target protein by an Ub-ligase enzyme (E3). This 
process is repeated until a minimum of four Ub monomers are covalently attached via 
lysine residue to the target protein at which time the 26S proteasome recognizes the 
protein and degrades it into short peptides via chymotrypsin-like, trypsin-like and 
caspase-like activities (Murton et al., 2008). Degradation of the protein fragments into 
individual amino acids is then completed by tripeptidyl-peptidase II and exopeptidases 
(Figure 1.15; Murton et al., 2008). 
 
The UPP is constantly degrading damaged proteins to maintain normal cellular function. 
Target specificity of this system is established through hundreds of Ub-ligases (Murton et 
al., 2008). Muscle RING Finger 1 (MuRF-1) and Muscle Atrophy F-box 
(MAFbx/atrogin-1) represent two skeletal muscle specific Ub-ligases which are regulated 
by forkhead box proteins as well as other transcriptional factors and responsible for the 
UPP mediated myofibrillar protein degradation associated with atrophy (Figure 1.16) 
(Otto and Patel, 2010). In all catabolic conditions evaluated, there is a common 
transcriptional induction of MuRF1 and atrogin-1 as well as other components of the 
proteasome (Figure 1.13) (Lecker et al., 2006; Sandri et al., 2010). Importantly, these 
ubiqutin ligases are the rate-limiting step in the ubiquitination reaction and increased 
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expression is sufficient to enhance protein degradation via UPP (Lecker et al., 2006; 
Sandri et al., 2010). Although there is strong evidence indicating a role for MuRF-1 and 
MAFbx in muscle atrophy the specific protein targets are still under investigation. MaFbx 
targets myogenic transcription factors (myogenin and MyoD) and the elongation 
initiation factor 3 subunit 5 which suggests a role in affecting muscle growth and protein 
synthesis (Figure 1.16) (Foletta et al., 2011). In contrast, MuRF-1 preferentially interacts 
with structural proteins including myosin heavy chain, myosin binding protein C, myosin 
light chains, titin and creatine kinase (Figure 1.16) (Foletta et al., 2011). MuRF-1 has also 
been reported to interact with glucose production and glycogen metabolism, however it is 
unknown whether proteins in these pathways are degraded (Figure 1.16) (Foletta et al., 
2011). Thus, MuRF-1 may act to control protein degradation and muscle energy 
metabolism. Collectively, transcriptional induction of the UPP typically leads to 
increased protein degradation along with a reduction in protein synthesis. 
 
As described above, the multinucleated nature and plasticity of myofibers enables this 
cell type to adapt to a variety of catabolic signals, including environmental and nutrient 
changes as well as toxic insults, by reducing muscle mass through processes like 
autophagy, atrophy and apoptosis. While these normal physiological processes represent 
adaptive cellular survival responses initiated to maintain cellular homeostasis, chronic 
stimulation or dysregulation of these pathways leads to excessive protein degradation and 
myofiber degeneration (Masiero and Sandri, 2010; Motojima et al., 2002; 2003; Nishida 
et al., 2009; Sandri et al., 2010). Additionally, if there is impairment in ATP synthesis, 
preventing myofibers from adapting to the toxic insult, these survival pathways will fail 
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and necrosis will ensue (Orrenius et al., 2011; Zong and Thompson, 2006). Therefore, a 
variety of factors including type of exposure and duration of a toxic insult as well as 
whether pathways involved with energetics are affected ultimately dictates the cellular 
fate of myofibers.  
 
Apoptosis is characterized morphologically by pyknosis, nuclear fragmentation and 
formation of condensed bodies. This ordered morphology depends on the ability of the 
dying cell to invoke ATP-dependent processes required for self degradation (Zong and 
Thompson, 2006). In contrast, necrosis is defined morphologically by electron-lucent 
cytoplasm, swelling of organelles, collapse of internal homeostasis which occurs when a 
cells is unable to produce sufficient ATP causing bioenergetic failure and rapid loss of 
plasma membrane integrity (Bursch et al., 2008; Zong and Thompson, 2006). Apoptosis 
is widely regarded as an active or programmed form of cell death whereas necrosis is 
considered uncontrolled or pathological. Despite the notion that necrosis is uncontrolled, 
accumulating evidence suggests this may not be completely accurate (Zong and 
Thompson, 2006). Instead it appears that necrosis can also regulate events that contribute 
to maintenance of tissue homeostasis (Zong and Thompson, 2006). Necrosis may in fact 
provide cells with an adaptive advantage over apoptosis because it enables an active 
recruitment of a proinflammatory defensive response and an activation of a satellite cell 
reparative process to damaged tissue which may otherwise compromise the integrity of 
the organism as a whole. In fact, similar to apoptosis, a myonuclear domain within a 
myofiber may undergo necrosis while the remaining portion of the cell remains viable. It 
is now believed that in response to a specific toxic insult a continuum of pathological 
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changes occurs with processes like atrophy, autophagy and apoptosis prevailing at low 
doses and necrosis at high doses, and features of both may also coexist within the same 
myofiber (Orrenius et al., 2011; Zong and Thompson, 2006). Similarly, it is believed that 
chronic stimulation of these pathways, characterized by excessive protein degradation 
may lead to myofiber degeneration (Masiero and Sandri, 2010; Motojima et al., 2002; 
Motojima and Seto, 2003; Nishida et al., 2009; Sandri et al., 2010). Regardless of the 
toxic insult, several common pathways including increased mitochondrial reactive 
oxygen species production, channel-mediated calcium uptake, activation of non-apoptotic 
proteases and rapid loss of cellular membrane potential lead to energetic failure which 
triggers necrosis (Zong and Thompson, 2006). Often times, these necrotic mediators are 
induced in the dying cell simultaneously and potentiate each other‟s ability to initiate 
necrosis.  
 
1.8. Role of HMG-CoA reductase in skeletal muscle cholesterol 
homeostasis 
 
All nucleated cells can synthesize cholesterol from acetyl-CoA through the mevalonate 
pathway. However the rate of cholesterol biosynthesis in rat skeletal muscle is less than 
1% of the liver, and significantly less than other major organs (Spady and Dietschy, 
1983). Furthermore, skeletal muscle shows the lowest uptake of LDL-C compared to 
other major organs and the rate of cholesterol synthesis in skeletal muscle does not 
respond to fluctuations in plasma LDL-C levels like other organs (Stange and Dietschy, 
1984; Turley et al., 1981). The mechanistic basis for this unique tissue-specific regulation 
of cholesterol is unknown but may be related to the fact that skeletal muscle is 
predominately comprised of post-mitotic cells which have a theoretical lifespan equal to 
40 
 
the organism. Accordingly, under normal physiological conditions differentiated adult 
myofibers may have a reduced need for synthesizing cholesterol compared to other 
tissues. The liver regulates cholesterol levels in the blood and would therefore be 
expected to show greater flux in this pathway compared to skeletal muscle. Furthermore, 
tissues undergoing a high cellular turnover rate would have a greater cholesterol need for 
membrane synthesis compared to skeletal muscle. In contrast, adult myofibers would 
only be expected to have an increased need for cholesterol during development and 
differentiation, hypertrophy or repair from injury since these processes require membrane 
synthesis. Evidence to support this hypothesis is based on the observation that HMG-
CoA reductase activity is critical for myogenesis and it has been demonstrated that 
inhibition of this enzyme results in a decrease in myogenin and myosin heavy chain 
proteins, considered early and late markers, respectively of myoblast differentiation and 
also prevents myoblast fusion into multinucleated syncitia (Martini et al., 2009). HMG-
CoA reductase is upregulated at an early stage of myogenesis and downregulated at the 
later stage of differentiation (Martini et al., 2009). At the early stage, the increase in 
HMG-CoA reductase protein levels are related to transcriptional induction and decreased 
enzyme degradation whereas the subsequent decrease is mediated by a reduction in 
transcription and increased protein degradation (Trapani et al., 2010).    
 
There is a strong correlation between cholesterol absorption and synthesis, and increases 
in skeletal muscle mass associated with resistance training (Riechman et al., 2009; 
Vinagre et al., 2007). This increase in cholesterol is important in membrane biosynthesis 
during the recovery and adaptation resulting in skeletal muscle hypertrophy (Riechman et 
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al., 2009). Furthermore, skeletal muscle damage resulting from various diseases like 
Muscular Dystrophy and Inclusion Body Myositis as well as statin-induced myopathy are 
associated with increases in skeletal muscle cholesterol or transcriptional induction of 
HMG-CoA reductase and the LDL receptor, suggesting this pathway is involved with 
repair of the damaged tissue (Jaworska-Wilczynska et al., 2002; Kuhn et al., 1990; 
Morikawa et al., 2005; Paiva et al., 2005; Riechman et al., 2009; Sidaway et al., 2009; 
Totsuka and Watanabe, 1982; Yokoyama et al., 2007). Together, these studies 
demonstrate that skeletal muscle regulation of cholesterol synthesis and uptake is 
different from other tissues like the liver. Furthermore, in skeletal muscle, cholesterol 
synthesis and uptake is most important during processes like development and 
differentiation, hypertrophy and repair from injury which require an increase in 
membrane synthesis. 
 
1.9. Proposed mechanisms of statin-induced myopathy  
Despite extensive research efforts, the underlying pathophysiology of statin myopathy 
remains unknown, but suggested mechanisms include decreased production of prenylated 
proteins, ubiquinone, and cholesterol, increased skeletal muscle uptake of cholesterol or 
phytosterols, mitochondrial dysfunction, changes in energy metabolism, catabolism of 
muscle proteins via UPP, disruption of calcium metabolism, and vitamin D deficiency 
(Buettner and Lecker, 2008; Draeger et al., 2006; Guis et al., 2006; Gupta and Thompson, 
2011; Hanai et al., 2007; Marcoff and Thompson, 2007; Mallinson et al., 2009; Schaars 
and Stalenhoef, 2008; Paiva et al., 2005; Phillips et al., 2002; Phillips and Haas, 2008; 
Thompson et al., 2003; Urso et al., 2005; Vaklavas et al., 2009; Yokoyama et al., 2007). 
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Given the biochemical relationship between these processes it is likely that many of these 
events contribute to or potentiate the underlying mechanism of statin myopathy. 
However, identifying the exact cascade of events initiating myotoxicity from the 
published literature is difficult because of conflicting results from in vivo and in vitro 
studies, conducted with a variety of different skeletal muscle cell lines lacking a fiber 
specific phenotype, and with drug concentrations that are often not biologically relevant. 
Furthermore, data favoring one etiology over another are largely based on cell culture 
experiments or acute studies in rodents given a toxicological dose which may not reflect 
the mechanism in humans with a chronic pharmacological statin dose (Antons et al., 
2006). 
 
The most compelling evidence suggests that statin myopathy is directly related to HMG-
CoA reductase inhibition as mevalonate supplementation prevents in vivo and in vitro 
myotoxicity (Flint et al., 1997a; Johnson et al., 2004; Nishimoto et al., 2003; Westwood 
et al., 2005). Further evidence that a mevalonate pathway deficiency may be responsible 
for muscle injury is based on the observation that an inborn error of metabolism resulting 
in mevalonate kinase deficiency causes myopathy (Buettner and Lecker, 2008). More 
specifically, statin-induced mevalonate deficiency is believed to cause depletion of 
isoprenoids and in vitro studies have demonstrated that statin-induced myotoxicity is 
ameliorated by supplementation with the isoprenoid geranylgeranyl (Cao et al., 2009; 
Flint et al., 1997a; Johnson et al., 2004; Sakamoto et al., 2007, 2011; Tanaka et al., 2010). 
In vitro studies conducted with a variety of cell types, including muscle, indicate that 
inhibition of protein isoprenylation with either selective inhibitors or depletion of 
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isoprenoids leads to an accumulation of unprocessed intracellular proteins and apoptosis 
(Flint et al., 1997a; Johnson et al., 2004; Matzno et al., 2005; Nakagawa et al., 1998; 
Ostrowski et al., 2007; Repko and Maltese., 1989; Sakamoto et al., 2007; Xu et al., 
2005).  
 
Despite some compelling evidence from cultured myotubes, the link between isoprenoid 
depletion and statin-induced apoptosis has not been empirically demonstrated in vivo. 
Furthermore, in both clinical and preclinical studies, statins induce vacuoles and 
degenerated organelles followed by necrosis (Bergman et al., 2003; Chucrallah et al., 
1992; Waclawik et al., 1993; Westwood et al., 2005). Accordingly, there is a discrepancy 
between the in vitro (apoptosis) and in vivo (necrosis) pathophysiology. To reconcile 
these differences, Sakamoto et al (2007) conducted experiments with isolated rat skeletal 
fast-twitch myofibers. In these terminally differentiated muscle cells, statins caused a 
time- and concentration-dependent toxicity which was prevented with the co-application 
of geranylgeranylpyrophosphate (GGPP). The ultrastructural changes with statins were 
similar to those described for clinical and preclinical studies, with vacuole formation 
lining the sarcolemma and in the perinuclear region and swelling of organelles (Sakamoto 
et al., 2007). These results suggest that primary myofibers may be the most appropriate in 
vitro model for investigating statin myotoxicity.  
 
Given that Rabs play an important role in intracellular membrane transport and are 
prenylated by GGPP, Sakamoto et al (2007) hypothesized that Rab GTPase inhibition 
may cause statin-induced vacuolation similar to the in vivo findings (Grosshans et al., 
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2006; Leung et al., 2006). To test this hypothesis, primary rat skeletal fast-twitch 
myofibers were treated with the Rab geranylgernayl transferase inhibitor perillyl alcohol. 
Treatment related myofiber vacuolation developed similar to the in vivo findings, 
suggesting that inactivation of Rab GTPases resulting from isoprenoid depletion may be 
involved with statin-induced vacuolation and toxicity. More recently, Sakamoto et al., 
(2011) demonstrated that suppression of Rab1 GTPase function and subsequent inhibition 
of ER-to-Golgi traffic are involved in statin-induced myotoxicity. While the exact 
relationship between geranylgeranyl depletion and myopathy has yet to be established the 
isoprenoids are important in GTPase function and intracellular vesicular transport 
therefore these processes represent potential targets.  
 
Geranylgeranylation is also required for ubiquinone synthesis and its reduction following 
statin treatment led to the ubiquinone depletion hypothesis of myopathy proposed in the 
1990s (Folkers et al., 1990; Willis et al., 1990). While statins decrease serum ubiquinone, 
muscle levels are unchanged and mitochondrial respiration is unaffected both in vitro and 
in vivo (Hargreaves et al., 2005; Johnson et al., 2004; Laaksonen et al., 1995; Marcoff et 
al., 2007; Nakahara et al., 1998: Phillips et al., 2010; Schaefer et al., 2004; Yamazaki et 
al., 2006). Moreover, ubiquinone supplementation has no effect on the risk of statin-
induced myopathy, thereby casting doubt on the role of ubiquinone in mediating statin-
induced myopathy (Levy and Kohlhaas, 2006). Additional geranylgeranylated products 
are important for skeletal muscle function and inhibition of any of these modifications by 
statins could underlie the mechanism of myotoxicity. Specifically, N-linked glycosylated 
proteins, like -dystroglycan play a central role in the dystrophin-glycoprotein complex 
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which requires polyprenylated dolichol for its modification (Buettner and Lecker, 2008). 
Despite these theoretical mechanisms of toxicity, no studies have been performed which 
directly determine the involvement of these modifications in statin myopathy.   
 
Cholesterol modulates membrane fluidity and changes in the ratio of cholesterol and 
phospholipids can significantly alter membrane properties, including ionic channels like 
sodium, potassium, chloride and membrane excitability (Sirvent et al., 2008). The 
mechanism of statin-induced myopathy was initially thought to involve depletion of 
cholesterol in skeletal muscle membranes (London et al., 1991). However, in vitro studies 
conducted with myoblasts from various species indicate that myotoxicity is likely 
unrelated to decreased cholesterol synthesis because neither squalane synthase nor 
squalane epoxidase inhibitors induce myotoxicity and statin-induced toxicity is 
unaffected by squalane supplementation (Flint et al., 1997b; Johnson et al., 2004; 
Nishimoto et al., 2003). Furthermore, while cholesterol synthesis is reduced, the actual 
levels of cholesterol are not decreased in skeletal muscle following statin therapy, thereby 
casting doubt on this mechanism (Draeger et al., 2006; Masters et al., 1995; Morikawa et 
al., 2005; Phillips et al., 2010; Trapani et al., 2011). However, this does not preclude 
differences in cholesterol content in some subcellular organelles, like the T-tubules that 
might be especially vulnerable to cholesterol depletion (Draeger et al., 2006). In contrast 
to statin-induced reduction in cholesterol, several in vivo studies have demonstrated that 
statin treatment actually increases the LDL-C receptor, cholesterol, plant sterols and lipid 
vacuoles in skeletal muscle and these changes precede myopathy (Paiva et al., 2005; 
Phillips et al., 2002; Phillips et al., 2010; Sakamoto et al., 2007; Trapani et al., 2011; 
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Waclawik et al., 1993; Westwood et al., 1993; Yokoyama et al., 2007). Skeletal muscle 
from statin treated patients with myalgia and normal CK have been described 
histologically as containing extensive lipid-filled vacuoles within the myofibers (Phillips 
et al., 2002). Similar vacuoles accumulate between myofibrils in statin treated rats and 
mice and this effect precedes myopathy (Sakamoto et al., 2007; Waclawik et al., 1993; 
Westwood et al., 2005; Yokoyama et al, 2007). It is unclear whether these changes are 
causally related to myopathy or simply a reflection of the hyperabsorption of sterols 
associated with statin use. The accumulation and abnormal localization of free cholesterol 
adversely effects cellular functions and can lead to cell death (Cui et al., 2002; Ikonon, 
2006, 2008; Ridgway et al., 1999; Warner et al., 1995). More specifically, fiber-specific 
perturbations in lipid and sterol metabolism have been demonstrated as part of the 
pathophysiology of muscle related disorders (Bruno and DiMauro, 2008; Hegarty et al., 
2003; Jaworska-Wilczynska et al., 2002; Sher et al., 2006; Sprott et al., 2000).  
 
Mitochondrial toxicity has been suggested as a mechanism of statin-induced myotoxicity. 
In patients treated with statins, the lactate/pyruvate ratio is increased suggesting impaired 
mitochondrial function (De Pinieux et al., 1996). Furthermore, a reduction in 
mitochondria, respiration, ATP and impaired mitochondrial function has been reported 
with statin treatment (Hubal et al., 2011; Kaufmann et al., 2006; Nishimoto et al., 2003; 
Phillips and Haas, 2008; Sirvent et al., 2008). Additionally, many patients with statin 
myopathy show an increase in urinary 3-methyglutaconic acid which is associated with 
mitochondrial disorders deficient in oxidative metabolism (Phillips and Haas, 2008). 
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However, whether these changes are initiating events or simply a biomarker of effects 
remains unknown.  
 
Several lines of evidence indicate mitochondrial deficiency may result from changes in 
impaired muscle energetics with statin treatment (Phillips and Haas, 2008). Recently, it 
was demonstrated that creatine supplementation prevents statin-myopathy in patients 
(Shewmon and Craig, 2010). Creatine is a kinetically limiting acceptor that controls 
mitochondrial respiration. Therefore, decreased intramuscular creatine could be involved 
with statin-induced mitochondrial deficiency. While muscle creatine levels have not been 
evaluated, urinary levels are markedly increased with statin treatment which is consistent 
with the notion that intramuscular creatine may be reduced (Aranibar et al., 2011). While 
the exact target of altered energy metabolism with statins is unknown these drugs have 
been shown to reduce fatty acid oxidation in skeletal muscle, and muscle biopsies often 
have deficiencies in carnitine palmityl transferase, respiratory chain enzymes or carnitine 
which would impair fatty acid oxidation (Fisher et al., 2007; Phillips and Haas, 2008; 
Phillips et al., 2009). Impaired carbohydrate oxidation is also associated with statin 
myopathy (Mallinson et al., 2009; Motojima and Seto, 2003; Phillips and Haas, 2008). 
Specifically, muscle glycogen content increases with statin treatment indicating glycogen 
oxidation is suppressed (Mallinson et al., 2009). Moreover, statin treatment causes an 
increase in skeletal muscle pyruvate dehydrogenase kinase 2 and 4 which indicates 
suppression of glycolysis and shunting of energy metabolism from glucose to an 
alternative source (Mallinson et al., 2009; Motojima and Seto, 2003). Consistent with an 
impairment in glycolysis and fatty acid oxidation, statin therapy upregulates the muscle 
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atrophy program including atrogin-1, MuRF1 and autophagy, with an increase in protein 
degradation and reduction in protein synthesis (Araki and Motojima, 2008; Aranibar et 
al., 2011; Hanai et al., 2007; Mallinson et al., 2009; Tuckow et al., 2011; Urso et al., 
2005; Vassallo et al., 2011). While transcriptional induction of the muscle atrophy 
program is dependent on geranylgeranyl depletion it is unknown whether this is a direct 
effect or an epiphenomenon reflecting impaired substrate (glucose and fatty acid) 
oxidation similar to fasting (Cao et al., 2009; Jagoe et al., 2002; Phillips and Haas, 2008).  
 
In addition to an adaptive response involving muscle atrophy, statin treatment leads to 
fiber switching from a fast- to a slow-twitch phenotype (Hanai et al., 2007; Trapani et al., 
2011). PPARγ coactivator 1α (PGC-1α) functions as a metabolic sensor initiating an 
adaptive response characterized by mitochondrial biogenesis and transformation of fast-
twitch muscle into a more oxidative phenotype (Lin et al., 2002). PGC-1α is 
transcriptionally induced with statin treatment, and overexpression in rodents protects 
against statin myopathy (Hanai et al., 2007; Vassallo et al., 2011). Consistent with this 
transformation, skeletal muscle from statin treated rats demonstrates a shift in myosin 
heavy chain isoform expression toward a slower phenotype (Trapani et al., 2011). 
Collectively, these investigative studies demonstrate that fast-twitch muscles are uniquely 
sensitive to statin-induced myopathy, and this effect may be related to fiber differences in 
mitochondrial content and energetics (Phillips and Haas, 2008). However, it is important 
to note that muscle toxicity, secondary to lipid-lowering, is not exclusive to statins. 
Rhabdomyolysis has been described with fibrates, niacin and ezetimibe and patients 
sensitive with one lipid lowering agent show myotoxicity with the other agents (Phillips 
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and Haas, 2008). Therefore, the most plausible mechanism to explain why such diverse 
therapies cause a similar myotoxicity is that lipid lowering is toxic to muscle energetics 
in some patients (Phillips and Haas, 2008). 
 
Statin-induced calcium dysregulation has also been proposed as a potential mechanism of 
myopathy (Dirks and Jones, 2006; Sirvent et al., 2008). In L6 myoblasts and primary 
human skeletal muscle cells, statins cause an increase in cytosolic calcium and apoptosis 
(Sacher et al., 2005). Altered calcium homeostasis has also been observed in rat muscle 
following statin treatment (Liantonio et al., 2007). It is believed that an alteration in 
isoprenoid synthesis is responsible for a cytosolic increase in calcium levels which 
activates calpains and mitochondrial-mediated apoptosis however this has never been 
empirically demonstrated (Dirks et al., 2006; Sirvent et al., 2008).   
 
Bioactive vitamin D or calcitriol is a steroid hormone that plays an important role in 
regulating body levels of calcium and phosphorus (Gupta and Thompson, 2011). In 
skeletal muscle, vitamin D regulates several processes, including calcium uptake which 
controls contraction and relaxation and phosphate uptake which regulates energy 
metabolism and causes a mitogenic effect in proliferating myoblasts (Gupta and 
Thompson, 2011). While the human body can synthesize vitamin D in the skin from sun 
exposure, it is still considered a vitamin since many people do not synthesize sufficient 
vitamin D and thus requires an exogenous source (Gupta and Thompson, 2011). 
Cholesterol is synthesized to 7-dehydrocholesterol (7-DHC) endogenously which is then 
converted to vitamin D3 in the skin by ultraviolet B light. Dietary sources are in the form 
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of vitamin D2 from plants and vitamin D3 from animals and these two forms are 
considered equivalent and interchangeable (Gupta and Thompson, 2011). Vitamin D2 
and D3 are converted to the major circulating forms by CYP3A4  hepatic 25-hydroxylase 
activity (Gupta and Thompson, 2011).  
 
Vitamin D deficiency causes myopathy in fast-twitch muscles and supplementation 
ameliorates these effects (Ceglia, 2008; Gupta and Thompson, 2011). Several clinical 
studies have linked vitamin D deficiency with statin myopathy and a resolution of this 
effect with supplementation (Ahmed et al., 2009; Duell and Connor, 2008; Glueck et al., 
2011; Gupta and Thompson, 2011). While these studies indicate vitamin D deficiency 
potentiates statin-induced myalgia in a subset of patients, a causal association has not 
been demonstrated. Several mechanisms have been proposed regarding the role of 
vitamin D deficiency as causal in statin myopathy (Gupta and Thompson, 2011). 
Specifically, a deficiency may reduce vitamin D receptors resulting in altered calcium 
and phosphate regulation in skeletal muscle. Additionally, CYP3A4 metabolizes vitamin 
D as well as statins (Gupta et al., 2004). Therefore, vitamin D deficiency may shunt 
CYP3A4 25-hydroxylase activity to increase circulating vitamin D levels thereby 
reducing metabolism of statins causing higher exposure levels (Gupta and Thompson, 
2011).   
 
1.10. Predisposing factors of statin-induced myopathy 
While the mechanism of statin-induced myopathy remains unknown, a variety of 
endogenous and exogenous factors have been identified which predispose patients to this 
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adverse effect (Table 1.3) (Buettner and Lecker, 2008; Fernandez et al., 2011; Phillips 
and Haas, 2008). Patients with a variety of disorders affecting energy metabolism 
including muscle myophosphorylase deficiency, carnitine palmityl transferase deficiency 
and myoadenylate deaminase deficiency are prone to rhabdomyolysis which occurs when 
the energy metabolism demands of the muscle exceed flux through the compromised 
metabolic pathway (Phillips and Haas, 2008).   
 
The risk of myopathy also increases with drug concentration and a variety of 
physicochemical and pharmacokinetic factors are known to contribute to the systemic 
exposure level of statins (Table 1.3) (Fernandez et al., 2011; Rosenson, 2004). In general, 
the pharmacokinetics of statins are associated with their physicochemical properties 
(Table 1.4). HMG-CoA reductase inhibitors are administered as either a prodrug, with a 
lactone ring or as the biologically active open acid hydrophilic form (Shitara and 
Sugiyama, 2006). The intestinal absorption and hepatic uptake of lipophilic and 
hydrophilic statins are predominately mediated by passive diffusion and transporters, 
respectively (Shitara and Sugyama, 2006). While lipophilicity enables efficient hepatic 
uptake, this property also allows the drug to permeate the plasma membrane, and this 
effect is considered an important determinant of skeletal muscle injury (Shitara and 
Sugyama, 2006). However, since the distribution of a lipophilic statin is 500-times 
greater in the liver compared to skeletal muscle it is likely that other factors contribute to 
myotoxicity (Seachrist et al., 2005; Sidaway et al., 2009; Steinke et al., 1996). The 
hydrophilic statins are unable to passively diffuse into the liver or skeletal muscle. 
However, a variety of organic anion-transporting polypeptides (OATP) mediate statin 
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uptake in the liver and skeletal muscle, and OATP1B1 polymorphisms have been 
identified which are strongly associated with an increased risk of statin-induced 
myopathy (Kivisto et al., 2007; Sakamoto et al., 2008; Shitara and Sugiyama, 2006; The 
SEARCH Collaborative Group, 2008).   
 
The metabolism of statins occurs by the cytochrome P450 (CYP) isozymes 3A and 2C 
(Table 1.4; Shitara and Sugyama, 2006). As such, co-administered drugs which are 
metabolized by these enzymes may serve as competing substrates for statins, thereby 
increasing the systemic exposure, and risk of myopathy (Shitara and Sugiyama, 2006). 
Approximately 60% of lipophilic statin-induced rhabdomyolysis cases are related to 
interaction with drugs known to inhibit CYP3A4 which increase the systemic exposure of 
the statin (Table 1.4; Law et al., 2006). Many of the hydroxyl acid forms of statins are 
glucuronidated and agents which inhibit glucuronidation may also increase the 
concentration of these drugs and the potential risk of myopathy (Rosenson, 2004). 
Additionally, since the acid and lactone structures interconvert, the extrahepatic cellular 
processes affecting the equilibrium of these two forms may be an important determinant 
in mediating skeletal muscle injury (Blankenberg Skottheim et al., 2008). 
 
In general, statins are rapidly eliminated (Table 1.4; half-life of 2-3 hours) with fecal and 
urinary excretion representing the major and minor excretion routes, respectively 
(Bischoff et al., 1998; Shitara and Sugiyama, 2006). As such, disorders affecting renal 
function or biliary excretion can increase the circulating concentration of these drugs and 
the potential for myopathy (Rosenson, 2004; Smith et al., 1991). Several efflux 
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transporters have been shown to transport statins and their expression is modulated 
during therapy with these drugs (Shitara and Sugiyama, 2006; Wong et al., 2008). 
Furthermore, nutritional status has also been shown to influence the adverse effects of 
statins by increasing systemic exposure through modification of transporters involved 
with hepatic uptake and elimination (Sugatani et al., 2010).   
 
Cerivastatin is often used as a model compound for investigating the mechanism of 
statin-induced myopathy because it showed the highest incidence of rhabdomyolysis 
compared to other drugs in this class (Table 1.5; Cziraky et al., 2006). As discussed 
above, several factors are important in contributing to statin-induced myopathy and co-
administration of cerivastatin with the fibrate gemfibrozil highlights the importance of 
systemic exposure (Kaspera et al., 2010; Noe et al., 2007). Cerivastatin is unique from 
the other statins in that it is primarily metabolized by CYP2C8 instead of CYP3A4 (Table 
1.4). Furthermore, cerivastatin is glucuronidated by UDP-glucuronosyl transferase 
(Kaspera et al., 2010). Gemfibrozil inhibits CYP2C8 and UGT-mediated glucuronidation, 
and its glucuronide (gemfibrozil glucuronide) is a mechanism based inhibitor of CYP2C8 
(Kaspera et al., 2010). Moreover, liver uptake of statins occurs by OATP1B1 which is 
inhibited by gemfibrozil (Noe et al., 2007). Accordingly, these factors are considered 
partially responsible for the increased systemic exposure and incidence of 
rhabdomyolysis associated with co-administration of cerivastatin and gemfibrozil 
(Kaspera et al., 2010; Noe et al., 2007). 
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Although the mechanism of statin-induced myopathy remains to be determined, there is 
substantial evidence indicating this is an on-target effect in which fast-twitch muscles are 
most sensitive. However, the fact that most patients do not experience skeletal muscle 
toxicity with statin therapy suggests HMG-CoA reductase inhibition is necessary but not 
sufficient for the development of toxicity. Accordingly, predisposing factors, like being 
female, increasing age and underlying metabolic muscle disorders affecting energy 
metabolism have been identified. Together, these risk factors indicate that statin-induced 
myopathy may be mediated in part by alterations in skeletal muscle energy metabolism, 
which is regulated in a fiber-, sex- and age-dependent manner. Collectively, these data 
demonstrate a variety of factors can increase the risk of developing statin-induced 
myopathy, with increased systemic exposure representing one of the most important. 
However, cerivastatin is an unusual statin because it had the highest incidence of 
rhabdomyolysis which eventually led to its removal from the market (Table 1.5; Cziraky 
et al., 2006).  
 
1.11. Experimental models used for investigating mechanisms of 
myopathy 
 
The rat is an ideal model for investigating mechanisms of statin myopathy because the 
dosing paradigm and time course for the development of injury are well defined, 
reproducible and considered predictive of the human response (Schaefer et al., 2004; 
Seachrist et al., 2005; Westwood et al., 2005). In the rat, simvastatin and cerivastatin, 
representative hydrophilic and lipophilic statins, cause a dose-dependent myopathy after 
10 days of dosing in fast-twitch muscle fibers whereas slow-twitch fibers are unaffected 
(Figure 1.17) (Schaefer et al., 2004; Seachrist et al., 2005; Westwood et al., 2005). The 
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rat is also considered an ideal model for studying mechanisms of fiber specific toxicity 
because individual skeletal muscles are homogenous, with the psoas consisting of 91% 
fast-twitch fibers and the soleus consisting of 84% slow-twitch fibers (Hamalainen et al., 
1993; Koerker et al., 1990). While it is believed that statins also preferentially target fast-
twitch muscles in humans the individual muscles are more heterogeneous in fiber 
composition than the rat (Zierath et al., 2004). Similar to humans, sex specific muscle 
injury is also observed in the rat, with females showing a greater incidence than males 
(Vassallo et al., 2009). Fiber- and sex-dependent myotoxicity in the rat is unrelated to 
differences in exposure or accumulation of statin in the muscle (Seachrist et al., 2005; 
Sidaway et al., 2009; Reinoso et al., 2002; Steinke et al., 1996). Therefore, the 
mechanism is likely dependent on biochemical and physiological properties of the female 
fast-twitch muscle and statin pharmacology as mevalonate supplementation prevents 
myopathy (Westwood et al., 2005).  
 
In general the rat is a useful model for studying mechanisms of statin-induced myopathy. 
However statins do not cause a hypocholesterolemic effect in this species (Fujioka et al., 
1995). Instead, with repeated dosing, hepatic HMG-CoA reductase is markedly induced 
and this compensatory effect results in increased serum cholesterol (Fujioka et al., 1995). 
Similarly, in the rat skeletal muscle, statin-induced myopathy causes a transcriptional 
induction of HMG-CoA reductase however this is not associated with increased enzyme 
activity since the IC50 (1-2 nM) is significantly less compared to the concentration (30 
nM) of cerivastatin (0.5 mg/kg) in the rat gastrocnemius (fast-twitch muscle) (Mullen et 
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al., 2010; Schaefer et al., 2004; Seachrist et al., 2005; Sidaway et al., 2009; Trapani et al., 
2011; Westwood et al., 2005).  
 
Several in vitro models, including rat derived L6, mouse derived C2C12 and human 
derived HSkMC skeletal muscle cells have also been used for studying mechanisms of 
statin-induced myopathy (Allen et al., 2005; Flint et al., 1997a, 1997b; Johnson et al., 
2004; Masters et al., 1995; Mullen et al., 2010; Nishimoto et al., 2003; Sacher et al., 
2005; Yamazaki et al., 2006). These cells are undifferentiated myoblasts which retain the 
ability in vitro to divide and differentiate into more specialized multinucleated myotubes 
expressing myofibrillar proteins representing a mixed fast- and slow-twitch phenotype 
(Allen et al., 2005; Ravenscroft et al., 2007). Conversion of myoblasts to myotubes 
(myogenesis) in vitro parallels the process observed in vivo following skeletal muscle 
damage in which the normally quiescent satellite cells begin proliferating, differentiating 
and fusing into multinucleated myotubes which replace the damaged muscle. While 
conversion of myoblast to myotubes is similar to the in vivo condition these cells never 
become fully differentiated myofibers. Therefore, while these in vitro models may be 
useful for studying mechanisms of toxicity it may be difficult to extrapolate mechanistic 
findings in vivo. 
 
A more relevant in vitro model has also been used in which fast- and slow-twitch muscles 
have been isolated from adult mice and rats and used for studying aspects of basic muscle 
physiology and pathophysiology of diseases (Bekoff and Betz 1977; Ravenscroft et al., 
2007; Sakamoto et al., 2008; Shefer and Yablonka-Reuveni, 2005). These post-mitotic 
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differentiated multinucleated myofibers maintain phenotypic characteristics of mature 
fast-twitch skeletal muscle cells for up to 10 days in culture (Ravenscroft et al., 2007). In 
contrast, other undifferentiated cell lines like the C2C12 myotubes are comprised 
predominately of proteins representing fetal isoforms (Ravenscroft et al., 2007). Recent 
efforts by Sakamoto et al (2008) have demonstrated the value in using this approach for 
investigating statin myopathy. Specifically, Sakamoto et al (2008) demonstrated that 
differentiated myofibers have functional Oatp1a4 and 2b1 transporters whereas these 
proteins are deficient in L6 myoblast. The LC50 value of fluvastatin myotoxicity in 
myofibers was 0.3 µM whereas it was 8.3 µM in L6 myoblast, an effect directly related 
to transporter expression in this differentiated phenotype (Sakamoto et al., 2008). 
 
1.12.  Assessment of drug-induced myopathy  
Since drug-induced rhabdomyolysis is a life threatening condition it is important to have 
biomarkers which can rapidly and accurately assess myopathy. Clinically, the diagnosis 
of drug-induced skeletal muscle injury is challenging because direct methods are invasive 
(biopsy) or difficult to interpret (e.g. magnetic resonance imaging), and indirect methods 
such as muscle soreness are subjective and commonly observed clinically with aging. 
Historically, several serological biomarkers including creatine kinase (CK) and aspartate 
aminotransferase (AST) have been used routinely to assess clinical and preclinical 
skeletal muscle injury (Bohlmeyer et al., 1994; Sorichter et al., 1999). However, these 
biomarkers have poor sensitivity, lack skeletal muscle specificity and are of limited 
diagnostic value (Bohlmyer et al., 1994; Sorichter et al., 1999; Vassallo et al., 2009). The 
ongoing need for reliable biomarkers of drug-induced skeletal muscle injury is 
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highlighted by the Critical Path Initiative‟s effort to identify new biomarkers which are 
skeletal muscle specific, sensitive to minimal injury and reflect reversibility during 
recovery from toxicity (Goodsaid et al., 2008). Ideal biomarkers should also be easily 
measurable, have a large dynamic range, long half-life and be translated to the clinic. 
Based on investigational studies, several potential skeletal muscle specific proteins 
including skeletal muscle troponin I (sTnI), myosin light chain 3 (Myl3), fatty acid 
binding protein 3 (FABP3), parvalbumin (Parva) and myoglobin (MB) meet these criteria 
and are currently under evaluation by the Critical Path Initiative (Table 1.5) (Arif, 2009; 
Berchtold et al., 1984; Berna et al., 2007; Bohlmeyer et al., 1994; Celio and Heizmann, 
1982; Dare et al., 2002; Lee and Vasan, 2005; Pritt et al., 2008; Schmitt and Pette, 1991; 
Simpson et al., 2005; Singh et al., 2005; Vanholder et al., 2000; Vassallo et al., 2009; 
Wilkinson and Grand, 1978). While these new biomarkers may enhance detection of 
drug-induced myotoxicity, there remains an ongoing interest to identify additional 
biomarkers which are more sensitive and specific than CK and AST. The life-threatening 
potential of statin-induced rhabdomyolysis provides an excellent example of where more 
sensitive and specific biomarkers would fulfill an unmet clinical need.   
 
1.13. Tools used for investigating mechanisms and biomarkers of 
myopathy 
 
Recent advances in investigative toxicology enable assessment of transcriptional and 
metabolic differences in fast- and slow-twitch muscles which may be important in the 
mechanism of statin-induced myopathy (Collings and Vaidya, 2008; Robertson et al., 
2011; Gatzidou et al., 2007; Xu et al., 2011). Transcriptomics is the quantitative 
evaluation of mRNA expression using microarrays which provides a genome-wide 
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perspective on the transcriptional effects associated with pathophysiological changes 
(Gatzidou et al., 2007). Metabolomics is a systems approach for studying in vivo 
metabolic profiles representing the total metabolite pool in biofluids or tissue extracts 
(Nicholson et al., 2002). This approach combines analytical technologies like nuclear 
magnetic resonance spectrometry (NMR) with statistics to provide a quantitative 
assessment of the metabolic response to pathophysiological changes (Gatzidou et al., 
2007; Nicholson et al., 2002). Together, these technologies provide an unbiased, 
comprehensive and ideally synergistic assessment of cellular perturbations in 
biochemical pathways which may be causally associated with a potential mechanism of 
toxicity. Furthermore, these tools have been useful in identifying new biomarkers of 
toxicity (Collings and Vaidya, 2008).  
 
1.14. Research objectives  
The major objective of this dissertation was to identify molecular and biochemical targets 
which are causally associated with the mechanism of cerivastatin-induced myopathy in 
the rat. To determine transcriptional and metabolite changes, global gene expression 
analysis and metabolomic profiling, respectively were conducted on skeletal muscles 
from rats in a cerivastatin dose response. Furthermore, gene expression analysis and 
metabolomic profiling were also conducted on naïve rats to define the fiber- and sex-
specific differences in skeletal muscles which may contribute to myopathy. Integration of 
these results led to the identification of a variety of changes, some of which were 
associated with the pathology, whereas others appeared causally related to the mechanism 
of toxicity. Therefore, based on these findings, specific hypotheses regarding modes of 
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toxicity were developed and investigated in a time course of cerivastatin-induced 
myopathy. Furthermore, a method for isolating and culturing primary rat fast-twitch 
differentiated myofibers was developed and used to further probe specific pathways 
causally related to the mechanism of cerivastatin-induced myopathy. An additional 
objective of this work was to identify biomarkers of drug-induced myopathy. To identify 
potential biomarkers, metabolomic profiling was conducted on urine collected from rats 
in the cerivastatin dose response study. These results led to the identification of two new 
potential biomarkers of drug-induced myopathy. To further determine the utility of these 
potential biomarkers in urine and serum investigative studies were conducted. Specific 
hypotheses for this research are described below. 
 
Hypothesis 1: Cerivastatin-induced myopathy in rats occurs in a fiber- and sex-
dependent manner which is recapitulated in isolated rat fast-twitch differentiated 
myofibers (Chapter 2). 
 
Hypothesis 2: Transcriptional profiles of skeletal muscles from rats are useful for 
identifying molecular targets causally related to the mechanism of cerivastatin-induced 
myotoxicity (Chapter 3).   
 
Hypothesis 3: Metabolomic profiles of skeletal muscles from rats are useful for 
identifying metabolic changes causally related to the mechanism of cerivastatin-induced 
myotoxicity (Chapter 4).  
 
Hypothesis 4: Cerivastatin-induced myopathy is causally related to alterations in 
cholesterol homeostasis (Chapter 5). 
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Hypothesis 5: Cerivastatin-induced myopathy is causally related to alterations in energy 
metabolism (Chapter 6). 
 
Hypothesis 6: Metabolomic profiling of urine is useful for identifying biomarkers of 
cerivastatin-induced myopathy (Chapter 7). 
 
Hypothesis 7: 3-Methylhistidine is a preclinical biomarker of drug-induced myopathy 
(Chapter 8). 
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Figure 1.1. HMG-CoA reductase inhibition by statins (Voet and Voet, 2005). HMG-
CoA reductase is the rate limiting step in cholesterol biosynthesis. The HMG-like moiety 
of statins occupies the HMG-binding pocket in the active site of the enzyme which 
competitively inhibits enzyme activity.  
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Figure 1.2. Domain structure of HMG-CoA reductase (DeBose-Boyd, 2008). HMG-
CoA reductase is composed of two distinct domains represented by an N-terminal 
hydrophobic membrane domain containing eight membrane spanning segments 
anchoring the protein to the endoplasmic reticulum and a C-terminal hydrophilic catalytic 
domain projecting into the cytosol.  
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Figure 1.3. Regulation of cholesterol metabolism (Ikonen, 2008). Intracellular 
accumulation of cholesterol leads to retention of the INSIG protein in the endoplasmic 
reticulum (ER) thereby preventing SREBP-SCAP transport to the Golgi by COPII-coated 
vesicles. In contrast, cholesterol deficiency results in transport of SREBP to the Golgi 
where it is cleaved by two proteases (S1P and S2P) and the transcription factor is 
transported to the nucleus where it binds the sterol-regulatory element (SRE) and induces 
sterol-regulated genes (e.g. HMG-CoA reductase and LDL-C receptor). HMG-CoA 
reductase is also post-transcriptionally regulated by sterols like lanosterol and 25-
hydroxycholesterol which causes proteasome degradation or ER retention, respectively. 
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Figure 1.4. Chemical structures of statins (Alegret and Silvestre, 2006; Shitara and 
Sugiyama, 2006; Sirtori, 1993). The HMG-CoA like moiety is common among all 
statins. However, both simvastatin and lovastatin are prodrugs as they contain an inactive 
close ring lactone whereas the other statins are administered as the active acid form. 
Structural differences in the statins contribute to their unique physicochemical and 
pharmacokinetic properties. 
 
 
 
mevastatin
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Figure 1.5. Products of the mevalonate pathway. Mevalonate is the precursor for 
numerous biologically relevant intermediates and statin-induced myopathy as well as the 
pleiotropic effects of these drugs have been associated with both farnesyl and 
geranylgeranyl depletion.  
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Figure 1.6. Satellite cell myogenesis following skeletal muscle damage (Zammit et 
al., 2006). Following skeletal muscle damage myogenic satellite cells initiate a genetic 
program to proliferate and differentiate into myotubes which repair the tissue by fusing 
with existing multinucleated myofibers.  
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Figure 1.7. Time course of changes in myeloid cell population (top) and expression 
of transcription factors involved with skeletal muscle regeneration (bottom; Tidball 
and Villalta, 2010). Following acute skeletal muscle injury, polymorphonuclear 
neutrophils (PMN) are recruited and then decline rapidly followed by invasion of M1 
phagocytic macrophages (Th1 response) and a gradual increase in nonphagocytic 
macrophages (Th2 response). Coincident with the invasion of myeloid cells, regeneration 
of skeletal muscle is initiated and dependent on the inflammatory response. 
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Figure 1.8. Skeletal muscle sarcomere (Marieb, 2000). The sarcomere is the functional 
unit of skeletal muscle which is responsible for transduction of chemical energy into 
mechanical work during muscle contraction. The sarcomere is composed of thick 
(myosin) and thin (actin) myofibrils held together by titin which provides a framework 
holding the contractile machinery in place. Calcium-mediated contraction is regulated by 
the concentration of calcium and dependent on troponin which is a loosely bound 
complex of three protein subunits (I, T and C) attached to tropomyosin in the thin 
filament. In a relaxed state, contraction is prevented because troponin T and I are bound 
to tropomyosin which blocks the attachments site for the myosin crossbridge. When the 
muscle is stimulated to contract by an action potential, the sarcoplasmic reticulum 
releases calcium which attaches to troponin C, causing a conformation change and 
exposing the site for myosin on the actin filament. When ATP is hydrolyzed, the actin 
filament bridges with and slides along myosin, contracting the sarcomere.  
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Figure 1.9. Organization of a skeletal muscle cell (Marieb, 2000). A skeletal muscle 
cell is surrounded by a plasma membrane (sarcolemma) and the cytoplasm (sarcoplasm) 
fills the space between the densely pack myofibrils. The mitochondria lie parallel to the 
myofibrils and provide ATP necessary for muscle contraction. The endoplasmic 
reticulum (sarcoplasmic reticulum) stores calcium which is released and sequestered 
when muscles are stimulated to contract and relax, respectively. The transverse tubule (T 
tubule) is an invagination in the sarcolemma containing L-type calcium channels which 
represent the major site for the coupling of excitation and contraction. The L-type 
calcium channels in T tubules activate in response to electrical stimulation and allow 
calcium to flow down the electrochemical gradient and into the cell.  
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Figure 1.10. Photomicrographs of skeletal muscle. Longitudinal (A) and cross-section 
(B) of skeletal muscle illustrating the sarcoplasm (*), sarcolemma (↓), nuclei ( ), red 
blood cells (^) and alternating pattern of dark myosin (A) and light actin (I) bands (box). 
A B
*
*
^
^
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Figure 1.11. Metabolic pathways that supply energy for muscle contraction. Energy 
required for muscle contraction is supplied by ATP hydrolysis. Phosphocreatine 
represents the first source of energy to reconstitute ATP as it has a higher amount of free 
energy. However, once phosphocreatine is depleted the muscle relies on intermediary 
metabolism including glycolysis which utilizes glucose from stored glycogen. Oxidative 
metabolism including products of glycolysis, fatty acids and amino acids are considered 
the last source of energy but most important for sustained, long-term contraction.   
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Figure 1.12. Signaling pathways involved with skeletal muscle hypertrophy and 
atrophy (Otto and Patel, 2010). Skeletal muscle has a remarkable plasticity which 
enables it to adapt functionally, morphologically and metabolically to the ever changing 
stimuli like exercise, environmental conditions and substrate availability. Muscle 
hypertrophy (anabolism) and atrophy (catabolism) represent two mechanisms by which 
the myofiber can adapt. Although many signaling pathways are involved in these 
processes, regulation of protein synthesis and degradation are considered the most 
important. 
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Figure 1.13. Role of autophagy and UPP in muscle atrophy during catabolic 
conditions like fasting (Rabinowitz and White, 2010). During normal physiology, 
skeletal muscle mass is maintained by tightly regulating protein degradation. However, 
during catabolic conditions, skeletal muscle is considered a protein reservoir which is 
mobilized to maintain gluconeogenesis, protein synthesis, and to provide alternative 
energy substrates for preservation of critical organ function, including skeletal muscle. 
This adaptive survival response is mediated by the autophagy-lysosome pathway which 
degrades long-lived proteins and organelles whereas the UPP degrades myofibrillar and 
most soluble short-lived proteins. Paradoxically, dysregulation representing inhibition or 
excessive skeletal muscle protein degradation can exacerbate other catabolic conditions 
and lead to pathogenic mechanisms, myofiber degeneration, morbidity and mortality.    
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Figure 1.14. Autophagy and reutilization of products in biosynthetic pathways 
(Rabinowitz and White, 2010). During autophagy, mitochondria, ribosomes, 
peroxisomes, ER, ribosomes, lipid droplets, cytosolic proteins, glycogen and protein 
aggregates are engulfed into the autolysosome, degraded, and released into the cytoplasm 
for reutilization in biosynthetic pathways.  
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Figure 1.15. Degradation of sarcomere myofibrils by calpain and the UPP (Jackman 
and Kandarian, 2004). Calpains cause the release of myofibrils by degrading several 
proteins including nebulin, titin and desmin which are involved with sarcomeric 
assembly. The UPP degrades target proteins like the myofibrils with substrates identified 
by the addition of ubiqutin (Ub) molecules. Ub is first bound to the Ub-activating enzyme 
(E1) via high-energy thioester bond and is subsequently transferred to the Ub-conjugating 
enzyme (E2) where it is conjugated to the target protein by an Ub-ligase enzyme (E3). 
This process is repeated until a minimum of four Ub monomers are covalently attached 
via lysine residue to the target protein at which time the 26S proteasome recognizes the 
protein and degrades it into short peptides via chymotrypsin-like, trypsin-like and 
caspase-like activities (Murton et al., 2008). Degradation of the protein fragments into 
individual amino acids is then completed by tripeptidyl-peptidase II and exopeptidases. 
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Figure 1.16. Catabolic signaling pathways involved in atrogin-1 and MuRF-1 
regulation (Foletta et al., 2011). The catabolic signals and proposed physiological 
outcomes of the skeletal muscle specific ubiquitin ligases (atrogin-1 and MuRF-1) are 
shown (rodent, R; human, H). A variety of diseases and injuries function as catabolic 
signals to regulate gene expression of atrogin-1 and MuRF-1 via several transcription 
factors resulting in skeletal muscle myofibrillar protein degradation, decreased protein 
synthesis, altered glucose metabolism and muscle remodeling.    
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Figure 1.17. Histopathology of skeletal muscle from a cerivastatin treated rat. 
Histopathology of a fast-twitch muscle from (A) control and (B) cerivastatin (1 mg/kg; 
14 days) treated rat showing severe myopathy characterized by myofibril lysis, 
hyalinization and cellular infiltration. 
  
A B
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Table 1.1. Clinical characteristics of statin myopathy
a
 
Term Clinical description 
Myopathy Any muscle disease 
Myalgia Muscle symptoms characterized by weakness, soreness, 
stiffness, cramping, aching either at rest or with exertion 
without elevated creatine kinase 
Myositis Muscle symptoms with an elevation in creatine kinase less 
than 10-times the upper limit of normal. 
Rhabdomyolysis Muscle symptoms with an increase in creatine kinase level 
10-times the upper limit of normal or higher. 
a
Tomaszewski et al., 2011; Vaklavas et al., 2009 
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Table 1.2. Characteristics of skeletal muscle fiber types
ab
 
Characteristic 
Slow-twitch 
Oxidative 
(Type I) 
Fast-twitch 
Oxidative 
(Type IIA) 
Fast-twitch 
Glycolytic 
(Type IIB or IIX/D
b
) 
Contractile characteristics 
Time to peak tension 1.0 0.4 0.4 
Ca2+ myosin ATPase 1.0 3.0 3.0 
Mg2+ actomyosin ATPase 1.0 2.8 2.8 
Maximum duration of use Hours <30 min <1 to 5 min 
Fatigue resistance High Fairly high Low 
Enzyme activities 
Creatine phosphokinase 1.0 1.3 1.3 
Phosphofructokinase 1.0 1.5 2.1 
Glycogen phosphorylase 1.0 2.1 3.1 
Citrate synthase 1.0 0.8 0.6 
Morphological characteristics 
Size of motor neuron Small Medium Large 
Capillary density 1.0 0.8 0.6 
Mitochondrial density 1.0 0.7 0.4 
Metabolic properties 
Oxidative potential 1.0 0.7 0.2 
Glycolytic potential 1.0 1.5 2.0 
Phosphocreatine 1.0 1.2 1.2 
Glycogen 1.0 1.3 1.5 
Triacylglycerol 1.0 0.4 0.2 
Myosin heave chain (MYH) MYH7 MYH2 
MYH4 – IIb 
MYH1 – IIx/d 
a
Zierath et al., 2004 
b
Type IIB and IIX/D were used interchangeably in the early literature because of species 
differences and inconsistent nomenclature.
 
However, humans only express IIX/D even 
though these are generally referred to as IIB fibers (Scott et al., 2001). In contrast, both 
IIB and IIX/D are expressed in rodents (Scott et al., 2001). Type IIX/D have intermediate 
characteristics between IIB and IIA fibers (Scott et al., 2001). 
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Table 1.3. Risk factors for statin myopathy
a
 
Endogenous risks Exogenous risks 
Advanced age (>80 years) Alcohol consumption 
Low body mass index and frailty Heavy exercise 
Female sex Surgery with severe metabolic demands 
Renal and hepatic dysfunction Drugs inhibiting CYP3A4  
Thyroid disorders Cyclosporine 
Hypertriglyceridemia Fibrates 
Diet Nicotinic acid 
Diabetes Calcium channel blockers (e.g. verapamil) 
Carnitine palmityl transferase II deficiency Amiodarone 
McArdle disease (myophosphorylase deficiency) Azole antifungals 
Myoadenylate deaminase deficiency Colchine 
Family history of muscle symptoms Digoxin 
Personal history of elevated CK or muscle symptoms HIV protease inhibitors 
Statin properties Warfarin 
High systemic exposure Macrolide antibiotics 
Lipophilicity Corticosteroids 
High bioavailability and limited protein binding Consuming > 1 L of grapefruit per day 
a
Antons et al., 2006; Chatzizisis et al., 2010 
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Table 1.4. Pharmacologic and pharmacokinetic properties of statins in humans
a
 
Variable Atorvastatin Cerivastatin Fluvastatin Lovastatin Pravastatin Rosuvastatin Simvastatin 
LDL 
cholesterol 
reduction 
(dose range, 
mg) 
38-54% 
(10-80) 
25-44% 
(0.2-0.8) 
17-33% 
(20-80) 
29-48% 
(20-80) 
19-48% 
(20-80) 
52-63% 
(10-40) 
29-48% 
(10-80) 
IC50 purified 
human 
HMG-CoA 
reductase 
8 10 28 NA 44 5 11 
Elimination 
half-life (h) 
15-30 2.1-3.1 0.5-2.3 2.9 1.3-2.8 19 2.3 
Bioavailability 
(%) 
12 60 19-29 5 18 20 5 
Protein 
binding (%) 
80-90 >99 >99 >95 43-55 88 94-98 
Solubility Lipophilic Lipophilic Lipophilic Lipophilic Hydrophilic Hydrophilic Lipophilic 
Cytochrome 
P450 
metabolism 
3A4 3A4, 2C8 2C9 3A4 - 2C9 3A4, 3A5 
a
Alegret and Silvestre, 2006; Shitara and Sugiyama, 2006 
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Table 1.5. Incidence of rhabdomyolysis with all statins
a
 
 
a
Cziraky et al., 2006 
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Table 1.6. Biomarkers of skeletal muscle toxicity 
Biomarker Tissue specificity Matrix 
Creatine kinase
a
 Skeletal and cardiac muscle Serum 
Aldolase
b
 Skeletal muscle and liver Serum 
Aspartate aminotransferase
c
 Skeletal muscle and liver Serum 
Skeletal muscle troponin I
d
 Fast-twitch muscle Serum 
Myosin light chain 3
e
 Slow-twitch muscle Serum 
Fatty acid binding protein 3
f
 Slow-twitch and cardiac muscle Serum 
Parvalbumin
g
 Fast-twitch muscle Serum 
Myoglobin
h
 Skeletal and cardiac muscle Urine 
a
Apple et al., 1984; Pritt et al., 2008; 
b
 Lebherz and Rutter, 1969; 
c
Pritt et al., 2008; 
d
Mullen and Barton, 2000; Vassallo et al., 2009; 
e
Berna et al., 2007; 
f
Pritt et al., 2008; 
g
Arif, 2009; Schmitt and Pette, 1991; 
h
Weber et al., 2007 
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Chapter 2 
 
 
Characterization of experimental models of cerivastatin-
induced myopathy 
 
 
2.1. Introduction 
Investigative studies of statin-induced myopathy have been frequently conducted in the 
rat because the effects in this species are considered predictive of the human toxicity. The 
development of statin myotoxicity in rats occurs in a time- and dose-dependent manner 
with female rats and fast-twitch muscles showing the greatest sensitivity (Seachrist et al., 
2005; Vassallo et al., 2009; Westwood, et al., 2005). In general, the dosing paradigm 
necessary to induce statin myopathy is reproducible across rat studies. However the study 
duration and dose necessary to achieve this effect vary and are dependent on the specific 
statin and the strain of rat. Likewise, mechanistic in vitro studies have been routinely 
conducted in undifferentiated rat myoblasts and myotubes as well as in differentiated 
myofibers. However, similar to the in vivo studies the concentration and time necessary 
to achieve statin myotoxicity vary.  
 
The goal of this work was to establish the dosing paradigm which causes statin myopathy 
in Sprague-Dawley rats and in isolated differentiated fast-twitch myofibers. Primary fast-
twitch rat myofibers were used for the current in vitro work because these cells maintain 
a differentiated state in culture and express statin transporters, including Oatp1a4 and 
Oatp2b1, whereas myoblasts and myotubes are undifferentiated and lack expression of 
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these transporters (Ravenscroft et al., 2007; Sakamoto et al., 2008). For this work, the 
dose response, time course, sex- and fiber-specific toxicity were investigated with 
cerivastatin, a compound which has been commonly used for investigative studies 
because it is considered the most toxic statin which was withdrawn from the market 
because of rhabodmyolysis-related deaths (Thompson et al., 2003).   
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2.2. Methods 
Chemicals. Cerivastatin (Na salt) was purchased from Sequoia Research Products 
(Pangbourne, United Kingdom). Methylcellulose A15C premium (cerivastatin vehicle) 
was purchased from the Dow Chemical Company (West Point, PA).  
 
Animals. Male (250-300 g) and female (175-225 g) Sprague-Dawley rats (8-9 weeks old; 
Charles River Laboratories, Portage, MI) were individually housed in temperature and 
humidity controlled rooms with a 12-h light/dark cycle. Animals were allowed free 
access to water and a standard lab diet (Harlan Teklad 2018C, Madison, WI) and 
acclimated for one week prior to dosing. The conduct of all animal studies was approved 
by the Bristol-Myers Squibb Animal Care and Use Committee. 
 
In vivo studies. Study 1: Female and male rats were randomized by weight and dosed by 
oral gavage with cerivastatin (0.5 and 1 mg/kg; 5 ml/kg) (n = 6 - 9 animals per group) or 
vehicle (0.5% methylcellulose) for 14 days. These dosages were selected based on the 
literature in which 0.5 and 1 mg/kg caused a minimal and severe myopathy, respectively 
in female rats (Westwood et al., 2005).  
 
Study 2: Female rats were randomized by weight and treated with cerivastatin (1 mg/kg) 
for 1, 6, 8, 10 or 14 days of dosing. Dosing times were selected based on the literature 
indicating that the development of myopathy requires a minimum of 8 doses followed by 
a time-dependent increase in severity and incidence of myotoxicity with up to 14 doses 
(Westwood et al., 2005). Female rats were used for this study because this sex was more 
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sensitive to cerivastatin-induced myopathy (Vassallo et al., 2009). At necropsy, rats were 
anesthetized by ip injection with sodium pentobarbital (150 mg/kg) (study 1) or with 
inhalation exposure with isoflurane (study 2) prior to exsanguination approximately 24 
hours after the last dose. Blood was collected for serum separation and tissues were 
harvested as described below.  
 
Histopathology. For both studies, skeletal muscles representing a slow-twitch (soleus), 
fast-twitch (quadriceps femoris, gastrocnemius and psoas) and a mixed (diaphragm) fiber 
type composition from the left side of the rat, the left coronal section of the heart and left 
lateral lobe of the liver were collected for histopathologic evaluation (Table 2.1) 
(Armstrong and Phelps, 1984; Hamalainen and Pette, 1993; Koerker et al., 1990). Tissues 
were fixed in 10% neutral buffered formalin and processed for hematoxylin and eosin 
staining. Histopathologic evaluation of tissues was conducted without knowledge of 
treatment group by light microscopy (magnification ×40). The severity of myotoxicity 
was graded based on an arbitrary scale of 1 – 3 (study 1) and 1 – 4 (study 2), representing 
a minimal (1) to severe myopathy (4). For study 2, a scale of 1 – 4 was used for 
histopathology to provide a greater range for  assessing the severity of myopathy. 
However, regardless of the scale used, a designation of 3 in study 1 was equivalent to a 
designation of 4 in study 2 and both represented severe myopathy. 
 
In vitro studies with isolated myofibers. Laminin covered plates were prepared by 
diluting laminin solution (Sigma) 20-times with DMEM and transferring 0.1 ml to each 
well on a 96-well clear bottom plate (Corning catalog # 3903) and incubating at 37˚C for 
a minimum of 2 hours or overnight. The laminin solution was removed from the 96-well 
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plate and reused up to 3-times. The wells were washed twice with phosphate buffered 
saline (PBS) and allowed to dry. Maintenance medium (70 µl), containing DMEM 
(Invitrogen), 1% penicillin-G / streptomycin (Gibco), 200 mM glutamine (Gibco) and 
20% controlled serum replacement-2 (Sigma) was transferred to each well and incubated 
at 37˚C for 2 hours prior to the addition of myofibers. 
  
Myofibers from the rat flexor digitorum brevis (FDB) fast-twitch muscle were isolated 
and cultured based on the published literature (Figure 2.1; Ravenscroft et al., 2007; 
Sakamoto et al., 2011). Female and male Sprague-Dawley rats (8-9-weeks old) were 
anesthetized with isoflurane and exsanguinated. The FDB muscles were isolated, 
connective tissue removed and the muscles were incubated at 37˚C for 3 hours in a 15 ml 
conicle with 5 ml of pre-warmed (37˚C) isolation medium containing DMEM, 10% fetal 
bovine serum (FBS; Gibco) and 1% penicillin-G / streptomycin with 0.3% collagenase 
(Sigma). After incubation, the isolation medium was discarded and 6 ml of pre-warmed 
proliferation medium containing DMEM, 10% FBS, 1% penicillin-G / streptomycin, and 
200 mM glutamine was immediately added to the muscles. The muscles were gently 
triturated approximately 25 times with a transfer pipette. The myofibers were incubated 
at 37˚C for 30 minutes to allow the cells to settle by gravity sedimentation. After 
incubation, the isolation medium was discarded and 6 ml of fresh maintenance medium 
was added to the myofibers. The muscles were triturated approximately 25 times with a 
transfer pipette. The myofibers were incubated at 37˚C for 30 minutes. After incubation, 
the maintenance medium was discarded and 6 ml of fresh pre-warmed maintenance 
medium was added. The muscles were triturated approximately 25 times and incubated at 
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37˚C for 30 minutes. This process was repeated until all of the clumps of cells were 
reduced to individual myofibers. The myofibers were resuspended in a final volume of 8 
ml of maintenance medium. For each myofiber suspension, 50 µl (approximately 50 
myofibers) was transferred to each well on a laminin covered 96-well plate containing 70 
µl of pre-warmed maintenance medium. Myofibers were incubated overnight which 
allowed them to attach to the laminin covered plates and then treated with cerivastatin or 
vehicle (maintenance media) the following morning. 
 
A concentration response of myotoxicity was determined by incubating myofibers with 1, 
3, 10, 30, 100, 300 and 1000 nM of cerivastatin or vehicle (maintenance) for 5 days. The 
time-dependent development of myotoxicity was determined by incubating myofibers 
with 300 nM for 1, 2, 3, 4, 5, 6 days. This concentration was selected because a toxic 
dose of cerivastatin in female rats is associated with a maximum plasma concentration 
(Cmax) of 221 nM (Reinoso et al., 2002; Steinke et al., 1996). Therefore, for the current 
work a slightly higher concentration was selected for testing. Morphological 
characteristics of myofibers treated with cerivastatin (1 µM) were determined daily for up 
to 5 days by light microscopy. To determine whether myotoxicity was dependent on 
HMG-CoA reductase inhibition, cerivastatin (1 µM) was incubated with and without 
mevalonate (100 µM) for 5 days. This concentration of mevalonate was selected based on 
the literature indicating 100 µM prevents statin-induced myotoxicity in vitro (Mullen et 
al., 2010).  
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For all in vitro myofiber experiments, cerivastatin stock solutions were prepared in 
phosphate buffered saline, diluted in maintenance medium and 30 µl of the appropriate 
concentration was added to each well containing approximately 50 myofibers for a final 
volume of 150 µl. Myotoxicity was determined by removing 50 µl of myofiber medium 
and diluting it with 50 µl of PBS. Viability was assessed by either trypan blue 
(Mediatech, Inc.) exclusion or measuring ATP in the myofibers according to the 
manufacturer‟s instructions (Promega CellTiter-Glo Luminescent Cell Viability Assay). 
CK and ATP results represent mean values ± SE of 3 - 4 separate experiments in which 4 
(time course) – 12 (concentration response) wells containing approximately 50 myofibers 
/ well were used for each treatment or time point.  
 
Clinical chemistry analysis. Serum samples and cell culture medium were stored at -
80 C immediately after collection and analyzed for CK, AST and ALT on a Seimens 
Advia 1800 chemistry autoanalyzer (Seimens Healthcare Diagnostics, Tarrytown, NY). 
Skeletal muscle troponin I (sTnI) was quantified by ELISA (Life Diagnostics, Inc., West 
Chester, PA) for study 1 and by electrochemiluminescence (Meso Scale Diagnostics, 
Maryland) for study 2. 
 
Data analysis. The mean concentration ± SE of CK, sTnI, AST, ALT and ATP were 
determined for each treatment group. Group means of treated rats were compared to their 
respective experimental control with a student‟s t-test or ANOVA (p < 0.05). 
Concentration response curves and LC50 values were determined in Graphpad Prism 
(Graphpad Software, Inc., California). 
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2.3. Results 
In vivo studies 
Cerivastatin caused a dose dependent, fast-twitch specific myofiber degeneration in 
female rats after 14 days of dosing (Figure 2.2, panel B; Table 2.2). In female rats, a mild 
to severe myopathy was observed in all fast-twitch muscles evaluated whereas the slow-
twitch fibers of the soleus were unaffected (Table 2.2). Histopathologic changes noted in 
the fast-twitch muscles included myofibril lysis and hyalinization along with the presence 
of cellular infiltrates and nuclear rowing indicating myofiber regeneration. At 0.5 mg/kg, 
mild muscle toxicity was observed and increased levels of sTnI, CK and AST were noted. 
At 1 mg/kg, a mild to severe muscle toxicity was observed and increased levels of sTnI, 
CK and AST were noted. Muscle toxicity was also observed in male rats but the 
incidence and severity were much less than female rats (Table 2.2). With cerivastatin 
treatment, cardiac myofiber degeneration was also noted in the left ventricle, 
predominately in female rats (Figure 2.2, panel D; Table 2.2). Histopathologic changes 
noted in the heart include myofiber vacuolization, hyalinization and atrophy with 
interstitial cellular infiltrates.  
 
Cerivastatin caused a time dependent, fast-twitch specific myofiber degeneration in 
female rats (Figure 2.3; Table 2.3). Histopathologic changes noted in fast-twitch muscles 
included myofibril lysis, hyalinization and cellular infiltration whereas the slow-twitch 
(soleus) muscle was unaffected (Figure 2.3). These changes were first noted in 25% of 
the animals after 8 days of cerivastatin treatment and the incidence of myopathy 
increased to 75% and 100% of the animals after 10 and 14 days, respectively (Table 2.3). 
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The severity of cerivastatin-induced myotoxicity also increased with time from a minimal 
injury after 8 days (Figure 2.3, panel B) to a severe myopathy after 14 days of 
cerivastatin treatment (Figure 2.3, panel D). In contrast to the histopathology, sTnI, CK 
and AST were only increased after 10 and 14 days of treatment. Cardiac myofiber 
necrosis was also observed after 10 and 14 days of cerivastatin and was characterized by 
myofiber vacuolization, hyalinization, atrophy and interstitial cell infiltration.  
 
In vitro studies 
Several different FDB myofiber isolation procedures were evaluated because initial 
experiments, using published protocol conditions, resulted in numerous broken cells. 
Myofibers damaged in the course of the isolation procedure do not survive and are easily 
distinguished from intact myofibers because they typically hypercontract. Follow up 
experiments indicated that several key steps within the harvesting and processing of the 
myofibers were important to obtain healthy viable myofibers which attach to the laminin 
covered plates. Specifically, the FDB muscles must be gently removed from the animal 
as stretching and cutting the tendon too close to the myofibers increases the number of 
damaged cells. The collagenase concentration and incubation time are important factors 
which should be controlled. Trituration of the muscles after collagenase treatment 
releases the individual myofibers, however if the muscles are forced into the pipette this 
will result in a significant increase in the number of damaged fibers. Therefore, patience 
and finesse are absolutely critical when triturating the muscles. The type and size of the 
laminin covered plates are also important variables. Initial experiments were conducted 
with 12 and 24 well plates and various volumes of medium. In all cases, the myofibers 
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did not attach to the laminin covered plate but instead remained in suspension. 
Commercially available laminin covered plates were also evaluated but again the 
myofibers remained in suspension. Final conditions, including 120 µl of medium as well 
as laminin covered plates prepared the day before isolation were identified as important 
factors needed to maximize the number of viable myofibers attached to the plate. The 
number of myofibers transferred to the laminin covered plate is also important because 
too many cells results in tangling which leads to the cells breaking. Furthermore, 
myofibers which are not fully triturated into individual cells end up as clumps on the 
plate and after several days in culture these muscle fibers began to fibrillate. Therefore, to 
minimize these unwanted conditions special care was taken to completely triturate the 
muscles into individual myofibers and approximately 50 cells were added to each well on 
a 96 well plate. 
 
FDB muscles were chosen for cell culture because these myofibers are short 
(approximately 1 µm long) whereas myofibers from muscles like the soleus are 8-times 
longer and are more susceptible to breaking (Bekoff and Betz, 1977; Calderon et al., 
2009; Shefer and Yablonka-Reuveni, 2005). Longer myofibers from several sources 
including extensor digitorum longus (EDL), tibialis anterior and the soleus were isolated 
and plated on 96 well laminin covered plates. Several isolation experiments were 
conducted and in all cases when the myofibers were evaluated by light microscopy on the 
96 well plate the cells were broken and hypercontracted. However, viable soleus 
myofibers, which attached to the laminin covered plates, were finally obtained with 
meticulous care and when only a 1 – 2 myofibers were placed in a well.  
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The concentration response of cerivastatin was determined in female and male rat FDB 
myofibers after 5 days of treatment (Figure 2.4). The LC50 for cerivastatin in female rats 
was determined to be 106 nM with a 95% confidence interval of 62-167 nM. To 
determine if sex differences in sensitivity to cerivastatin toxicity is maintained in vitro 
male rat myofibers were isolated and treated under the same conditions. The LC50 for 
cerivastatin in male rats was determined to be 32 nM with a 95% confidence interval of 
23-46 nM. 
 
The time-dependent myotoxicity was determined in female rat FDB myofibers treated 
with cerivastatin (300 nM) for up to 6 days. Daily evaluation of ATP levels indicated that 
a steady decline in viability was initiated on day 3 and continued until day 6 (Figure 2.5, 
panel A). Similarly, daily evaluation of CK in the medium indicated a significant increase 
after 3 days which increased on day 4 followed by a sharp decrease on days 5 and 6 
(Figure 2.5, panel B). Despite a general correlation between ATP and CK changes on 
days 3 and 4 the level of CK was highly variable and decreased on days 5 and 6, 
suggesting it was degraded and thus may not be a reliable marker. 
 
The morphology of female rat myofibers was evaluated by light microscopy immediately 
after the cells attached to the laminin covered plates and daily for up to 6 days. Myofibers 
looked similar across the time course and were characterized by cross striations and 
peripherally located nuclei which are indicative of differentiated viable myofibers (Figure 
2.6; Table 2.4). In contrast, cerivastatin (1 µM) treated female rat myofibers exhibited 3 
distinct morphological stages. Stage 1 was represented by days 1 – 2 in which the 
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morphology of the treated myofibers was similar to control. Stage 2 occurred between 
days 3 – 4 in which several myofibers began developing blebs or vacuoles on the plasma 
membrane and the cells appeared swollen. Stage 3 was characterized by an increase in 
the number of blebs and the myofibers appeared dark in color, without striations and 
many of the cells were detached from the laminin covered plate (Figure 2.6; Table 2.4).  
 
To determine whether myotoxicity was dependent on HMG-CoA reductase inhibition 
cerivastatin (1 µM) was incubated with and without mevalonate for 5 days. Consistent 
with previous in vitro and in vivo experiments, cerivastatin caused a marked decrease in 
myofiber viability whereas mevalonate supplementation prevented toxicity (Figure 2.7). 
These results demonstrate that mevalonate supplementation prevents myotoxicity, and 
suggests that decreased levels of one or more downstream products likely contributes to 
toxicity. 
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2.4. Discussion 
The goal of this work was to establish the dosing paradigm which causes myopathy in 
Sprague-Dawley rats and in isolated differentiated fast-twitch rat myofibers using 
cerivastatin as a model compound. The in vivo studies confirmed that cerivastatin-
induced myopathy is a fast-twitch muscle specific effect in which female rats are more 
sensitive than males. Furthermore, the development of myopathy occurred in a dose-
dependent manner with 1 mg/kg showing the most severe toxicity. The cerivastatin (1 
mg/kg) time course study indicated that the development of myopathy requires a 
minimum of 8 daily doses with increased incidence and severity following longer dosing 
duration. Together, the dose response and time course for cerivastatin-induced myopathy 
in Sprague-Dawley rats was consistent with previously published results in Wistar 
Hannover rats (Westwood et al., 2005). Furthermore, this is the first report of 
cerivastatin-induced cardiotoxicity. Given that the focus of this dissertation is on 
cerivastatin-induced skeletal muscle toxicity the mechanism of cardiomyopathy was not 
pursued. However, this was an unexpected finding given that slow-twitch muscles were 
resistant to cerivastatin-induced toxicity and this fiber type and cardiac muscle are similar 
in regards to energy metabolism.    
 
Although most in vitro research on mechanisms of statin-induced myopathy has involved 
undifferentiated myoblasts and myotubes recent evidence indicates that differentiated 
myofibers may be more appropriate and representative of the in vivo pathophysiology 
(Ravenscroft et al., 2007; Sakamoto et al., 2007, 2008). Therefore, a method for 
harvesting and culturing differentiated fast-twitch myofibers from the rat FDB muscle 
was developed and conditions associated with cerivastatin-induced myotoxicity were 
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determined. Importantly, these results demonstrate that cerivastatin-induced toxicity in 
isolated FDB myofibers recapitulates the in vivo myopathy at relevant concentrations, 
and mevalonate supplementation prevents the toxicity. Specifically, the development of 
toxicity in FDB myofibers was time-dependent, with an LC50 between 30 – 100 nM, 
depending on sex which is consistent with the in vivo concentration of cerivastatin (30 
and 200 nM) reported in skeletal muscles and plasma, respectively in female rats showing 
evidence of myopathy (Seachrist et al., 2005; Sidaway et al., 2009; Westwood et al., 
2005). Despite this correlation, a lower LC50 for male compared to female rat myofibers 
was observed in vitro which is opposite of what was observed in vivo. While the 
mechanism of this sex specific sensitivity to statin myopathy is unknown these results 
suggest that in vivo factors may be important in the pathophysiology. It has been 
proposed that statin myopathy is the result of transcriptional induction of the muscle 
specific ubiquitin ligases, including atrogin-1 and MuRF-1 with subsequent and 
excessive myofibrillar protein degradation (Hanai et al., 2007). Testosterone has been 
shown to suppress transcriptional induction of these ubiquitin ligases (Foletta et al., 
2011). However, these myofibers were cultured in the absence of serum and thus 
testosterone. Therefore, it is possible that testosterone plays a role in mediating in vivo 
sex differences in statin-induced myopathy. However, this mode of action was not 
pursued further. Recently, differential gene expression of whole mouse skeletal muscles 
was compared to isolated differentiated mouse myofibers (Chemello et al., 2011). Genes 
highly expressed in non-muscle cells were downregulated, and based on their functional 
role were derived from blood cells, endothelial cells or Schwann cells (Chemello et al., 
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2011). Accordingly, sex differences in statin-induced myopathy may also be related to 
specific in vivo conditions which were not recapitulated in vitro.  
 
Cerivastatin-induced myofiber effects were evaluated by measuring viability and toxicity 
with ATP and CK, respectively. ATP values were highly reproducible across experiments 
whereas CK was more variable and showed a marked decrease at later time points, 
presumably due to protease degradation. These results are consistent with the fact that the 
preclinical utility of CK is limited because of its marked variability (Bohlmeyer et al., 
1994). Unexpectedly, CK was significantly increased on day 3 whereas ATP was not 
significantly reduced until day 4 in vitro. However, it is likely that CK was released from 
viable or stressed, but not necrotic cells. The formation of blebs or vacuoles which was 
first noted on day 3 may represent one mechanism by which the stressed myofibers 
release cytoplasmic contents, including CK prior to a significant reduction in ATP. Such 
a mechanism has been described for cardiac myocytes under ischemic conditions in 
which the cells produce blebs on the surface of the plasma membrane and release 
cytoplasmic contents, including enzymes, without undergoing necrosis (Brancaccio et al., 
2010). During re-oxygenation these blebs can be reabsorbed or shed into the circulation. 
In contrast, when ischemia is protracted, the blebs grow, collapse and cell necrosis ensues 
(Brancaccio et al., 2010). Therefore, changes in CK and ATP provide information on two 
different biochemical and pathophysiological processes in the myofibers. The early 
increase in CK is likely related to myofiber stress whereas a decrease in ATP, 
representing a late response indicates the cells were not able to adapt and necrosis 
ensued.      
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Myofibers have been isolated and cultured from a variety of limb muscles including 
extensor digitorum longus, tibialis anterior and the soleus (Shefer and Yablonka-Reuveni, 
2005). However, myofibers from these sources are significantly longer (e.g. soleus is 8-
times longer than the FDB muscle), tend to tangle and break and this was observed in the 
current study. However, after several experiments and meticulous care, myofibers from 
the soleus attached to the lamin covered plate when only 1 - 2 cells were transferred to a 
well. Given the emphasis of this work on fast-twitch myotoxicity additional experiments 
in the slow-twitch myofibers were not pursued.  
 
In summary, the current work demonstrates that cerivastatin-induced myopathy occurs in 
a dose- and time-dependent manner with fast-twitch muscles from female rats showing 
the greatest sensitivity. Furthermore, an in vitro culture system was established for the 
evaluation of fast-twitch muscle fiber toxicity. These results demonstrate that 
cerivastatin-induced toxicity in isolated myofibers recapitulates the in vivo effects at 
relevant drug concentrations and mevalonate supplementation prevents the toxicity. 
Collectively, these results provide an in vivo and in vitro dosing paradigm which can be 
used to investigate mechanisms of toxicity.  
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Figure 2.1. Anatomical location and function of the flexor digitorum brevis muscle. 
The FDB muscle divides into four tendons which insert into the lateral four phalanges of 
the foot where it functions as a flexor.  
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Figure 2.2. Muscle histopathology of female rats treated with cerivastatin (Vassallo 
et al., 2009). Quadriceps femoris muscle from control (A) and cerivastatin-treated rat 
(female; 1 mg/kg; B) illustrates severe skeletal myofiber degeneration and necrosis 
including myofibril lysis and hyalinization (*), cellular infiltration, and nuclear rowing, 
indicative of myofiber regeneration (arrow). Myocardium of left ventricle from control 
(C) and cerivastatin-treated rat (female; 1 mg/kg; D) illustrates cardiac myofiber 
degeneration. Histopathologic changes observed with cerivastatin were characterized by 
myofiber vacuolization, hyalinization and atrophy with interstitial cellular infiltration. 
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Figure 2.3. Time course of cerivastatin-induced myotoxicity in female rats. 
Representative fast-twitch muscles from control (A) and cerivastatin-treated female rat (1 
mg/kg) showing two necrotic myofibers (arrows) illustrating a minimal grade 1 injury (B; 
Day 9), a mild grade 2 injury (C; Day 11), and a severe grade 4 myopathy showing 
degeneration and necrosis characterized by myofibril lysis, hyalinization and cellular 
infiltration (D; Day 15). 
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Figure 2.4. Concentration response of cerivastatin-induced toxicity in female and 
male rat myofibers. Myofibers were treated with cerivastatin (0, 1, 3, 10, 30, 100, 300 
and 1000 nM) for five consecutive days at which time ATP was determined in 12 wells 
containing approximately 50 myofibers per well. The 95% confidence interval for female 
and male rats was 62-167 nM and 23-46 nM, respectively. Results represent the mean ± 
SE of three separate experiments.  
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Figure 2.5. Time course of cerivastatin-induced toxicity in female rat myofibers. 
Myofibers were treated with cerivastatin (300 nM) for up to six consecutive days. On 
each day, CK (A) and ATP (B) levels were determined and compared to untreated 
myofibers. Results represent the mean ± SE of four separate experiments. 
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Figure 2.6. Cerivastatin-induced morphological changes in female rat myofibers.  
Mature differentiated cultured myofibers maintain characteristic striated pattern and 
peripherally located nuclei (A). Myofibers were treated with vehicle (B) or cerivastatin 
(C; 1 µM) for 4 days and morphological changes were qualitatively evaluated by light 
microscopy. Vehicle treated myofibers showed normal morphology with peripherally 
located nuclei (red arrows) whereas cerivastatin treated myofibers appeared swollen, with 
the presence of numerous blebs on the plasma membrane which are characteristic of 
stressed cells releasing cytoplasmic contents  (yellow arrows).   
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Figure 2.7. Mevalonate supplementation prevents cerivastatin-induced myotoxicity. 
Female rat myofibers were treated with cerivastatin (1 µM) with or without mevalonate 
(100 µM) for five days at which time ATP was determined. Results represent the mean ± 
SE of three separate experiments. 
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Table 2.1. Muscles collected for histopathology 
 
 Fiber type, %
a
  
Muscle I [SO] IIA [FOG] IIB [FG] Reference 
Soleus (Sol) 84 16 0 Koerker et al., 1990 
Diaphragm (Dia) 35 38 27 Kumagai et al., 2001 
Quadriceps femoris (Quad) 8 65 27 Koerker et al., 1990 
Gastrocnemius (Gastroc) 4 38 58 Ariano et al., 1973 
Psoas 1 8 91
b
 Hamalainen and Pette, 1993 
Flexor digitorum brevis 6 61 33 Ihlemann et al., 2001 
    a
Muscle fiber type - Type I, slow oxidative [SO]; Type IIa, fast oxidative glycolytic 
[FOG]; Type IIb fast glycolytic [FG] 
 
b
In the psoas, the FG muscle (91%) consists of IIB (46%) and IIX/D (45%) fibers 
(Hamalainen and Pette, 1993). Type IIB and IIX/D were used interchangeably in 
the early literature because of species differences and inconsistent nomenclature. 
However, humans only express IIX/D even though these are generally referred to 
as IIB fibers. In contrast, both IIB and IIX/D fibers are expressed in rodents (Scott 
et al., 2001). Type IIX/D fibers have intermediate characteristics between IIb and 
IIa (Scott et al., 2001). 
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a
Results represent the mean and SE of 6 - 9 rats / sex / group dosed for 14 consecutive 
days.  
b
< Indicates at least one value in the group is less than the detection limit (5.9 ng/ml). (-) 
indicates all values in the group were  the detection limit. 
c
This group had two values  1330 ng/mL, therefore the mean underestimates the actual 
concentration. 
d
Results represent tissues affected by treatment. No adverse histological effects were 
observed in the soleus or liver. Number of animals with muscle necrosis and degeneration 
/ number of animals per group. The mean severity score in () is based on an arbitrary 
severity scale of 1, 2 and 3 (most severe). (-) denotes no significant histopathologic 
finding. 
*
Significantly different from control (p < 0.05). 
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a
Results represent the mean and SE of eight treated rats per day whereas the control 
group consists of twenty rats representing four animals from days 1, 6, 8, 10 and 14. The 
histopathology results represent tissues affected by treatment.  
   b
< Indicates at least one value in the group is less than the detection limit (0.8 ng/ml).  
c
Results represent tissues affected by treatment. No adverse histological effects were 
observed in the soleus or liver. Results represent the number of animals with skeletal or 
cardiac myofiber necrosis and degeneration / number of animals per group. The mean 
severity score in () is based on an arbitrary score of 1 to 4 (most severe). (-) denotes no 
significant findings observed.  
*Significantly different from control (p < 0.05). 
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Table 2.4. Morphological changes of female rat myofibers treated with cerivastatin. 
Days of 
treatment 
Morphological changes 
Control Cerivastatin (1 µM) 
1 - 2 Normal Normal 
3 - 4 Normal 
Many of the myofibers were swollen and 
contained up to 100 blebs. 
5 - 6 Normal 
The number of myofibers containing blebs 
increased and many of the myofibers were dark 
in color, without striations and detached from 
the laminin covered plate. 
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Chapter 3 
 
 
Transcriptional profiles of skeletal muscles with and without 
cerivastatin treatment in female and male rats 
 
 
3.1. Introduction 
Skeletal muscles are predominately divided into two major fiber types; fast-twitch 
glycolytic (Type IIB or IIX/D) which are best adapted for rapid activity involving high 
velocity contractions and slow-twitch oxidative (Type I) which are specialized for 
continuous activity and possess greater blood supply, myoglobin and mitochondria 
(Chapter 1.6; Table 1.2; Pett and Staron, 1997; Zierath et al., 2004). Furthermore, fibers 
known as fast-twitch oxidative (Type IIA) possesses intermediate characteristics when 
compared to the other two fiber types (Chapter 1.6; Table 1.2; Pett and Staron, 1997; 
Zierath et al., 2004). Skeletal muscle fiber composition is determined in part by genetic 
factors, functional and metabolic demands, innervation and differential expression of 
distinct myofibrillar and metabolism proteins which allow fine tuning of muscle 
performance (Baldwin and Haddad, 2002; Chemello et al., 2011; Fluck and Hoppeler, 
2003; Schiaffino and Reggianai, 1996). Furthermore, sexual dimorphism of skeletal 
muscle is also well known, with gene expression differences in energy metabolism, 
which are most pronounced in fast-twitch muscle fibers (Chapter 1.7.2.; Maher et al., 
2008; Welle et al., 2008). 
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Transcriptional profiles of skeletal muscles from mice and humans have been previously 
determined and are consistent with the known fiber- and sex-specific differences 
described above (Campbell et al., 2001; Chemello et al., 2011; Kang et al., 2005; Maher 
et al., 2009; Welle et al., 2008; Yoshioka et al., 2007). However, fiber- and sex-specific 
gene expression profiles of the rat have not yet been determined. Establishing fiber- and 
sex-specific gene expression profiles of skeletal muscles in the rat during normal 
physiology makes it possible to determine differential transcriptional changes associated 
with pathological conditions mediated by toxicity, and exacerbated by infiltrated immune 
cells, connective tissue replacement and muscle regeneration (Haslett and Kunkel, 2002; 
Marotta et al., 2009; Yan et al., 2003). Accordingly, differential transcriptional profiling 
may provide insight into the molecular events involved with mechanisms of toxicity 
which can occur in a fiber- and sex-dependent manner (Chapter 1.7). Specifically, it is of 
particular interest to understand the transcriptional changes associated with statin-induced 
myotoxicity which predominately occurs in female fast-twitch skeletal muscles (Tables 
2.2 and 2.3).  
 
Gene expression analysis has been conducted following statin treatment. However, it has 
been difficult to develop a unified and compelling transcriptional profile, representing the 
molecular changes characteristic of statin-induced myopathy, because these studies have 
either been conducted in undifferentiated cultured muscle cells or in humans with 
heterogeneous muscle fiber types (Draeger et al., 2010; Hubal et al., 2011; Laaksonen et 
al., 2006; Morikawa et al., 2005; Urso et al., 2005; Yu et al., 2009). Despite these 
inconsistencies, transcriptional profiling is considered a powerful and appropriate tool to 
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investigate the molecular changes associated with statin-induced myotoxicity. However, 
the approach taken for the current work was significantly different from previous 
investigations. Specifically, rats were selected because this species is considered a useful 
model for studying mechanisms of statin-induced myopathy (Chapter 2). Furthermore, 
homogenous or “pure” skeletal muscles, consisting of >80% fast- or slow-twitch fibers 
were evaluated (Table 2.1). Using skeletal muscles consisting of a homogenous fiber type 
enables the determination of a fiber- and sex-specific gene expression profile during 
normal physiology and the differential effects associated with statin-induced myotoxicity. 
Therefore, it was hypothesized that gene expression profiles could discriminate fast- and 
slow-twitch skeletal muscles as well as sex-related differences in fast-twitch skeletal 
muscles from the rat. Additionally, it was hypothesized that the gene expression profile 
of these skeletal muscles may be useful in identifying pathways altered with cerivastatin-
induced myopathy.  
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3.2. Methods 
Study design. This investigation was conducted on samples obtained from study 1 
described in Chapter 2. Skeletal muscles including a representative fast-twitch fiber 
(psoas) and slow-twitch fiber (soleus) were harvested from the right side of the rat and 
stored at -80˚C pending RNA isolation (Table 2.1)  
 
RNA isolation. Frozen muscle tissues were individually pulverized in liquid nitrogen and 
50 mg was used for RNA isolation. RNA was isolated using TRIzol RNA extraction 
(Invitrogen Corporation, Carlsbad, CA) with the RNeasy RNA extraction kit (Qiagen, 
Valencia, CA) according to the manufacturers' instructions. Complete removal of DNA 
was achieved by using Qiagen's RNase-Free DNase. RNA concentration (260 nm 
absorbance) and quality (260 / 280 nm absorbance) were determined with a Nanodrop® 
ND-1000 spectrophotometer (NanoDrop Technologies, Inc., Wilmington, DE) and the 
integrity of the 18S and 28S ribosomal RNA bands was assessed by electrophoresis on 
RNA 6000 Nano labchips with a 2100 Bioanalyzer (Agilent Technologies, Palo Alto,
 
CA).   
 
Expression profiling. RNA labeling, hybridization and staining were carried out 
according to the Eukaryotic Target Preparation protocol in the Affymetrix® (Santa Clara, 
CA)Technical Manual for GeneChip® Expression Analysis. Total RNA (5 μg) was used 
to generate double-stranded cDNA using Superscript reverse transcriptase (Invitrogen 
Life Technologies) and a T7-oligo (dT) primer (Affymetrix®). The resulting cDNA was 
purified using the GeneChip Sample Cleanup Module according to the manufacturer's 
protocol (Affymetrix®). The purified cDNA was amplified using BioArray high yield 
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RNA transcription labeling kit (Enzo) according to the manufacturer's instructions to 
produce biotin labeled cRNA (complement RNA) which was then purified using 
GeneChip Sample Cleanup Module (Affymetrix®) and quantified. Labeled cRNA (20 
μg) was fragmented at 94°C for 35 min. Fragmented cRNA (15 g) was hybridized to the 
Affymetrix® HT Rat Focus Array containing 24,249 probe sets for 16 hours at 45°C. The 
hybridized arrays were washed and stained using Streptavidin–Phycoerythrin (Molecular 
Probes) and amplified with affinity purified biotinylated anti-streptavidin (Vector 
Laboratories, Inc, Burlingame, CA) using a GeneChip® Fluidics Station 450 
(Affymetrix®). The arrays were scanned in Affymetrix® high-resolution GeneChip 
scanner 3000 at 570 nm using Genechip Operating software (GCOS, Ver.1.2).  
 
Data analysis. All transcriptional data were analyzed with Rosetta Resolver software 
(Seattle, WA). Initial evaluation of the transcriptional intensity profiles for all skeletal 
muscles was conducted by principal component analysis (PCA). Skeletal muscle 
transcriptional profiles for each group were analyzed with an error weighted ANOVA to 
determine the differential expression of genes based on skeletal muscle fiber type and sex 
in vehicle treated rats. Furthermore, the differential expression of genes in skeletal 
muscles from cerivastatin relative to the vehicle treated groups was also determined. For 
these analyses, 5 female and male fast-twitch muscles and 4 female slow-twitch muscles 
from vehicle treated rats were used. Additionally, 8 and 6 fast-twitch muscles from 
female rats receiving 0.5 or 1 mg/kg of cerivastatin, respectively and 5 fast-twitch 
muscles from male rats receiving 1 mg/kg of cerivastatin were used. For the slow-twitch 
muscles, 8 female rats receiving 0.5 or 1 mg/kg of cerivastatin were used. 
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For differential gene expression analysis, probe sets were eliminated if they did not meet 
a  p value of <0.01 and a minimum fold change of ≥ ±1.5. These criteria were selected to 
increase stringency and reduce false positives. Specifically, probe sets with low 
intensities tend to have greater variation, therefore a higher fold change was selected to 
reduce this inherent noise (Stevenson et al., 2003). However, even with these stringent 
criteria, several thousand transcripts were differentially expressed when comparing 
skeletal muscle fiber types as well as following cerivastatin (1 mg/kg) treatment in the 
fast-twitch muscle relative to vehicle treated rats. Therefore, an additional enrichment 
step was included to further filter the data and focus the analysis. 
 
The HT Rat Focus microarrays contain 24,249 probe sets and approximately 50% of 
these were expressed in skeletal muscle. Furthermore, probe sets which were expressed at 
a low level may represent specific binding or result from factors which affect background 
noise. Accordingly, to reduce the contribution of noise-based error, which could increase 
the number of differentially expressed transcripts, the most abundant probe sets were 
determined as this approach has been shown to correlate with the skeletal muscle 
phenotype (Yoshioka et al., 2007; Table 1.2). For comparison of fiber and sex differences 
in skeletal muscles, the top 1% most abundantly expressed transcripts were collated and 
the differential expression of these probe sets was determined with a p value of <0.01 and 
a minimum fold change of ≥ ±1.5. In a similar manner, the top 2% most abundantly 
expressed transcripts in fast-twitch muscles from cerivastatin (1 mg/kg) treated female 
rats was collated and the differential expression of these probe sets was determined 
relative to vehicle treated female rats with a p value of <0.01 and a minimum fold change 
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of ≥ ±1.5. A value of 2% was selected for this analysis to include a more representative 
characterization of the transcriptional changes following cerivastatin treatment.  
 
Additional analysis of the transcriptional data was also conducted to identify common 
transcripts which were differentially expressed with a p value of <0.01 in both fast- and 
slow-twitch muscles following cerivastatin (1 mg/kg) treatment and in a dose dependent 
manner in fast-twitch muscles. Furthermore, common probe sets which were 
differentially expressed in the fast-twitch muscle from female rats treated with 0.5 mg/kg 
and male rats treated with 1 mg/kg of cerivastatin were also determined with a p value of 
<0.01 since these tissues showed minimal to no myopathy. The goal of these additional 
analyses was to determine whether common differentially expressed transcripts exist in a 
fiber- or sex-dependent manner in skeletal muscles following cerivastatin treatment 
which may represent molecular targets or pathways important in the mechanism of 
cerivastatin-induced myopathy. Additionally, given the pharmacology of statins, a 
targeted evaluation of transcripts in the mevalonate pathway and cholesterol regulation 
was also conducted for all analyses.  
 
Established annotations of the differentially expressed transcripts, as well as their 
accompanying accession numbers were used to categorize genes based on function with 
an emphasis on skeletal muscle biology and toxicity. These functional categories 
included energy metabolism (glycolysis, citric acid cycle, oxidative phosphorylation and 
creatine phosphate synthesis), sarcomere and cytoskeleton, immune, inflammatory 
response and cell stress, metabolism, proteolysis, extracellular matrix, regulation of 
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transcription and translation, transporters, calcium homeostasis, miscellaneous and those 
without ontology. Confirmation of gene ontology was conducted by interrogation of 
several databases including KEGG, Ingenuity®, Gene Expression Omnibus and the 
literature. 
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3.3. Results 
PCA analysis of all the transcriptional profiles indicated two points of separation. 
Specifically, fast-twitch and slow-twitch muscle fibers were separated in principal 
component 2 regardless of treatment. Additionally, the fast-twitch muscles from both 
female and male rats were clustered together indicating that the transcriptional profiles 
were similar. Furthermore, the slow-twitch muscles, regardless of treatment, were 
generally clustered together indicating the transcriptional profiles were similar. In 
contrast, fast-twitch muscles from vehicle and cerivastatin treated female rats were 
separated in principal component 1 indicating the transcriptional profiles were 
significantly different (Figure 3.1).  
 
In female rats, there were 2,678 differentially expressed transcripts between fast- and 
slow-twitch muscles. In fast-twitch muscles, the most abundant transcripts, which were 
differentially expressed relative to slow-twitch muscles were consistent with the 
established phenotype for this muscle fiber (Tables 1.2, 3.1 and 3.2; Chemello et al., 
2011). Specifically, transcripts involved with the glycolytic pathway and glycogen 
metabolism were more highly expressed. Furthermore, probe sets specific to the fast-
twitch muscle sarcomere, including myosin (Mybpc2, Myh1 and Myh4), troponin (Tnni2 
and Tnnt3), Actn3, and myozenin 1 had higher constitutive expression relative to the 
slow-twitch muscle (Chemello et al., 2011). Additionally, parvalbumin which is a 
calcium binding protein, the sarcoplasmic reticulum calcium ATPase (Atp2a1) and Ldha 
which are highly expressed in fast-twitch muscles were significantly upregulated relative 
to slow-twitch muscles (Chemello et al., 2011).  
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In slow-twitch muscles, the most abundant transcripts, which were differentially 
expressed relative to fast-twitch muscles were also consistent with the established 
phenotype for this muscle fiber (Tables 1.2, 3.3 and 3.4; Chemello et al., 2011). 
Specifically, transcripts involved with the slow-twitch muscle sarcomere, including 
myosin (Myh7, Myl3 and Mlc2), troponin (Tnnc, Tnni1 and Tnnt1) and myozenin 2 were 
all significantly upregulated relative to the fast-twitch muscle as previously reported in 
mice (Chemello et al., 2011). Furthermore, Fabp3, myoglobin and Hadhb, which are 
predominately expressed in slow-twitch muscles were also significantly higher relative to 
the fast-twitch muscle. However, myoglobin and Hadhb were only increased by 1.2- and 
1.3-fold, respectively. Several additional transcripts specific to the slow-twitch muscle 
were more highly expressed relative to the fast-twitch muscle, including Ldhb, Atp2a2, 
fhl1, Cryab, Csrp3 and Ankrd2 (Chemello et al., 2011). Moreover, several heat shock 
protein transcripts (Hspb7, Cryab, Hspb1), genes involved with redox cycling (Gpx1 and 
Ca3) and probe sets without ontology were more highly expressed in the slow-twitch 
muscle. Unexpectedly, transcripts involved with energy metabolism, including oxidative 
phosphorylation and creatine kinase were ubiquitously abundant in both fiber types 
which is consistent with the role of skeletal muscle in energy metabolism. Although there 
was a general correlation between the most abundant transcripts and the muscle fiber 
phenotype, genes involved with fatty acid oxidation were not highly abundant in the 
slow-twitch muscle as expected with the current statistical constraints. However, targeted 
analysis of the 2,678 differentially expressed transcripts revealed many genes involved 
with fatty acid oxidation, including acyl-CoA dehydrogenases which were more highly 
expressed in the slow-twitch muscle. Transcripts involved with the mevalonate pathway 
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and cholesterol regulation were not abundantly or differentially expressed in a fiber-
dependent manner. 
 
Differential expression of the most abundant transcripts in female and male fast-twitch 
muscles revealed no differences. To further investigate sex differences, 137 out of 12,018 
detectable probes were differentially expressed in female relative to male fast-twitch 
muscles, with most transcripts showing less than a ± 2 fold change (Tables 3.5 and 3.6). 
However, several transcripts, including some without ontology, showed a marked 
increase of 3 to 51 fold indicating these may be important in contributing to sex 
differences in the fast-twitch muscle. Specific sex differences were noted for genes 
involved with energy metabolism, including insulin related transcripts (Igf2, Igfbp6 and 
Irs1) as well as those involved with Acetyl-CoA formation (Pdk4 and Acas2l), fatty acid 
oxidation (Ehhadh), oxidative phosphorylation (Ucp3), circadian rhythm (Per2) and 
transcriptional regulation (Thrb, Atf3, Nr4a1 and Cited2). However, skeletal muscles 
from females are generally believed to oxidize more fatty acids than males yet this 
finding was not reflected under the current statistical constraints. Following a more 
detailed analysis of the data, six additional genes involved with fatty acid oxidation, 
namely acyl-CoA dehydrogenase, enoyl-CoA hydratase, isovaleryl-CoA dehydrogenase, 
branched chain keto acid dehydrogenase, methylmalonate-semialdehyde dehydrogenase 
and methylcrotonyl-CoA carboxylase were all significantly higher in female fast-twitch 
muscles (p<0.01), however the fold increase was between 1.2 and 1.5. Unexpectedly, 
guanidinoacetate methyltransferase was 1.5-times more highly expressed in the male rat 
fast-twitch muscle suggesting sex differences in creatine metabolism. A large number of 
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genes involved with the immune, inflammatory response and cell stress were generally 
more highly upregulated in females. However, the biological significance of these sex 
differences is unknown. Most of the differentially expressed transcripts were represented 
by two categories, including miscellaneous (20%) and without ontology (40%). 
Transcripts involved with the mevalonate pathway and cholesterol regulation were not 
differentially expressed in a sex-dependent manner. 
 
In a manner consistent with the lack of myotoxicity observed with cerivastatin (0.5 
mg/kg), 26 out of 12,769 probes were transcriptionally altered, with all changes less than 
3-fold in the female fast-twitch muscle (Table 2.2). The predominate changes were 
transcripts involved with glucose and lipid metabolism (Pdk4, Klf15 and G0s2), 
regulators of muscle mass (Cited2, Lmcd1 and Csrp3), cell stress (Sesn1 and Dnajb1) and 
the nuclear receptor Nr1d1 suggesting cerivastatin treatment may modulate energy 
metabolism in the fast-twitch muscle prior to the onset of myopathy (Table 3.7).  
 
Consistent with severe myopathy observed with cerivastatin (1 mg/kg), 7,021 out of 
13,947 detectable probes were differentially expressed in the female fast-twitch muscle 
(Table 2.2). In a retrospective evaluation of transcriptional profiling data, Foster et al. 
(2007) demonstrated that target organ toxicity was associated with at least 5% of total 
transcripts changing. Accordingly, the high percentage of transcripts changed in this 
study was likely reflective of the marked pathology observed in these rats. Therefore, 
instead of looking at all transcriptional changes, a subset representing the most abundant 
transcripts following cerivastatin treatment were collated and the differential expression 
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of these probe sets relative to vehicle treated rats was determined (Tables 3.8 to 3.13). In 
general, transcripts involved with energy metabolism were downregulated as expected 
whereas probes involved with the cytoskeleton showed a significant increase which may 
reflect skeletal muscle remodeling (Table 3.8). In contrast, sarcomeric proteins specific to 
the fast-twitch muscle were downregulated which is consistent with destruction of the 
myofibrillar apparatus (Table 3.8). A variety of genes involved with the immune, 
inflammatory response and cell stress (Spp1, Mt1a, Timp1, Cd68 and Ifitm1), 
metabolism (Np, Sat, Txn1, Prdx5, Gpx1, Prdx1), proteolysis (Ctsl, Scpep1, Ctsb and 
Psmb4), and the extracellular matrix (Fn1, Col3a1, Dcn, Colla2, Rpsa) were upregulated 
along with dysregulation of several transporters and calcium binding proteins consistent 
with the pathophysiology (Table 3.9, 3.11 and 3.12). Furthermore, a variety of probes 
involved with regulation of transcription and translation were significantly upregulated, 
however this change may be independent of myogenesis as the muscle regulator factors 
did not show a pattern of change reflecting this process (Tables 3.10 and 3.11; Figure 
1.6). Unexpectedly, a variety of transcripts in the mevalonate pathway (Hmgcr, Pmvk, 
Sqle, Lss, Cyp51, Sc4mol, Idil and Fdft1) and those involved with cholesterol regulation 
(Soat1, Lip1, Abca1, Abcg1, Npc2, Ldlr, Oldlr, Vldlr and Srebf2) were significantly 
upregulated (Table 3.13). The most profound change in this category was Ch25H which 
increased 19-fold. Additionally, several other genes involved with bile acid synthesis 
were also induced including Cyp7b1 and Hsd3b7 whereas Cyp27a1 was downregulated 
(Table 3.13).  
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In the fast-twitch muscle from male rats treated with cerivastatin (1 mg/kg) only 54 out of 
11,921 detectable probes were differentially expressed and this is consistent with the lack 
of myopathy (Table 2.2, 3.14). Specifically, several transcripts for nuclear receptors were 
upregulated, including Nr1d1, Nr1d2 and Nr4a1 whereas the transcription factor Foxo1a 
was downregulated. Additionally several genes involved with a stress response were 
transcriptionally induced, including Hspa1a, Hspa1b, Dnajb1 and Cygb.  
 
In the slow-twitch muscles from cerivastatin (0.5 mg/kg) treated female rats 57 out of 
13,573 detectable probes were differentially expressed (Table 3.15). Specifically, several 
transcripts involved with energy metabolism were induced, including Hk2, nuclear 
receptors Nr4a2 and Nr4a3 and the peroxisome proliferative activated receptor, gamma, 
coactivator 1 alpha (Ppargc1a or PGC-1α). Alterations in energy metabolism were also 
supported by transcriptional modulation of Ucp3 and Rrad which results in increased 
oxidative phosphorylation and modulation of glucose and lipid utilization, respectively 
(Table 3.15; Bezaire et al., 2007; Casey et al., 2008). More than 50% of the differentially 
expressed transcripts were without ontology. 
 
In the slow-twitch muscles from cerivastatin (1 mg/kg) treated female rats 29 out of 
13,500 detectable probes were differentially expressed (Table 3.16). A perturbation in 
energy metabolism was suggested by a transcriptional increase in the nuclear receptor 
Nr1d2 and the kinase Phka1 which increases glycogen degradation for glycolysis. 
Transcriptional induction of Mt1a was increased 10-fold indicating oxidative stress and 
Il10 was increased suggesting an anti-inflammatory response (Table 3.16; Chapter 1.6.1). 
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Additional transcriptional changes were also observed, including upregulation of the 
transporters Kctd13 and Trpv4 which may indicate a dysregulation of electrolyte 
(calcium and potassium) homeostasis (Table 3.16).  
 
To further examine the fiber specific response the differential expression of common 
probes in fast- and slow-twitch muscles from cerivastatin (1 mg/kg) relative to vehicle 
treated female rats was determined (Table 3.17). Four probes, including the nuclear 
receptor Nr1d2, the priming enzyme for glycogen synthesis, Gyg1, and two transcripts 
without ontology (LOC684802 and RGD1307838), showed a differential response 
relative to the respective vehicle group (Table 3.17). To further examine the dose 
response, differential expression of common probes in fast-twitch muscles from female 
rats treated with 0.5 and 1 mg/kg of cerivastatin relative to vehicle treated rats was 
determined (Table 3.18). Several transcripts involved with energy metabolism (G0s2, 
Klf15 and Tulp4), regulation of muscle mass (Csrp3 and Lmcd1) as well as the cell stress 
response (Dnajb1 and Sesn1) were differentially expressed at both dosages  (Table 3.18). 
Furthermore, Nr1d2 was also differentially expressed and was the only transcript to 
change in a fiber and dose dependent manner. Fast-twitch muscles from female and male 
rats treated with 0.5 and 1 mg/kg of cerivastatin, respectively showed minimal to no 
myopathy. Therefore, the differential expression of common probes in these muscles 
relative to vehicle treated rats was determined (Table 3.19). For this analysis, only three 
common probes were identified including one involved with the stress response (Dnajb1) 
as well as the nuclear receptors Nr1d1 and Nr1d2.  
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3.4. Discussion 
Transcriptional profiles of fiber- and sex-specific differences have been previously 
determined in mice and humans (Campbell et al., 2001; Chemello et al., 2011; Kang et 
al., 2005; Maher et al., 2009; Welle et al., 2008; Yoshioka et al., 2007; Zierath et al., 
2004). Furthermore, differential expression profiles have been useful for investigating 
specific molecular targets and pathways associated with skeletal muscle injury, atrophy 
and hypertrophy in several species (Bialek et al., 2011; Chen et al., 2007; De Souza et al., 
2006; Komamura et al., 2003; Mahoney et al., 2008;  Marotta et al., 2009; Pearen et al., 
2009; Sanoudou et al., 2003; Spurlock et al, 2006; Stevenson et al., 2003). Although the 
rat is commonly used for evaluation of preclinical drug-induced myopathy, fiber- and 
sex-specific transcriptional profiles have not been established in this species. Therefore, 
the goal of the current work was to determine the fiber- and sex specific transcriptional 
profiles of skeletal muscles in naïve rats and use differential gene expression to 
investigate molecular targets or pathways causally related to statin-induced myopathy 
(Table 2.2). 
 
In the current work, differential expression of the most abundant transcripts correlated 
with the skeletal muscle fiber phenotype, including energy metabolism and sarcomeric 
proteins which has been previously shown in mice (Yoshioka et al., 2007). Furthermore, 
these results were consistent with the protein expression pattern and biochemistry 
previously established for these muscle fibers in other species (Campbell et al., 2001; 
Guyton and Hall, 2006; Kang et al., 2005; Okumura et al., 2005; Zierath et al., 2004). 
However, some of the transcripts, like hemoglobin and those involved with the 
extracellular matrix may have originated from other cell types in the muscle, including 
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fibroblasts in the connective layers, endothelial and smooth cells in the vessel walls, 
blood cells within the vessels, nerves and Schwann cells around the axons which has 
been previously described in mice (Chemello et al., 2011). Despite this limitation, 
transcriptional profiling was able to discriminate between fast- and slow-twitch muscle 
fibers in the rat. 
 
The most abundant transcripts in female and male fast-twitch muscles were not different, 
indicating the phenotype of these muscles are similar. However, differential expression of 
all probe sets indicated subtle changes in several functional categories with a large 
number of transcripts without ontology. The most profound sex difference was 
represented by transcripts involved with energy metabolism. Specifically a more 
oxidative phenotype in female rats was observed which is consistent with literature 
reports in mice and humans (Haren et al., 2011; Maher et al., 2009; Salehzadeh et al., 
2011; Yoshioka et al., 2007).  
 
The fast-twitch muscles from cerivastatin (1 mg/kg) treated female rats showed a severe 
myopathy which was reflected by the profound transcriptional response in which 
approximately 50% of the detectable probes were differentially expressed. As noted in 
the results, differential expression of such a large number of transcripts is associated with 
pathology (Foster et al., 2007). Therefore, a limitation of the present results is that 
transcriptional changes were only analyzed after 14 days of dosing cerivastatin (1 
mg/kg), a time when there was severe myopathy in the fast-twitch muscles. Since this 
frank pathology likely obscures subtle, potentially informative transcriptional changes, 
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while favoring the identification of genes involved with energy metabolism, cell stress 
and inflammation a comprehensive evaluation of the transcriptional changes was not 
conducted. Instead, only a survey of the most abundant transcripts was evaluated to 
determine the major functional categories modulated with myopathy. However, there was 
an unexpected upregulation for many of the transcripts in the mevalonate pathway and 
cholesterol regulation. While upregulation of cholesterol biosynthesis transcripts is a 
common response associated with hepatotoxicity, HMG-CoA reductase inhibition is also 
known to cause a similar compensatory hepatic effect in the absence of pathology, 
particularly in the rat (Foster et al., 2007; Fujioka et al., 1995). Therefore, it is unknown 
whether this skeletal muscle specific response is mediated by pharmacology, toxicity or 
regeneration. However, Morikawa et al (2005) also showed transcriptional induction of 
genes in the cholesterol biosynthetic pathway in L6 myotubes and in a human skeletal 
muscle cell line following statin treatment and suggested this response may be related to 
the pathogenesis of muscle damage. Furthermore, Draeger et al (2010) observed a similar 
transcriptional induction of HMG-CoA reductase in human muscles following statin 
treatment.  
 
In skeletal muscles from cerivastatin treated rats with minimal to no myopathy the 
transcriptional profiles may be more informative of specific molecular targets which are 
causally related to the mechanism of statin-induced myopathy. More specifically, while 
there were a variety of fiber- and sex-specific transcriptional differences which may be 
important, there was also a common response across muscles characterized by 
modulation of several nuclear receptors including Nr1d1, Nr1d2, Nr4a1, Nr4a2 and 
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Nr4a3 as well as transcripts involved with energy metabolism, including the coactivator 
PGC-1α in the slow-twitch muscle which is necessary and sufficient to increase 
mitochondrial content, respiratory capacity and fiber switching to a more oxidative 
phenotype (Wende et al., 2005).  
 
The nuclear receptors Nr1d1 and Nr1d2 regulate a number of physiological functions, 
including circadian rhythm, carbohydrate and lipid metabolism, skeletal muscle 
differentiation and inflammation (Burris, 2008). The ligand for Nr1d1 and Nr1d2 is heme 
which increases affinity of the receptors to promoters thereby modulating repression of 
genes involved with a variety of physiological functions (Buriss, 2008). Intracellular 
heme levels are also coupled to PGC-1α expression, therefore a link between nutritional 
status, heme levels and skeletal muscle function exists (Burris, 2008). Heme is a 
porphyrin that is an essential prosthetic group for many proteins critical for muscle 
function including myoglobin and cytochrome oxidase (Buriss, 2008). Heme also 
increases expression of myoglobin, mitochondrial biogenesis, aerobic capacity and 
differentiation in skeletal muscle and these effects may be mediated by PGC-1α 
expression (Burris, 2010). Therefore, a direct link exists between transcriptional 
induction of Nr1d1 and Nr1d2 and skeletal muscle function. In contrast, the orphan 
nuclear receptors in the Nr4a subfamily function as ligand-independent transcription 
factors. These nuclear receptors are early-response genes induced by a variety of stimuli, 
including growth factors, cell stress and inflammation and are involved with regulating 
important functions including energy metabolism, proliferation, differentiation, survival 
and inflammation (Zhao and Bruemmer, 2010). While these transcriptional results do not 
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demonstrate a mode of action for statin-induced myopathy they do provide potential 
molecular targets which may be causally related to the mechanism. Furthermore, a 
common theme of altered energy metabolism and cell stress was observed suggesting 
differential regulation of these pathways in a fiber- and sex-dependent manner may be 
important. This conclusion is consistent with recent literature reports indicating that 
statin-induced myopathy is a metabolic muscle disease in which glucose utilization and 
mitochondrial function is impaired in fast-twitch muscles (Mallinson et al., 2009; Phillips 
and Haas, 2008). 
 
An important observation from this work is that female slow-twitch muscles were not  
resistant to the adverse effects of cerivastatin treatment. While myopathy was not 
observed, transcriptional induction of Mt1a was noted in the slow-twitch muscle 
suggesting oxidative stress. However, these changes may have been mediated by severe 
fast-twitch myopathy, which is associated with oxidative stress in these animals. 
Accordingly, evidence of oxidative stress in the slow-twitch muscle may be secondary to 
this effect in the fast-twitch muscle. Recent work by Bouitbir et al (2011) in humans and 
rats indicated that the generation of reactive oxygen species (ROS) represents the 
triggering factor which induces mitochondrial dysfunction and reduces mitochondrial 
biogenesis in fast-twitch muscles and this effect is rescued by antioxidants and 
overexpression of PGC-1α which induces genes involved with ROS removal. In contrast, 
significantly less ROS is generated in the heart and transcriptional induction of PGC-1α 
and β and mitochondrial biogenesis is considered the mediator of cardiac protection from 
statin treatment (Bouitbir et al., 2011). Given that the slow-twitch phenotype is more 
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similar to the heart than fast-twitch fibers it may be that similar mechanisms, including 
PGC-1α expression protects slow-twitch muscle fibers from statin-induced myopathy. 
Although this is a plausible mechanism, cardiotoxicity was observed with cerivastatin 
(Table 2.2), whereas the slow-twitch muscles were resistant. Therefore, additional factors 
are likely important in the mechanism of cerivastatin-induced myopathy in fast-twitch 
muscles. 
 
In summary, the current work demonstrates that gene expression profiles can discriminate 
fiber- and sex-specific transcriptional differences in the rat which are consistent with  
other species. Furthermore, this work provides novel molecular targets in the skeletal 
muscle which may be important in mediating cerivastatin-induced myopathy. Follow up 
investigative studies were conducted in subsequent chapters to further explore the role of 
altered cholesterol homeostasis and energy metabolism as potential mechanisms of 
cerivastatin-induced myopathy. 
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Figure 3.1. PCA analysis of skeletal muscle transcriptional profiles. A PCA analysis 
of all treatment groups identified two points of separation. Specifically, fast- and slow-
twitch muscle fibers from female rats were separated in principal component 2, whereas 
fast-twitch muscles from vehicle and cerivastatin treated female rats showing evidence of 
severe myopathy were separated in principal component 1. In contrast, fast-twitch 
muscles from both female and male rats clustered together, and regardless of treatment all 
slow-twitch muscles were generally clustered together.  
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Category Accession #
Differential gene 
expression
b Sequence name Sequence Description
Glycolysis
BI283882 3.6 Gpi glucose phosphate isomerase 
BI291434 3.5 Pfkm phosphofructokinase, muscle 
NM_017025 3.2 Ldha lactate dehydrogenase A 
NM_053297 3.0 Pk pyruvate kinase isozyme M2 - rat 
NM_031715 2.7 Pfkm phosphofructokinase, muscle 
NM_017328 2.4 Pgam2 phosphoglycerate mutase 2 
NM_012949 2.0 Eno3 enolase 3, beta 
NM_022922 1.9 Tpi1 triosephosphate isomerase 1
NM_012495 1.6 Aldoa aldolase A 
NM_017008 1.5 Gapd glyceraldehyde-3-phosphate dehydrogenase 
Glycogen metabolism
AI717476 3.2 Pygm muscle glycogen phosphorylase 
BI277505 2.9 Pgm1 phosphoglucomutase 1
AW919180 2.4 Pygm muscle glycogen phosphorylase 
BI275633 2.3 Pygm muscle glycogen phosphorylase
Citric acid cycle and oxidative phosphorylation
NM_058213 2.2 Atp2a1 ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 
NM_033235 - Mdh1 malate dehydrogenase 1, NAD (soluble) 
NM_013177 - Got2 glutamate oxaloacetate transaminase 2 \
NM_053756 - Atp5g3 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 3
AA893531 - Atp5f1 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit b, isoform 1
NM_019383 - Atp5h ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d 
NM_017311 - Atp5g1 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 1 
M19044 - Atp5b ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide 
BI275939 - Atp5c1 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 
J05266 - Atp5a1 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit, isoform 1
AF010323 - Atp5e ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit 
BG666921 - Ndurfb9 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9 
BG666002 - Ndufa4 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4 
AI231358 - Ndufs7 NADH dehydrogenase (ubiquinone) Fe-S protein 7 (predicted) 
AI555535 - Ndurfb3 NADH dehydrogenase (ubiquinone) 1 beta subcomplex 3 
NM_012812 - Cox6a2 cytochrome c oxidase, subunit VIa, polypeptide 2 
NM_019360 - Cox6c cytochrome c oxidase, subunit VIc 
NM_012786 - Cox8h cytochrome c oxidase subunit VIII-H (heart/muscle)
X15030 - Cox5a cytochrome c oxidase, subunit Va 
AI104240 - Cycs cytochrome c, somatic 
NM_017202 - Cox4i1 cytochrome c oxidase subunit IV isoform 1 
AA866477 - Cox7b cytochrome c oxidase subunit VIIb 
NM_022503 - Cox7a3 cytochrome c oxidase, subunit 7a 3 
NM_053586 - Cox5b cytochrome c oxidase subunit Vb 
BI296109 - Uqcrc2 ubiquinol-cytochrome c reductase core protein II 
BG670074 - Uqcrb ubiquinol-cytochrome c reductase binding protein 
Creatine phosphate synthesis
NM_012530 - Ckm creatine kinase, muscle 
AA799557 - Ckmt2 creatine kinase, mitochondrial 2 
Sarcomere and cytoskeleton
AW533848 13.4 Mybpc2 myosin binding protein C, fast-type 
BG378588 11.1 Mybpc2 myosin binding protein C, fast-type 
BI277545 9.6 Myh1 type 2X myosin heavy chain 
NM_133424 7.2 Actn3 actinin alpha 3 
BM391169 4.2 Myh4 myosin, heavy polypeptide 4, skeletal muscle 
AI716887 4.2 RGD1561064 similar to myozenin 1 
AF372216 2.4 Tpm1 tropomyosin 1, alpha
NM_017185 2.3 Tnni2 troponin 1, type 2, skeletal fast 
BF521859 2.2 Tnnt3 troponin T3, skeletal, fast 
NM_019131 2.2 Tpm1 tropomyosin 1, alpha 
NM_012605 1.8 Myl2 myosin, light polypeptide 2 
NM_019212 - Acta1 actin, alpha 1, skeletal muscle 
NM_020104 - Myl1 myosin, light polypeptide 1 
BF417385 - Tpm2 tropomyosin 2, beta 
BI289527 - Tmod4 tropomodulin 4 
NM_022531 - Des desmin 
BF552973 - Myot titin immunoglobulin domain protein (myotilin)
AI104533 - Ttn similar to N2B-Titin Isoform 
a
The most abundantly expressed transcripts represent the top 1% (125 probes) of the 12,482 probe sets expressed on the microarray.
a
The most abundantly expressed transcripts had an arbitrary intensity of 3,017 to 10,822 whereas all other transcripts had an intensity of 12 to 3,016.
b
Differential gene expression representing the fold change was determined at p<0.01 with a fold change ≥ ±1.5. (-) Indicates no transcriptional difference.
Table 3.1. Differential expression of the most abundantly expressed genes in the female rat fast- relative to slow-twitch skeletal muscles
ab
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Category Accession #
Differential gene 
expression
b Sequence name Sequence Description
Immune, inflammatory response and cell stress
D29960 - Hspd6 heat shock protein, alpha-crystallin-related, B6
AA866458 - Csda cold shock domain protein A 
NM_024351 - Hspa8 heat shock protein 8 
NM_012935 -1.9 Cryab crystallin, alpha B 
Metabolism
NM_022676 2.1 Pp1r1a protein phosphatase 1, regulatory (inhibitor) subunit 1A 
J02811 2.1 Ampd1 adenosine monophosphate deaminase 1 (isoform M) 
AB030829 - Ca3 carbonic anhydrase 3 
AI411388 - Oaz1 ornithine decarboxylase antizyme 1
NM_019292 -1.9 Ca3 carbonic anhydrase 3 
Regulation of transcription and translation
BI281697 - RPl17a ribosomal protein L7a 
AI177054 - Rpl27a ribosomal protein L27a
NM_017152 - Rps17 ribosomal protein S17 
NM_022506 - Rp131 ribosomal protein L31 
BG666892 - RP19 ribosomal protein L9 
AI229633 - RPS29 ribosomal protein S29 
AA848284 - Rps23 ribosomal protein S23 
BM388159 - RPl32 ribosomal protein L32 
NM_031103 - RPl19 ribosomal protein L19 
AI598536 - RPl26 ribosomal protein L26 
NM_017153 - Rps3a ribosomal protein S3a 
BG666872 - Rps16 ribosomal protein S16 
AA944861 - Rps2 ribosomal protein S2
AW914118 - Rpl35 ribosomal protein L35 
NM_031099 - Rpl15 ribosomal protein L5 
AA799501 - Rps4x ribosomal protein S4, X-linked 
NM_022672 - Rps14 ribosomal protein S14 
NM_022402 - Arbp acidic ribosomal phosphoprotein P0 
NM_012660 - Eef1a2 Elongation factor 1a2 
BI282111 - Nsep1 nuclease sensitive element binding protein 1
NM_133583 - Ndrg2 N-myc downstream regulated gene 2 
AW434961 - Hfe2 RGM domain family, member C 
BI279866 - L18a similar to 60S ribosomal protein L18a 
BG673187 -1.8 Fhl1 four and a half LIM domains 1 
Transporters
BG666999 - Slc25a4 solute carrier family 25 (mitochondrial adenine nucleotide translocator) member 4 
M23984 - Slc255a3 solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 3 
NM_031355 - Vdac3 voltage-dependent anion channel 3
NM_031353 - Vdac1 voltage-dependent anion channel 1 
NM_012505 - ATP1a2 ATPase, Na+/K+ transporting, alpha 2 polypeptide
Miscellaneous
AI175539 8.4 Pvalb parvalbumin 
BI302005 2.3 Mlf1 myeloid leukemia factor 1 
BF284168 1.7 H19 H19 fetal liver mRNA 
NM_021588 - Mb myoglobin 
AI179404 - Hba-a1 hemoglobin alpha 2 chain
AI179404 - Hba-a1 hemoglobin alpha 2 chain
NM_033234 - Hbb hemoglobin beta chain complex 
NM_012848 - Fth1 ferritin, heavy polypeptide 1 
NM_053867 - Tpt1 tumor protein, translationally-controlled 1 
BI282332 - MGC105647 similar to Nur77 downstream protein 2 
AA800892 - RGD1563599 similar to putative SH3BGR protein
AI012372 - Sui1-rs1 suppressor of initiator codon mutations, related sequence 1 
D16554 - Ubb polyubiquitin 
AI406651 - Serf2 small EDRK-rich factor 2 
AA944393 - MGC72942 similar to CG6105-PA 
Without ontology
BI276959 2.4
BG663128 1.8
AI230164 -
AI170758 -
AA849795 -
AI180257 -
AI104151 -
AA799471 -
AI008105 -
BF395095 -
AI228039 -
AI104326 -
a
The most abundantly expressed transcripts represent the top 1% (125 probes) of the 12,482 probe sets expressed on the microarray.
a
The most abundantly expressed transcripts had an arbitrary intensity of 3,017 to 10,822 whereas all other transcripts had an intensity of 12 to 3,016.
b
Differential gene expression representing the fold change was determined at p<0.01 with a fold change ≥ ±1.5. (-) Indicates no transcriptional difference.
Table 3.2. Differential expression of the most abundantly expressed genes in the female rat fast- relative to slow-twitch skeletal muscles
ab
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Category Accession #
Differential gene 
expression
b Sequence name Sequence description
Glycolysis
AA848319 4.9 Ldhb lactate dehydrogenase B 
NM_017008 -1.5 Gapd glyceraldehyde-3-phosphate dehydrogenase 
NM_012495 -1.6 aldoa aldolase A 
NM_022922 -1.9 Tpi1 triosephosphate isomerase 1 
NM_012949 -2.0 Eno3 enolase 3, beta 
NM_017328 -2.4 Pgam2 phosphoglycerate mutase 2 
Fatty acid oxidation
NM_133618 - Hadhb
Citric acid cycle and oxidative phosphorylation
NM_017290 4.0 Atp2a2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 
AI172491 1.7 LOC361596 similar to NADP+-specific isocitrate dehydrogenase 
NM_033235 - Mdh1 malate dehydrogenase 1, NAD (soluble)
AI172320 - Sdhb succinate dehydrogenase complex, subunit B, iron sulfur 
NM_024398 - Aco2 aconitase 2, mitochondrial 
M19044 - Atp5b ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide 
NM_053756 - Atp5g3 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 3 
BI275939 - Atp5c1 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 
J05266 - Atp5a1 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit, isoform 1
AF010323 - Atp5e ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit 
AA893531 - Atp5f1 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit b, isoform 1 
NM_019383 - Atp5h ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d 
NM_017311 - Atp5g1 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 1 
BG666921 - Ndufb9 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9 
BG666002 - Ndufa4 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4 
AI555535 - Ndurfb3 NADH dehydrogenase (ubiquinone) 1 beta subcomplex 3 
AI231358 - Ndufs7 NADH dehydrogenase (ubiquinone) Fe-S protein 7 
NM_012786 - Cox8h Cytochrome c oxidase subunit VIII-H (heart/muscle) 
NM_019360 - Cox6c cytochrome c oxidase, subunit VIc 
NM_017202 - Cox4i1 cytochrome c oxidase subunit IV isoform 1 
AA866477 - Cox7b cytochrome c oxidase subunit VIIb 
X15030 - Cox5a cytochrome c oxidase, subunit Va 
NM_022503 - Cox7a3 cytochrome c oxidase, subunit 7a 3 
NM_053586 - Cox5b cytochrome c oxidase subunit Vb 
AI104240 - Cycs cytochrome c, somatic 
NM_012812 - Cox6a2 cytochrome c oxidase, subunit VIa, polypeptide 2
BI296109 - Uqcrc2 ubiquinol-cytochrome c reductase core protein II 
BG670074 - Uqcrb ubiquinol-cytochrome c reductase binding protein 
NM_058213 -2.2 Atp2a1 ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 
Creatine phosphate synthesis
NM_012530 - Ckm creatine kinase, muscle 
AA799557 - Ckmt2 creatine kinase, mitochondrial 2 
Sarcomere and cytoskeleton
AA849895 10.0 Ankrd2 ankyrin repeat domain 2 (stretch responsive muscle) 
BF395647 9.4 Myh7 myosin, heavy polypeptide 7, cardiac muscle, beta 
NM_017184 7.4 Tnni1 troponin I, skeletal, slow 1 
AI104354 7.2 Myoz2 myozenin 2 
NM_017240 6.7 Myh7 myosin, heavy polypeptide 7, cardiac muscle, beta 
AF399874 6.2 Tnnt1 troponin T1, skeletal, slow 
AI710682 5.1 Tncc troponin C, cardiac/slow skeletal 
NM_057144 4.9 Csrp3 cysteine-rich protein 3 
NM_012606 4.3 Myl3 myosin, light polypeptide 3 
BF419995 3.1 Mlc2 myosin regulatory light chain 2, ventricular/cardiac muscle isoform 
BF284889 2.3 Actn2 actinin alpha 2 
BM386665 1.8 Nrap nebulin-related anchoring protein 
NM_019212 - Acta1 actin, alpha 1, skeletal muscle 
BM389619 - Mybpc1 myosin binding protein C, slow type 
NM_020104 - Myl1 myosin, light polypeptide 1 
BF417385 - Tpm2 tropomyosin 2, beta 
BI289527 - Tmod4 tropomodulin 4 
NM_022531 - Des desmin 
AI104533 - Ttn similar to N2B-Titin Isoform 
BF552973 - Myot titin immunoglobulin domain protein (myotilin)
BE113393 - Synpo2 similar to Synaptopodin-2
BI296011 - Cfl2 cofilin 2, muscle 
NM_012605 -1.8 Myl2 myosin, light polypeptide 2 
BF521859 -2.2 Tnnt3 troponin T3, skeletal, fast 
NM_019131 -2.2 Tpm1 tropomyosin 1, alpha 
NM_017185 -2.3 Tnni2 troponin 1, type 2 
a
The most abundantly expressed transcripts represent the top 1% (131 probes) of the 13,112 probe sets expressed on the microarray.
a
The most abundantly expressed transcripts had an arbitrary intensity of 2,927 to 9,916 whereas all other transcripts had an intensity of 12 to 2,922.
b
Differential gene expression representing the fold change was determined at p<0.01 with a fold change ≥ ±1.5. (-) Indicates no transcriptional difference.
hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A 
hydratase (trifunctional protein), beta subunit 
Table 3.3. Differential expression of the most abundantly expressed genes in the female rat slow- relative to fast-twitch skeletal muscles
ab
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Category Accession #
Differential gene 
expression
b Sequence name Sequence description
Immune, inflammatory response and cell stress
BM390305 8.0 Hspb7 heat shock 27kD protein family, member 7 (cardiovascular) 
NM_012935 1.9 Cryab crystallin, alpha B 
NM_031970 1.8 Hspb1 heat shock 27kDa protein 1 
D29960 - Hspb6 heat shock protein, alpha-crystallin-related, B6 
NM_024351 - Hspa8 heat shock protein 8 
AA866458 - Csda cold shock domain protein A 
Metabolism
S41066 2.4 Gpx1 glutathione peroxidase 1 
NM_019292 1.9 Ca3 carbonic anhydrase 3 
AB030829 - Ca3 carbonic anhydrase 3
Regulation of transcription and translation
BI298356 2.3 Fhl1 four and a half LIM domains 1 
BG673187 1.8 Fhl1 four and a half LIM domains 1 
AI177054 - Rp127a ribosomal protein L27a 
BI281697 - Rp17a ribosomal protein L7a 
NM_017152 - Rps17 ribosomal protein S17 
AA848284 - Rps23 ribosomal protein S23 
BI279866 - MGC72957 similar to 60S ribosomal protein L18a 
BG666892 - Rpl9 ribosomal protein L9 
NM_031103 - Rpl19 ribosomal protein L19 
AI229633 - Rps29 ribosomal protein S29 
NM_022506 - Rp131 ribosomal protein L31 
NM_017153 - Rps3a ribosomal protein S3a 
BG666872 - Rps16 ribosomal protein S16   
AW914118 - Rp135 ribosomal protein L35 
NM_022672 - Rps14 ribosomal protein S14 
BM388159 - Rp132 ribosomal protein L32
NM_031706 - Rps8 ribosomal protein S8 
AI598536 - Rp126 ribosomal protein L26 
AA799501 - Rps4x ribosomal protein S4, X-linked 
NM_031099 - Rpl5 ribosomal protein L5 
AA944861 - Rps2 ribosomal protein S2 
BG375811 - Rps24 ribosomal protein S24 
NM_022402 - Arbp acidic ribosomal phosphoprotein P0 
AW914090 - Rplp1 ribosomal protein, large, P1 
Transporters
BG666999 - Slc25a4 solute carrier family 25 (mitochondrial adenine nucleotide translocator) member 4 
M23984 - Slc25a3 solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 3 
NM_031353 - Vdac1 voltage-dependent anion channel 1 
Miscellaneous \
NM_024162 2.3 Fabp3 fatty acid binding protein 3 
BI285575 2.2 Col1a1 collagen, type 1, alpha 1 
NM_021588 - Mb myoglobin
AI179404 - Hba-a1 hemoglobin alpha 2 chain 
AI179404 - Hba-a1 hemoglobin alpha 2 chain 
NM_012848 - Fth1 ferritin, heavy polypeptide 1 
BI275716 - Col3a1 collagen, type III, alpha 1
NM_053867 - Tpt1 tumor protein, translationally-controlled 1 
AI012372 - Sui1-rs1 suppressor of initiator codon mutations, related sequence 1 
NM_012512 - B2m beta-2 microglobulin 
NM_133583 - Ndrg2 N-myc downstream regulated gene 2 
BI282111 - Nsep1 nuclease sensitive element binding protein 1
AI233054 - Qpc low molecular mass ubiquinone-binding protein 
BI282332 - MGC105647 similar to Nur77 downstream protein 2 
AA891707 - Usmg5 upregulated during skeletal muscle growth 5 
BF284168 -1.7 H19 H19 fetal liver mRNA
Without ontology
AI230220 33.4
AI599017 5.5
BM384301 2.8
AI230164 -
AI170758 -
AI180257 -
AA849795 -
AI104151 -
AA799471 -
AI008105 -
AI228039 -
AA944393 -
BF395095 -
BG663128 -1.8
a
The most abundantly expressed transcripts represent the top 1% (131 probes) of the 13,112 probe sets expressed on the microarray.
a
The most abundantly expressed transcripts had an arbitrary intensity of 2,927 to 9,916 whereas all other transcripts had an intensity of 12 to 2,922.
b
Differential gene expression representing the fold change was determined at p<0.01 with a fold change ≥ ±1.5. (-) Indicates no transcriptional difference.
Table 3.4. Differential expression of the most abundantly expressed genes in the female rat slow- relative to fast-twitch skeletal muscles
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Table 3.5. Differential expression of genes in the fast-twitch muscle from female relative to male rats
a
Category Accession #
Differential gene 
expression
a Sequence name Sequence Description
Energy metabolism 
NM_031511 2.1 Igf2 insulin-like growth factor 2 
BI303527 2.1 Arrdc3 arrestin domain containing 3 
NM_022290 2.1 Tnmd tenomodulin 
NM_053551 2.0 Pdk4 pyruvate dehydrogenase kinase, isoenzyme 4 
BI295878 1.8 Kat3 kynurenine aminotransferase III 
NM_134387 1.6 Dcxr dicarbonyl L-xylulose reductase 
NM_022400 1.6 Bcat2 branched chain aminotransferase 2, mitochondrial 
 U92069 1.6 Ucp3 uncoupling protein 3 
AY057895 1.5 Adrb2 adrenergic receptor, beta 2 
NM_133606 1.5 Ehhadh enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase 
BG673588 1.5 Igfbp6 insulin-like growth factor binding protein 6 
AI176565 1.5 Acas2l acetyl-Coenzyme A synthetase 2 (AMP forming)-like 
NM_012793 -1.5 Gamt guanidinoacetate methyltransferase 
NM_012969 -1.6 Irs1 insulin receptor substrate 1 
Immune, inflammatory response and cell stress
NM_133380 2.1 Il4r interleukin 4 receptor 
AF307302 1.9 H2-Aa histocompatibility 2, class II antigen A, alpha 
X89963 2.1 Thbs4 thrombospondin 4 
NM_053843 1.7 Fcgr2a similar to Fc gamma (IgG) receptor II (low affinity) alpha precursor - rat 
BF387360 1.7 RGD1559482 similar to immunoglobulin superfamily, member 7 
L12458 1.7 Lyz lysozyme 
NM_013069 1.7 Cd74 CD74 antigen (invariant polpypeptide of major histocompatibility class II antigen-associated) 
BG671521 1.6 Hspca heat shock protein 1, alpha 
NM_031348 1.6 Fcna ficolin A 
BI285141 1.6 Cd24 CD24 antigen 
BF418957 1.6 C1qa complement component 1, q subcomponent, alpha polypeptide 
AW915763 1.5 Serping1 serine (or cysteine) peptidase inhibitor, clade G, member 1 
AI411618 1.5 C1qg complement component 1, q subcomponent, gamma polypeptide 
NM_017079 1.5 CD1d1 CD1d1 antigen 
AA925924 -1.6 Crlf1 cytokine receptor-like factor 1 
AI176519 -1.9 Ler3 immediate early response 3 
AI406687 -1.9 Cklfsf6 chemokine-like factor super family 6 
AI407339 -2.3 Ifi1 interferon inducible protein 1 
Metabolism
L32601 2.2 Akr1c18 20 alpha-hydroxysteroid dehydrogenase 
NM_031509 1.6 Gsta5 glutathione S-transferase A5 
NM_022547 1.6 Fthfd formyltetrahydrofolate dehydrogenase 
AI411117 -1.6 Tst thiosulfate sulfurtransferase 
AF319950 -1.6 Glrx1 glutaredoxin 1 (thioltransferase) 
NM_022278 -1.6 Glrx1 glutaredoxin 1 (thioltransferase) 
AI408948 -1.8 Ca2 carbonic anhydrase 2 
Regulation of transcription and translation
NM_012912 3.4 Atf3 activating transcription factor 3 
J03933 2.2 Thrb thyroid hormone receptor beta 
NM_031678 1.8 Per2 period homolog 2
BM384099 1.8 Ndrg1 N-myc downstream regulated gene 1
NM_024388 1.7 Nr4a1 nuclear receptor subfamily 4, group A, member 1 
AI013390 -1.6 Cited2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain
NM_053698 -1.8 Cited2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 
AI556378 -2.2 Cited 4 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4 
Extracellular matrix
NM_080698 3.3 Fmod fibromodulin 
AW251280 2.9 Tna tetranectin (plasminogen binding protein) 
BE116084 2.1 Xlkd1 extra cellular link domain-containing 1 
AA945955 1.9 Ogn osteoglycin 
a
Differential gene expression representing fold change was determined at p<0.01 with a fold change ≥ ±1.5. 
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Table 3.6. Differential expression of genes in the fast-twitch muscle from female relative to male rats
a
Category Accession #
Differential gene 
expression
a Sequence name Sequence Description
Miscellaneous
BG668493 4.6 Stmn2 stathmin-like 2
NM_053440 3.7 Stmn2 stathmin-like 2 
NM_080892 2.1 Selenbp1 selenium binding protein 2 
BI284420 1.8 STRA6 similar to retinoic acid-responsive protein
BI279526 1.8 RT1-Db1 RT1 class II, locus Db1 
NM_031832 1.8 Lgals3 lectin, galactose binding, soluble 3 
AA818521 1.7 Thbd thrombomodulin 
BG667163 1.7 Ddx3x DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3, X-linked 
NM_053296 1.7 Glrb glycine receptor, beta subunit 
BG662620 1.7 Eif2s3x similar to eukaryotic translation initiation factor 2, subunit 3, structural gene X-linked 
AJ131902 1.7 Gas7 growth arrest specific 7 
BM389311 1.6 RGD1564930 similar to novel protein Tensin 
Y00480 1.6 RT1-Da RT1 class II, locus Da 
BI286025 1.5 Lmod1 leiomodin 1 (smooth muscle)
BF284017 -1.5 Raph1 Ras association (RalGDS/AF-6) and pleckstrin homology domains 1, transcript variant 2 
AW520792 -1.6 Vasp vasodilator-stimulated phosphoprotein 
BM389208 -1.6 Gimap4 GTPase, IMAP family member 4 
M58040 -1.6 Tfrc transferrin receptor 
BI282699 -1.6 Abr active BCR-related gene 
AW253616 -1.7 Slc8a1 solute carrier family 8 (sodium/calcium exchanger), member 1 
BM387083 -1.7 Sema6a sema domain, transmembrane domain (TM), and cytoplasmic domain
BF525047 -1.8 Actc1 actin alpha cardiac 1 
AA800705 -2.0 Actc1 actin alpha cardiac 1 
J05087 -2.2 Atp2b3 ATPase, Ca++ transporting, plasma membrane 3 
AI112577 -2.4 Gng3 guanine nucleotide binding protein (G protein), gamma 3 subunit 
NM_133621 -2.4 Hod homeobox only domain 
Without ontology
AI228978 51.2
AI103917 33.7
BG374488 6.7
AA799294 5.7
BF418649 3.0
BF408611 3.0
BM391248 2.4
AI103530 2.1
BI278231 2.1
AI171466 2.0
AI598546 2.0
AW433665 2.0
AA956555 2.0
BE111083 1.9
BF414266 1.9
H32997 1.9
AA945579 1.8
BI275923 1.8
AI043817 1.7
AA858930 1.7
AI716248 1.7
BE107890 1.6
BE108345 1.6
AA817956 1.6
AI411941 1.6
BF555488 1.6
BI294018 1.6
BI282107 1.5
AI227627 1.5
BF417285 1.5
AI406802 -1.5
AA859508 -1.5
AA891759 -1.6
BE113016 -1.6
AI043888 -1.6
BI280865 -1.7
AI711147 -1.7
U30831 -1.7
H33003 -1.7
AA819332 -1.7
BF386499 -1.8
AI044729 -1.9
BI274589 -2.0
AA957707 -2.0
AI228970 -2.0
AI711147 -2.0
BF395080 -2.0
BF544005 -2.1
AA957509 -2.1
AW253907 -2.5
AI010831 -2.6
a
Differential gene expression representing fold change was determined at p<0.01 with a fold change ≥ ±1.5. 
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Table 3.7. Differential expression of genes in the fast-twitch muscle from cerivastatin (0.5 mg/kg) relative to vehicle treated female rats
a
Category Accession #
Differential gene 
expression
a Sequence name Sequence Description
Energy metabolism 
NM_053551 1.8 Pdk4 pyruvate dehydrogenase kinase, isoenzyme 4 
Regulation of transcription and translation
M25804 2.2 Nr1d1 nuclear receptor subfamily 1, group D, member 1 
NM_053698 1.9 Cited2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 
AI013390 1.7 Cited2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2
AI602501 1.6 Lmcd1 LIM and cysteine-rich domains 1
NM_057144 1.6 Csrp3 cysteine-rich protein 3
NM_053536 1.5 Klf15 Kruppel-like factor 15 
BF564195 -1.5 Crem cAMP responsive element modulator
Immune, inflammatory response and cell stress
AI104331 1.6 Sesn1 sestrin 1 
AA945704 -1.7 Dnajb1 DnaJ (Hsp40) homolog, subfamily B, member 1 
BM384926 -2.0 Dnajb1 DnaJ (Hsp40) homolog, subfamily B, member 1 
Miscellaneous
AW918724 1.5 Enah enabled homolog (Drosophila) 
BE117201 -1.6 Uxs1 UDP-glucuronate decarboxylase 1 
BI289103 -1.8 Slc44a4 Ng22 protein (Ng22)  
NM_022296 -1.9 Xylt2 xylosyltransferase II 
AI177358 -2.0 Slc25a25 solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 25 
AI406939 -2.6 G0s2 G0/G1 switch gene 2 
Without ontology
BE100456 1.9 RGD1559442
AI231999 1.7 LOC689256
AI070270 -1.5 Tob2
AI712476 -1.6 1391431
BI296430 -1.6 1378055
BF414266 -1.7 Sart3
AA858930 -1.6 Pde4b
AA891759 1.6 RGD1309437
BG381715 -1.5 BG381715
a
Differential gene expression representing fold change was determined at p<0.01 with a fold change ≥ ±1.5. 
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Table 3.8. Differential expression of the most abundantly expressed genes in the fast-twitch muscle from cerivastatin (1 mg/kg) relative to vehicle 
treated female rats
ab
Category Accession #
Differential gene 
expression
b Sequence name Sequence Description
Glycolysis
NM_012554 2.9 Eno1 Alpha enolase 
NM_017008 -1.8 Gapdh glyceraldehyde-3-phosphate dehydrogenase 
NM_053297 -2.1 Pkm2 pyruvate kinase 
NM_017025 -2.2 Ldha lactate dehydrogenase A 
NM_012495 -2.2 Aldoa aldolase A 
NM_022922 -2.6 Tpi1 triosephosphate isomerase 1 
NM_012949 -4.2 Eno3 enolase 3, beta
Citric acid cycle and oxidative phosphorylation
BE111722 13.4 Ndufs2 NADH dehydrogenase (ubiquinone) Fe-S protein 2 
NM_130823 3.1 Atp6v0c ATPase, H+ transporting, V0 subunit C 
BG673321 2.0 Cox8a cytochrome c oxidase, subunit VIIIa 
NM_017202 - Cox4i1 cytochrome c oxidase subunit IV isoform 1 
AI230604 - Cox6b1 cytochrome c oxidase, subunit VIb polypeptide 1 
BF281400 -1.5 Atp5j2 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit f, isoform 2 
NM_019383 -1.6 Atp5h ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d
BG670074 -1.7 Uqcrb ubiquinol-cytochrome c reductase binding protein 
NM_022503 -1.7 Cox7a2 cytochrome c oxidase, subunit 7a 3 
AA893531 -1.7 Atp5f1 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit b, isoform 1 
M19044 -1.8 Atp5b ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide 
NM_053586 -1.8 Cox5b cytochrome c oxidase subunit Vb 
NM_019360 -1.8 Cox6c cytochrome c oxidase, subunit VIc 
AA866477 -1.8 Cox7b cytochrome c oxidase subunit VIIb 
AI233054 -1.8 Qpc low molecular mass ubiquinone-binding protein 
X15030 -1.8 Cox5a cytochrome c oxidase, subunit Va 
NM_053756 -1.9 Atp5g3 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c 
BG666002 -1.9 Ndufa4 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4 
BG666921 -1.9 Ndufb9 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9 
AF010323 -2.0 Atp5e ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit 
AI104240 -2.1 Cycs cytochrome c, somatic 
J05266 -2.1 Atp5a1 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit, isoform 1
BI275939 -2.2 Atp5c1 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1
NM_012812 -2.7 Cox6a2 cytochrome c oxidase, subunit VIa, polypeptide 2 
NM_058213 -3.6 Atp2a1 ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 
Creatine phosphate synthesis
NM_012530 -2.4 Ckm creatine kinase, muscle 
Sarcomere and cytoskeleton
NM_019289 9.7 Arpc1b actin related protein 2/3 complex, subunit 1B 
BF525047 7.8 Actc1 actin alpha cardiac 1 
BG666614 7.3 Cfl1 cofilin 1 
AA800705 7.0 Actc1 actin alpha cardiac 1 
BI285434 5.0 Tuba6 tubulin, alpha 6 
NM_031140 4.2 Vim vimentin 
AW920881 3.3 Actr2 ARP2 actin-related protein 2 homolog (yeast)
NM_031144 3.3 Actb actin, beta
NM_031986 3.3 Sdcbp syndecan binding protein 
AI009775 3.2 Arpc2_predicted actin related protein 2/3 complex, subunit 2 
NM_031144 3.1 Actb actin, beta 
BI285502 2.9 LOC684520 myosin, light polypeptide 6, alkali, smooth muscle and non-muscle 
BG666668 2.7 Actg1 similar to cytoplasmic beta-actin, transcript variant 2 
NM_022511 2.7 Pfn1 profilin 1 
BG668902 2.2 Tmsb4x thymosin, beta 4
NM_057144 2.4 Csrp3 cysteine-rich protein 3 
NM_053319 1.8 Dynll1 dynein, cytoplasmic, light chain 1 
X05566 - Mrlcb similar to Myosin regulatory light chain 2-A, smooth muscle isoform 
NM_053867 - Tpt1 tumor protein, translationally-controlled 1 
NM_022531 - Des desmin 
AF002281 -1.5 Pdlim3 PDZ and LIM domain 3 
NM_019212 -1.6 Acta1 actin, alpha 1, skeletal muscle 
NM_020104 -1.9 Myl1 myosin, light polypeptide 1 
NM_012605 -1.9 Mylpf myosin, light polypeptide 2 
BF417385 -2.0 Tpm2 tropomyosin 2, beta 
BF521859 -2.2 Tnnt3 troponin T3, skeletal, fast 
NM_019131 -2.6 Tpm1 tropomyosin 1, alpha 
AF372216 -2.6 Tpm1 tropomyosin 1, alpha
NM_017185 -2.7 Tnni2 troponin 1, type 2 
AI104533 -3.7 Ttn N2B-Titin Isoform 
NM_133424 -5.4 Actn3 actinin alpha 3 
a
The most abundantly expressed transcripts represent the top 2% (278 probes) of the 13,947 probe sets expressed on the microarray.
a
The most abundantly expressed transcripts had an arbitrary intensity of 1,411 to 6,526 whereas all other transcripts had an intensity of 14 to 1,410.
b
Differential gene expression representing the fold change was determined at p<0.01 with a fold change ≥ ±1.5. (-) Indicates no transcriptional difference.
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Table 3.9. Differential expression of the most abundantly expressed genes in the fast-twitch muscle from cerivastatin (1 mg/kg) relative to vehicle 
treated female rats
ab
Category Accession #
Differential gene 
expression
b Sequence name Sequence Description
Immune, inflammatory response and cell stress
AB001382 100.0 Spp1 secreted phosphoprotein 1 
AF411318 60.1 Mt1a metallothionein 1
NM_053819 51.9 Timp1 tissue inhibitor of metalloproteinase 1 
AI177761 31.7 Cd68 CD68 antigen 
BG380285 26.1 Ifitm1 interferon induced transmembrane protein 1 
NM_053843 16.1 Fcgr3 similar to Fc gamma (IgG) receptor II (low affinity) alpha precursor - rat 
L81174 13.3 Ankrd1 ankyrin repeat domain 1 
AF154349 13.2 Lgmn legumain 
BM389261 12.3 Ifi30 interferon gamma inducible protein 30 
NM_053843 12.1 Fcgr3 Fc receptor, IgG, low affinity III
NM_031832 11.0 Lgals3 lectin, galactose binding, soluble 3 
L12458 8.2 Lyz lysozyme 
NM_017125 5.0 Cd63 CD63 antigen 
NM_021989 4.5 Timp2 tissue inhibitor of metalloproteinase 2 
AI178772 3.8 Ptma prothymosin alpha 
NM_013132 3.6 Anxa5 annexin A5 
NM_022536 3.5 Ppib peptidylprolyl isomerase B 
NM_012904 3.5 Anxa1 annexin A1 
BG671399 3.0 Ppia peptidylprolyl isomerase A 
BG057543 2.5 Tra1 tumor rejection antigen gp96 
NM_012512 2.1 B2m beta-2 microglobulin 
NM_019904 1.8 Lgals1 lectin, galactose binding, soluble 1 
NM_031812 1.6 Cd164 CD164 antigen 
NM_031970 - Hspb1 heat shock 27kDa protein 1 
BI285700 - Hspcb heat shock 90kDa protein 1, beta 
NM_012966 - Hspe1 heat shock 10 kDa protein 1 
NM_024351 - Hspa8 heat shock protein 8 
AI237389 - Hspcb heat shock 90kDa protein 1, beta 
NM_012935 - Cryab crystallin, alpha B 
AA866458 -1.9 Csda cold shock domain protein A 
Metabolism 
AI102495 10.0 Np nucleoside phosphorylase 
AA893220 7.5 Sat spermidine/spermine N1-acetyl transferase 
NM_053800 2.6 Txn1 thioredoxin 1 
NM_053610 2.2 Prdx5 peroxiredoxin 5 
S41066 2.1 Gpx1 glutathione peroxidase 1 
NM_031000 1.8 Akr1a1 aldo-keto reductase family 1, member A1 
NM_057114 1.8 Prdx1 peroxiredoxin 1 
NM_017050 - Sod1 superoxide dismutase 1 
BI275294 - Glul glutamine synthetase 1 
BI296610 - Glul glutamine synthetase 1 
NM_013177 -1.8 Got2 glutamate oxaloacetate transaminase 2 
AB030829 -3.0 Ca3 carbonic anhydrase 3 
Proteolysis
AI176595 7.0 Ctsl cathepsin L 
BI283159 6.1 Scpep1 serine carboxypeptidase 1 
BM389083 5.5 Ppgb protective protein for beta-galactosidase
NM_022597 5.1 Ctsb cathepsin B 
BG666933 1.9 Cst3 cystatin C 
NM_031687 1.6 Uba52 ubiquitin A-52 residue ribosomal protein fusion product 1 
NM_013013 1.6 Psap prosaposin 
NM_031629 1.5 Psmb4 proteasome (prosome, macropain) subunit, beta type 4 
AW525776 - Laptm4a lysosomal-associated protein transmembrane 4A 
NM_031237 - Ube2d3 ubiquitin-conjugating enzyme E2D 3
BG663093 - Sqstm1 sequestosome 1 (Sqstm1), transcript variant 1  
D16554 - Ubb polyubiquitin
NM_017283 - Psma6 proteasome (prosome, macropain) subunit, alpha type 6 
D16554 - Ubb polyubiquitin 
Extracellular matrix
AA893484 3.9 Fn1 fibronectin 1 
BI275716 1.8 Col3a1 collagen, type III, alpha 1 
BM390253 1.7 Dcn decorin 
BM388837 1.6 Col1a2 procollagen, type I, alpha 2 
NM_017138 1.6 Rpsa laminin receptor 1 
D28875 - Sparc secreted acidic cysteine rich glycoprotein 
BI285575 - Col1a1 collagen, type 1, alpha 1 
a
The most abundantly expressed transcripts represent the top 2% (278 probes) of the 13,947 probe sets expressed on the microarray.
a
The most abundantly expressed transcripts had an arbitrary intensity of 1,411 to 6,526 whereas all other transcripts had an intensity of 14 to 1,410.
b
Differential gene expression representing the fold change was determined at p<0.01 with a fold change ≥ ±1.5. (-) Indicates no transcriptional difference.
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Table 3.10. Differential expression of the most abundantly expressed genes in the fast-twitch muscle from cerivastatin (1 mg/kg) relative to vehicle 
treated female rats
ab
Category Accession #
Differential gene 
expression
b Sequence name Sequence Description
Regulation of transcription and translation
AA892367 4.6 Rpl3 ribosomal protein L3 
BI284436 4.2 Eif4a1 eukaryotic translation initiation factor 4A1 
NM_134353 3.8 Pabpc1 poly(A) binding protein, cytoplasmic 1 
AI177503 3.2 H3f3b H3 histone, family 3B 
BI279561 2.7 Naca nascent-polypeptide-associated complex alpha polypeptide 
NM_017172 2.4 Zfp36l1 zinc finger protein 36, C3H type-like 1 
NM_0+B20533539 2.3 Eef1a1 eukaryotic translation elongation factor 1 alpha 1 
AW251450 2.2 Mustn1 musculoskeletal, embryonic nuclear protein 1 
NM_031709 2.0 Rps12 ribosomal protein S12 
BG665124 2.0 Rps3 ribosomal protein S3 
X61043 2.0 Eef1a1 eukaryotic translation elongation factor 1 alpha 1
NM_031109 1.9 Rps10 ribosomal protein S10 
NM_013043 1.9 Tsc22d1 TSC22 domain family, member 1 
NM_031101 1.8 Rpl13 ribosomal protein L13 
AI175551 1.8 Eef1b2 eukaryotic translation elongation factor 1 beta 2
NM_022179 1.8 Hk3 ribosomal protein L13A 
AA799768 1.8 Rps9 ribosomal protein S9 
NM_031102 1.8 Rpl18 ribosomal protein L18 
BG668512 1.7 Rps19 ribosomal protein S19 
AI170643 1.7 LOC499782 similar to 60S ribosomal protein L12
NM_017151 1.7 Rps15 ribosomal protein S15 
BF281388 1.7 Rps18 ribosomal protein S18 
NM_031065 1.6 Rpl10a ribosomal protein L10A
BF410811 1.6 Rps21 ribosomal protein S21 
AW142090 1.6 Rpl36a ribosomal protein L36a 
AW914097 1.6 Rps20 ribosomal protein S20 
AI237597 1.6 Hspca heat shock protein 1, alpha 
NM_031706 1.6 Rps8 ribosomal protein S8 
AA944073 1.6 Rpl41 ribosomal protein L41 
AA874811 1.6 Rpl14 ribosomal protein L14 
BM390456 1.5 H3f3b H3 histone, family 3A, transcript variant 1  
AA800007 1.5 Rpl15 ribosomal protein L15 
NM_017150 1.5 Rpl29 ribosomal protein L29 
BG671311 1.5 Rpl17 ribosomal protein L17 
AI013910 1.5 Rpl34 ribosomal protein L34 
NM_053597 1.5 Rps27 ribosomal protein S27 
NM_013224 1.5 Rps26 ribosomal protein S26
AI407731 1.5 Rps28 ribosomal protein S28 
BE107613 1.5 Rps13 ribosomal protein S13 
H35210 1.5 LOC681221 similar to 60S ribosomal protein L38
NM_053971 1.5 Rpl6 ribosomal protein L6 
a
The most abundantly expressed transcripts represent the top 2% (278 probes) of the 13,947 probe sets expressed on the microarray.
a
The most abundantly expressed transcripts had an arbitrary intensity of 1,411 to 6,526 whereas all other transcripts had an intensity of 14 to 1,410.
b
Differential gene expression representing the fold change was determined at p<0.01 with a fold change ≥ ±1.5. (-) Indicates no transcriptional difference.
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Table 3.11. Differential expression of the most abundantly expressed genes in the fast-twitch muscle from cerivastatin (1 mg/kg) relative to vehicle 
treated female rats
ab
Category Accession #
Differential gene 
expression
b Sequence name Sequence Description
Regulation of transcription and translation
NM_031570 1.5 Rps7 similar to ribosomal protein S7 
NM_017160 - Rps6 ribosomal protein S6 
AA848284 - Rps23 ribosomal protein S23 
NM_022697 - Rpl28 ribosomal protein L28
BI284252 - Rpl11 ribosomal protein L11 
NM_031113 - Rps27a ribosomal protein S27a 
BG375811 - Rps24 ribosomal protein S24 
NM_021264 - Rpl35a ribosomal protein L35a 
NM_031100 - Rpl10 ribosomal protein L10 
BI283681 - Eif5a eukaryotic translation initiation factor 5A 
AI177054 - Rpl27a ribosomal protein L27a
BI282255 - Rps5 ribosomal protein S5
NM_031103 - Rpl19 ribosomal protein L19 
NM_031110 - Rps11 ribosomal protein S11 
AI409193 - Rpl8 ribosomal protein L8 
BM388159 - Rpl32 ribosomal protein L32 
AW914118 - Rpl35 ribosomal protein L35
NM_022672 - Rps14 ribosomal protein S14 
AI228150 - Rpl22 ribosomal protein L22 
NM_022402 - Arbp acidic ribosomal phosphoprotein P0 
NM_022514 - Rpl27 ribosomal protein L27
NM_022510 - Rpl4 ribosomal protein L4 
AA925327 - Rpl23 ribosomal protein L23
BI279866 - MGC72957 similar to 60S ribosomal protein L18a 
NM_017245 - Eef2 eukaryotic translation elongation factor 2 
U92700 - Rps2 ribosomal protein S2 
BG667162 - Eif4g2 eukaryotic translation initiation factor 4, gamma 2 
AI172199 - Rpl23a similar to 60S ribosomal protein L23a 
NM_022506 - Rpl31 ribosomal protein L31 
NM_022699 - Rpl30 ribosomal protein L30 
AA944861 - Rps2 ribosomal protein S2 
NM_017153 - Rps3a ribosomal protein S3a 
NM_031099 - Rpl5 ribosomal protein L5 
NM_017152 - Rps17 ribosomal protein S17 
BF281221 - Rpl7 ribosomal protein L7 
AI598536 - Rpl26 ribosomal protein L26 
AA799501 - Rps4x ribosomal protein S4, X-linked 
BG666872 - Rps16 ribosomal protein S16
NM_031106 - Rpl37 ribosomal protein L37
BG666892 - Rpl9 ribosomal protein L9
BI297634 - Rpl24 ribosomal protein L24 
AW914090 - Rplp1 ribosomal protein, large, P1
NM_017283 - Psma6 proteasome (prosome, macropain) subunit, alpha type 6 
BF281215 - Rpl37a ribosomal protein L37a 
BI281697 - Rpl7a ribosomal protein L7a 
BM391203 - Eef1g eukaryotic translation elongation factor 1 gamma 
AI229633 - Rps29 ribosomal protein S29 
AF388527 - Serbp1 PAI-1 mRNA-binding protein 
NM_022674 - H2afz H2A histone family, member Z
AI012372 - Sui1-rs1_predicted suppressor of initiator codon mutations, related sequence 1 
BI282111 - Nsep1 nuclease sensitive element binding protein 1 
AF242550 - Cnbp1 cellular nucleic acid binding protein 1 
AA799736 - Chchd2 coiled-coil-helix-coiled-coil-helix domain containing 2 
BG673187 - Fhl1 four and a half LIM domains 1 
BI298356 - Fhl1 four and a half LIM domains 1 
AA891707 -1.7 Usmg5 upregulated during skeletal muscle growth 5
Transporters
AI012445 4.0 Slc25a5 solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5
AF161588 1.8 Gabarap gamma-aminobutyric acid receptor associated protein 
M23984 -1.9 Slc25a3 solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 3 
BG666999 -2.6 Slc25a4 solute carrier family 25 (mitochondrial adenine nucleotide translocator) member 4 
Calcium homeostasis
NM_012618 16.6 S100a4 S100 calcium-binding protein A4 
BG378926 5.6 S100a11 S100 calcium binding protein A11 
AF140232 4.7 S100a6 S100 calcium binding protein A6 
NM_031114 4.1 S100a10 S100 calcium binding protein A10 
X13933 1.5 Calm1 calmodulin 1 
BI279113 - Calm1 calmodulin 1 
a
The most abundantly expressed transcripts represent the top 2% (278 probes) of the 13,947 probe sets expressed on the microarray.
a
The most abundantly expressed transcripts had an arbitrary intensity of 1,411 to 6,526 whereas all other transcripts had an intensity of 14 to 1,410.
b
Differential gene expression representing the fold change was determined at p<0.01 with a fold change ≥ ±1.5. (-) Indicates no transcriptional difference.
145 
 
 
 
 
 
 
 
Table 3.12. Differential expression of the most abundantly expressed genes in the fast-twitch muscle from cerivastatin (1 mg/kg) relative to vehicle 
treated female rats
ab
Category Accession #
Differential gene 
expression
b Sequence name Sequence Description
Miscellaneous
NM_133298 45.1 Gpnmb glycoprotein (transmembrane) nmb 
U13253 14.5 Fabp5 fatty acid binding protein 5, epidermal 
J02582 9.4 Apoe apolipoprotein E 
NM_017113 8.5 Grn granulin 
AA945178 8.4 Srprb Transferrin 
L01122 6.1 Ftl1 ferritin light chain 2 
NM_019905 5.7 Anxa2 annexin A2 
BM385031 5.3 Plp2 proteolipid protein 2 
BF550246 5.0 Crip1 cysteine-rich protein 1 
NM_012862 4.0 Mgp matrix Gla protein 
BI287960 4.0 Npc2 Niemann Pick type C2 (Npc2) 
BM386513 2.5 Cltc clathrin, heavy polypeptide 
BG671677 2.1 App amyloid beta (A4) precursor protein 
AA799627 2.0 Sepp1 selenoprotein P, plasma, 1
BE329198 1.6 Arf1 ADP-ribosylation factor 1 
NM_130734 1.5 Gnb2l1 Bos taurus guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1
BI278308 - Itm2b integral membrane protein 2B 
AA925473 - Cdc42 cell division cycle 42 homolog (S. cerevisiae) 
AI177362 - Fau Finkel-Biskis-Reilly murine sarcoma virus ubiquitously expressed 
BF282337 - Itm2b integral membrane protein 2B 
NM_130743 - Ifi27l putative ISG12(a) protein 
NM_012848 - Fth1 ferritin, heavy polypeptide 1 
AI411388 - Oaz1 ornithine decarboxylase antizyme 1 
U30789 - Txnip upregulated by 1,25-dihydroxyvitamin D-3 
AI406651 - Serf2 small EDRK-rich factor 2 
BI277035 - Gnas GNAS complex locus 
AI179404 - Hba-a1 hemoglobin alpha 2 chain 
AI179404 - Hba-a1 hemoglobin alpha 2 chain 
NM_033234 - Hbb hemoglobin beta chain complex 
AA944393 -1.7 MGC72942 similar to CG6105-PA
BF284168 -1.8 H19 H19 fetal liver mRNA (H19) on chromosome 7 
Without ontology
BM383531 37.6
BI294018 12.1
NM_017154 4.8
AA799542 1.7
BI282748 1.5
AI180257 -
AI170758 -
AI104151 -
AA849795 -
AI577319 -
AI230164 -
AI008105 -
NM_017314 -
BG663128 -2.4
a
The most abundantly expressed transcripts represent the top 2% (278 probes) of the 13,947 probe sets expressed on the microarray.
a
The most abundantly expressed transcripts had an arbitrary intensity of 1,411 to 6,526 whereas all other transcripts had an intensity of 14 to 1,410.
b
Differential gene expression representing the fold change was determined at p<0.01 with a fold change ≥ ±1.5. (-) Indicates no transcriptional difference.
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Table 3.13. Differential expression of genes in the fast-twitch muscle related to the mevalonate pathway and cholesterol regulation from 
cerivastatin (1 mg/kg) relative to vehicle treated female rats
a
Category Accession #
Differential gene 
expression
a Sequence name Sequence Description
Mevalonate pathway and cholesterol regulation
AI169398 19.2 Ch25h cholesterol 25-hydroxylase 
NM_031118 18.8 Soat1 Acyl-CoA: cholesterol acyltransferase 1
NM_031118 11.9 Soat1 Acyl-CoA: cholesterol acyltransferase 1
NM_017136 10.3 Sqle squalene epoxidase 
NM_080886 6.6 Sc4mol sterol-C4-methyl oxidase-like 
NM_053539 5.6 Idi1 isopentenyl-diphosphate delta isomerase 
NM_012941 4.8 Cyp51 cytochrome P450, subfamily 51 
NM_013134 4.5 Hmgcr 3-hydroxy-3-methylglutaryl-Coenzyme A reductase
D45252 4.5 Lss lanosterol synthase 
NM_012732 4.3 Lip1 lipase A, lysosomal acid 
AW918387 4.0 Abca1 ATP-binding cassette, sub-family A, member 1 
NM_053502 4.0 Abcg1 ATP-binding cassette, sub-family G, member 1 
BI287960 4.0 Npc2 Niemann Pick type C2 
NM_133306 3.7 Oldlr1 oxidized low density lipoprotein receptor 1 
BM390399 2.9 Hmgcr 3-hydroxy-3-methylglutaryl-Coenzyme A reductase 
BG664123 2.9 Cyp51 cytochrome P450, subfamily 51
BF283070 2.3 Cyp7b1 cytochrome P450, family 7, subfamily b, polypeptide 1 
BI294974 1.8 Ldlr Low density lipoprotein receptor
BG378288 1.5 Pmvk phosphomevalonate kinase
AI170663
b
1.3 Srebf2 Sterol regulatory element binding factor 2
AW530769 -1.9 Fdft1 farnesyl diphosphate farnesyl transferase 1 
M73231 -3.1 Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 
AA849857 -3.3 Vldlr very low density lipoprotein receptor
NM_013155 -3.8 Vldlr very low density lipoprotein receptor
AF286470 -7.3 Srebf1 sterol regulatory element binding factor 1 
BF398848 -7.5 Srebf1 sterol regulatory element binding factor 1 
a
Differential gene expression in the female fast-twitch muscle from cerivastatin (1 mg/kg) relative to vehicle treated rats (p<0.01 with a fold change ≥ ±1.5). 
b
Srebf2 was only induced by 1.3 fold but was included given its relevance to cholesterol regulation (p<0.01). 
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Category Accession #
Differential gene 
expression
a Sequence name Sequence Description
Regulation of transcription and translation
M25804 2.0 Nr1d1 nuclear receptor subfamily 1, group D, member 1 
BF288243 1.8 Klf2 Kruppel-like factor 2
BM385790 1.8 Klf2 Kruppel-like factor 2
AI230048 1.8 Dbp D site albumin promoter binding protein 
NM_024385 1.6 Hhex hematopoietically expressed homeobox 
U15660 1.6 Nr1d2 nuclear receptor subfamily 1, group D, member 2 
NM_024388 1.6 Nr4a1 nuclear receptor subfamily 4, group A, member 1 
AF000942 1.6 Id3 Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 
M86708 1.5 Id1 Inhibitor of DNA binding 1, helix-loop-helix protein 
BI291626 -1.5 Ell2 elongation factor RNA polymerase II 2 
BG671389 -1.5 Cpeb4 cytoplasmic polyadenylation element binding protein 4 
AI010275 -1.5 Cpeb2 cytoplasmic polyadenylation element binding protein 2 
BF406350 -1.9 Foxo1a forkhead box protein O1A
AB012600 -2.0 Arntl aryl hydrocarbon receptor nuclear translocator-like 
Immune, inflammatory response and cell stress
NM_031971 2.7 Hspa1a heat shock 70kD protein 1B 
BI278231 2.7 Hspa1b heat shock 70kDa protein 1B
BM384926 2.2 Dnajb1 DnaJ (Hsp40) homolog, subfamily B, member 1 
AA945704 2.1 Dnajb1 DnaJ (Hsp40) homolog, subfamily B, member 1 
NM_130744 1.6 Cygb cytoglobin 
BI285141 1.5 Cd24 CD24 antigen 
NM_053843 -1.5 Fcgr3 Fc receptor, IgG, low affinity III
AI406687 -1.5 Cmtm6 chemokine-like factor super family 6 
NM_053843 -1.5 Fcgr3 Fc receptor, IgG, low affinity III
AW534837 -1.6 Fkbp5 FK506 binding protein 5 
NM_053727 -1.7 Nfil3 nuclear factor, interleukin 3 regulated 
Metabolism
L32601 1.9 Akr1c18 20 alpha-hydroxysteroid dehydrogenase 
BG374483 1.7 Per3 period homolog 3 (Drosophila) 
BE110108 1.6 Dusp1 dual specificity phosphatase 1 
U02553 1.6 Dusp1 dual specificity phosphatase 1 
NM_019292 -1.5 Ca3 carbonic anhydrase 3 
Miscellaneous
AW143798 1.8 Ccnd1 cyclin D1 
AI028877 1.5 Smoc2 SPARC related modular calcium binding 2 
AI104533 -1.5 Ttn similar to N2B-Titin Isoform 
AW530219 -1.5 Ryr1 ryanodine receptor 1, skeletal muscle 
AI235468 -1.6 Dst dystonin
BI299621 -1.6 Igf2r Insulin-like growth factor receptor 2
AA818910 -1.7 Arrdc3 arrestin domain containing 3 
BF408410 -2.2 Phf13 PHD finger protein 13 
Without ontology
AI235245 2.0
AW529368 1.9
BG380221 1.8
AI407827 1.6
AA957707 1.6
BE096504 1.5
BF284190 1.5
AI548649 -1.5
BI289300 -1.5
BI288556 -1.5
AA850695 -1.6
BF284310 -1.6
BG381541 -1.6
BE096356 -1.6
BI291447 -1.7
AI639159 -1.7
AA818846 -1.8
a
Differential gene expression representing fold change was determined at p<0.01 with a fold change ≥ ±1.5. 
Table 3.14. Differential expression of genes in the fast-twitch muscle from cerivastatin (1 mg/kg) relative to vehicle treated male rats
a
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Table 3.15. Differential expression of genes in the slow-twitch muscle from cerivastatin (0.5 mg/kg) relative to vehicle treated female rats
a
Category Accession #
Differential gene 
expression
a Sequence name Sequence Description
Energy metabolism 
NM_053338 2.9 Rrad Ras-related associated with diabetes 
NM_031347 2.4 Ppargc1a peroxisome proliferative activated receptor, gamma, coactivator 1 alpha
NM_012735 2.0 Hk2 hexokinase 2 
U92069 -2.3 Ucp3 uncoupling protein 3
Regulation of transcription and translation
AI548994 2.3 Sox9 SRY-box containing gene 9 
AI013512 2.0 Zfp297b zinc finger protein 297B 
AI072788 2.0 1385978 SRY-box containing gene 9 
AI008458 1.6 Sox9 elongation factor RNA polymerase II 
BF284716 -1.5 Ankrd15 ankyrin repeat domain 15 
BE109033 -1.9 Eif2c1 eukaryotic translation initiation factor 2C, 1 
AI102530 -2.1 Nab2 Ngfi-A binding protein 2 
NM_017352 -3.1 Nr4a3 nuclear receptor subfamily 4, group A, member 3 
L08595 -4.1 Nr4a2 nuclear receptor subfamily 4, group A, member 2 
Immune, inflammatory response and cell stress
NM_053352 1.5 Cmkor1 chemokine orphan receptor 1
BF285187 -2.2 Ier5 immediate early response 5 
Metabolism
AB062758 1.6 Dhrs4 dehydrogenase/reductase (SDR family) member 4 
Extracellular matrix
BM388837 -1.8 Col1a2 procollagen, type I, alpha 2 
Z78279 -2.2 Col1a1 collagen, type 1, alpha 1 
Miscellaneous
AW531877 2.5 Efna1 ephrin A1 
NM_053599 2.3 Efna1 ephrin A1 
BM392291 2.0 Rab30 RAB30, member RAS oncogene family 
AA799330 1.7 Pelo pelota homolog 
AI102065 1.5 Hebp1 heme binding protein 1 
NM_031135 -1.7 Klf10 TGFB inducible early growth response 
AI175728 -1.8 Pepd growth arrest specific 1 
BG666712 -1.8 Gpm6b glycoprotein m6b 
NM_021835 -1.9 Jun v-jun sarcoma virus 17 oncogene homolog
AI406939 -3.1 G0s2 G0/G1 switch gene 2 
Without ontology
AW535970 4.6
BF398967 2.9
BG376846 2.6
AI410107 2.5
BF402138 2.5
BF404786 2.4
BF410417 2.1
AI638990 2.0
BF408105 2.0
AI029813 2.0
BF283075 1.9
BF387399 1.9
BI285697 1.8
BM390772 1.8
BI294137 1.7
BF559640 1.7
BE114414 1.6
BF282700 1.6
AI104846 1.5
AW531902 -1.5
BM391419 -1.5
BI291229 -1.5
AF109674 -1.6
BF414338 -1.7
BI289462 -1.7
BE116111 -1.7
AI548601 -2.1
BF418649 -2.7
BF405036 -3.2
AI170665 -4.1
a
Differential gene expression representing fold change was determined at p<0.01 with a fold change ≥ ±1.5. 
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Table 3.16. Differential expression of genes in the slow-twitch muscle from cerivastatin (1 mg/kg) relative to vehicle treated female rats
a
Category Accession #
Differential gene 
expression
a Sequence name Sequence Description
Energy metabolism
BF418932 -1.7 Phka1 phosphorylase kinase alpha 1
Regulation of transcription and translation
U15660 1.8 Nr1d2 nuclear receptor subfamily 1, group D, member 2 
AI230048 1.6 Dbp D site albumin promoter binding protein 
AW921151 1.5 Nola2 nucleolar protein family A, member 2 
BE102391 -1.8 Crebl2 cAMP responsive element binding protein-like 2 
Immune, inflammatory response and cell stress
AF411318 9.5 Mt1a metallothionein 1
L02926 1.8 Il10 interleukin 10 
Metabolism
L32601 -2.0 Akr1c18 20 alpha-hydroxysteroid dehydrogenase 
Transporters
AI045333 2.1 Kctd13 potassium channel tetramerisation domain containing 13
NM_023970 1.8 Trpv4 transient receptor potential cation channel, subfamily V, member 4 
Calcium homeostasis
AI175539 -6.8 Pvalb parvalbumin 
Miscellaneous
BF282632 1.9 Tspan4 transmembrane 4 superfamily member 7 
BF283227 -1.5 Garnl1 GTPase activating RANGAP domain-like 1, transcript variant 2  
BM388946 -1.5 Wsb1 WD repeat and SOCS box-containing 1 
AI070638 -1.5 LOC679252 myeloid/lymphoid or mixed-lineage leukemia 3, transcript variant 3 
BF554226 -1.5 Trio triple functional domain (PTPRF interacting), transcript variant 5 
AW530903 -1.6 Arid5b AT rich interactive domain 5B 
BG666712 -2.0 Gpm6b glycoprotein m6b 
Without ontology
BM383531 8.3
BF391448 2.5
AI501145 1.8
AA818474 1.5
AI103917 -1.5
BI300794 -1.5
BI273855 -1.6
AI412155 -1.7
BI289460 -1.7
BF391129 -1.9
BI274506 -2.5
a
Differential gene expression representing fold change was determined at p<0.01 with a fold change ≥ ±1.5. 
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Table 3.17. Differential expression of common genes in muscles from cerivastatin (1 mg/kg) relative to vehicle treated female rats
a
Differential gene expression
a
Sequence description Fast-twitch muscle Slow-twitch muscle
metallothionein 1a (Mt1a) 60.1 9.5
LOC682651 37.6 8.3
transmembrane 4 superfamily member 7  (tspan4) 6.7 1.9
interleukin 10 (Il10)  3.1 1.8
glucosamine (N-acetyl)-6-sulfatase (Gns) 2.3 1.3
TAF9 RNA polymerase II, TATA box binding protein (TBP)-associated factor (Taf9) 2.8 1.3
transient receptor potential cation channel, subfamily V, member 4 (Trpv4) 2.2 1.8
nucleolar protein family A, member 2 (Nola2) 1.8 1.5
LOC684802 1.8 -1.6
RGD1307838 1.4 -1.1
parvalbumin (Pvalb) -11.7 -6.8
phosphorylase kinase alpha 1 (Phka1) -10.1 -1.7
LOC683555 -5.3 -1.2
glycoprotein m6b (Gpm6b) -3.8 -2.0
malic enzyme 1 (Me1) -3.2 -1.4
20 alpha-hydroxysteroid dehydrogenase (Akr1c18) -2.9 -2.0
cryptochrome 1 (Cry1)  -2.8 -1.7
Sos2 -2.5 -1.3
golgi autoantigen, golgin subfamily a, 4 (Golga4)  -2.3 -1.2
cAMP responsive element binding protein-like 2 (Crebl2) -2.0 -1.8
Nuclear receptor subfamily 1, group D, member 2 (Nr1d2) -2.1 1.4
radixin (Rdx) -2.0 -1.2
myeloid/lymphoid or mixed-lineage leukemia 3, transcript variant 5 (Mll3) -1.8 -1.3
H19 fetal liver mRNA (H19) -1.8 -1.2
GTPase activating RANGAP domain-like 1, transcript variant 2 (Garnl1) -1.8 -1.5
glycogenin 1 (Gyg1)  -1.7 1.1
1373634 -1.3 -1.2
a
Differential gene expression in female muscles from cerivastatin (1 mg/kg) relative to vehicle treated rats (p<0.01). 
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Differential gene expression
a
Sequence description 0.5 mg/kg 1 mg/kg
RGD15594 1.9 3.0
Cysteine-rich protein 3 (Csrp3) 1.6 2.4
Amyloid beta precursor protein (Appbp1) -1.2 2.1
Sart3 -1.7 1.6
DNAjb1 (Hsp40), subfamily B, member 1 (Dnajb1) -2.0 1.4
Solute carrier family 25, member 25 (Slc25a25) -2.0 -8.8
G0/G1 switch gene 2 (GOs2) -2.6 -7.6
ADP ribosylation factor-like 6 interacting protein 2 -1.1 -4.1
Kruppel-like factor 15 (Klf15) 1.5 -4.0
1378055 -1.6 -3.8
Sestrin 1 (Sesn1) 1.6 -3.4
Transducer of ERBB2 (Tob2) -1.5 -3.2
RGD13094 1.6 -3.0
unc-51 like kinase 2 (Ulk2) -1.2 -2.8
1391431 -1.6 -2.7
Transmembrane protein 23 (Tmem23) 1.3 -2.4
RGD73502 1.3 -2.4
RGD13076 -1.2 -2.3
Nuclear receptor subfamily 1, member 2 (Nr1d2) 1.3 -2.1
LOC68925 1.7 -2.0
Nuclear transcription factor Y gamma (Nfyc) 1.2 -1.8
Zinc finger protein 541 (Znf541) 1.2 -1.8
1372308 -1.3 -1.8
LIM and cysteine rich domains 1 (Lmcd1) 1.6 -1.8
tubby-like protein 4 (Tulp4) -1.4 -1.4
a
Differential expression of common genes in female muscles from cerivastatin (0.5 and 1 mg/kg) relative to vehicle treated rats (p<0.01). 
Table 3.18. Dose response of differentially expressed common genes in the fast-twitch muscle from cerivastatin relative to vehicle 
treated female rats
a
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Differential gene expression
a
Sequence description Female (0.5 mg/kg) Male (1 mg/kg)
DnaJ (Hsp40), subfamily B, member 1 (Dnajb1) -2.0 2.2
Nuclear receptor subfamily 1, member 2 (Nr1d2) 1.3 1.6
Nuclear receptor subfamily 1, member 1 (Nr1d1) 2.2 2.0
a
Differential expression of common genes in the fast-twitch muscle from cerivastatin treated female (0.5 mg/kg) and male (1 mg/kg) relative to vehicle treated rats (p<0.01). 
Table 3.19. Differentially expressed common genes in the fast-twitch muscle from cerivastatin treated female (0.5 mg/kg) and male (1 mg/kg) relative to 
vehicle treated rats
a
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Chapter 4 
 
 
Metabolomic profiles of skeletal muscles with and without 
cerivastatin treatment in female and male rats 
 
 
4.1. Introduction 
Gene expression analysis of skeletal muscles from cerivastatin treated rats indicated that 
alterations in energy metabolism and cholesterol homeostasis may be involved with the 
mechanism of cerivastatin-induced myopathy (Chapter 3). However, there remains a 
significant gap in knowledge regarding how alterations in skeletal muscle energy 
metabolism and cholesterol homeostasis may be causally related to statin-induced 
myopathy. Accordingly, it was hypothesized that understanding the metabolic changes in 
skeletal muscle following cerivastatin treatment may provide further insight into the 
specific biochemical targets and pathways involved with the development of myopathy.   
 
Metabolomics is a systems biology approach for studying metabolic profiles representing 
the total metabolite pool in tissue extracts or biofluids (Nicholson et al., 2002). This 
approach combines analytical technologies like 
1
H nuclear magnetic resonance 
spectrometry (NMR) with statistics to provide a quantitative, comprehensive and ubiased 
assessment of the metabolic response to physiological or pathophysiological changes 
(Gatzidou et al., 2007; Nicholson et al., 2002). Although NMR metabolomics provides an 
assessment of the total metabolic pool, the sensitivity of this technique is limited to 
compounds in the concentration range >0.1 µM. Despite this limitation, NMR 
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metabolomics has been successfully applied to investigate metabolite profiles associated 
with a variety of myopathies and physiological stress in vivo as well as in myotubes, and 
these studies have revealed significant changes in biochemical pathways, including early 
alterations in mitochondrial energetics (Griffin et al., 2001, 2009; Lin et al., 2011; 
Sharma et al., 2003a, 2003b; Slade et al., 2006; Straadt et al., 2010a, 2010b; Sprott et al., 
2000; Xu et al., 2011; Wu et al., 2011). Separately, metabolomic profiling of urine has 
been useful for identifying metabolite changes originating from skeletal muscle and 
representing biomarkers of disease progression (Chung et al., 2003, 2005). Importantly, 
these studies suggest NMR metabolomic profiling of skeletal muscles may also be useful 
for evaluating metabolic changes associated with statin-induced myopathy. 
 
Fast-twitch muscles from female rats are most sensitive to statin-induced myopathy 
(Figure 2.1 and Table 2.2). Therefore, a major goal of this work was to use NMR 
metabolomic profiling to determine whether fiber- and sex-specific metabolite 
differences are present in naïve rats. An additional goal of this work was to use NMR 
metabolomic profiling to determine metabolite changes in skeletal muscles, representing 
potential biochemical targets and pathways, involved with cerivastatin-induced 
myopathy. For this work, metabolomic profiling was conducted on both aqueous and 
lipophilic extracts of skeletal muscles from representative fast-twitch (psoas) and slow-
twitch (soleus) fibers from female and male rats (Table 2.1). Separately, metabolomic 
profiling of urine was also conducted in Chapter 7 to identify skeletal muscle specific 
metabolites which may represent potential biomarkers of cerivastatin-induced myopathy.
155 
 
4.2 Methods 
Study design. This investigation was conducted on fast-twitch (psoas) and slow-twitch 
(soleus) skeletal muscles obtained from study 1, described in Chapter 2.2.  
 
Folch extraction of skeletal muscle. Frozen muscle tissues were individually pulverized 
in liquid nitrogen and a portion (100 mg psoas and 50 mg soleus) was extracted 
according to the method of Folch (1957). The psoas represents a large muscle, therefore 
to maximize the NMR signal 100 mg of tissue was used. In contrast, the soleus weighs 
approximately 100 mg so only 50 mg was used, with the remaining tissue used for RNA 
isolation. Metabolite extraction was performed by homogenizing the tissue in a bead mill 
(Retsch MM 300, Haan Germany) for 4 minutes (30 Hz) with 10 volumes of ice-cold 
methanol. Following centrifugation (8000g, 4˚C) for 15 minutes, the supernatant (0.6 ml 
for psoas; 0.3 ml for soleus) was transferred to water/chloroform (0.4 ml / 1 ml for psoas; 
0.2 ml / 0.6 ml for soleus) and vortexed for 10 seconds and then shaken in a bead mill (30 
Hz) for 10 minutes at room temperature. Samples were centrifuged (6000g, 4˚C) for 25 
minutes and the methanol / aqueous (hydrophilic phase) and chloroform (lipophilic 
phase) were separated, dried under nitrogen at room temperature and analyzed by 
1
H 
NMR. Samples were stored at -80˚C until analysis. 
 
1
H NMR metabolomic profiling. Aqueous extracts were reconstituted in 0.6 ml of 
deuterated water (D2O) with trimethylsilyl propionate (TSP) as an internal standard. 
Samples were measured in a 5 mm NMR tube using Iconnmr (NMR software) in a 
Bruker 600 MHz spectrometer with a 5 mm TCI MicroCryoProbe at 300K with standard 
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1D proton parameters as follows: 256 scans, 8 dummy scans, 16 ppm spectral width, 2 
seconds of relaxation delay, noesy1dpr pulse sequence program with water suppression 
and 32K of free induction decay. Chloroform samples were dissolved in 0.6 ml of 
deuterated chloroform (CDCl3) with 0.05% tetramethylsilane (TMS) as an internal 
standard, and measured with the conditions described for the aqueous extracts, however a 
zg30 pulse sequence program was used without water suppression. All samples in each 
group were measured using a constant receiver gain to allow for quantitation. 
 
LC-MS analysis. The lipophilic skeletal muscle extracts were also analyzed for a panel of 
sterols by LC-MS based on a proprietary method at Lipomics Technologies (West 
Sacramento, California). 
 
Data analysis. NMR spectra were visually inspected to determine qualitative differences. 
Metabolites showing a marked change, with well resolved signals were identified using 
standard spectra from The Human Metabolome Database and the Bruker proprietary 
database. The intensity of each metabolite resonance was assessed by integration of the 
signal and normalization to the internal standard (TSP or TMS) signal. For each 
metabolite, the relative mean ± SE fold change was determined for each treatment group. 
Sterol results from Lipomics Technologies were reported as either nmol or µmol / g of 
tissue. Group means were compared with a Student‟s t-test or ANOVA using StatView 
(SAS Institute, Cary, NC) at p<0.05 prior to determining the relative fold change.  
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4.3. Results  
To determine sex differences in metabolites from naïve rats, NMR metabolomic profiles 
of aqueous extracts of the psoas from female and male rats were compared. In general, 
the metabolomic profiles showing the aliphatic (Figure 4.1; 0.5–4.5 ppm) and aromatic 
(Figure 4.2; 5.7-9.5 ppm) regions of the psoas were similar between female and male rats.  
However, creatine was 16% (p = 0.01) higher in male rats, with no difference in 
phosphocreatine. The chemical shift (3.1-3.5 ppm) for the two taurine triplets was highly 
variable because of pH differences across samples. The non-muscle metabolite, 1,2-
propanediol was also detected in both muscles and attributed to the use of sodium 
pentobarbital, as this anesthesia contains 1,2-propanediol as the vehicle for delivery of 
the barbiturate.  
 
The metabolomic profiles of the lipophilic extracts of the psoas were similar between 
female and male rats (Figure 4.3). In general, the resonances in the lipophilic extracts 
were typically broad, which was expected. However, this broadening reduced resolution 
and limited metabolite identification. Despite this limitation, cholesterol was identified 
based on sharp resonances at 0.68 and 1.01 ppm, representing the C18 and C19 methyl 
groups, respectively (Figures 4.3 and 6.1). Furthermore, phosphatidylcholine was 
identified based on the resonance at 3.30 ppm, representing the (CH3)3-N group, and 
several resonances consistent with CH2 groups in phospholipids were identified. There 
were no sex differences in the concentration of cholesterol or phosphatidylcholine. 
Additionally, methanol was also present in these samples (3.50 ppm) resulting from the 
extraction.  
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To determine fiber differences in metabolites from naïve female rats, NMR metabolomic 
profiles of aqueous extracts of the psoas were compared to the soleus. The metabolomic 
profiles indicated that the fiber types have a similar distribution and concentration of 
metabolites (Figure 4.4 and 4.5). However, lactate was higher in the psoas whereas 
taurine, fumarate and an unknown metabolite at 1.25 ppm were higher in the soleus.  
 
The metabolomic profiles of the lipophilic extracts of the psoas and soleus appeared 
qualitatively different in female rats and this was likely related to better resolution for 
many of the metabolites in the soleus as a result of less tissue used in the Folch extraction 
(Figure 4.6). Despite better resolution, further characterization of specific phospholipids 
in muscles was not pursued. However, higher levels of cholesterol were noted in the 
soleus.  
 
The fiber- and sex-specific histopathology of the skeletal muscles from cerivastatin 
treated rats was previously described in Chapter 2.3 (Figure 2.1 and Table 2.2). To 
determine metabolomic changes associated with cerivastatin treatment aqueous extracts 
from the psoas and soleus were evaluated by NMR. Metabolomic profiles of the aqueous 
extracts of the psoas from female rats indicated several metabolite changes associated 
with cerivastatin (1 mg/kg) treatment (Figure 4.7 and 4.8; Table 4.1). Metabolites 
representing a perturbation in energy metabolism (lactate, phosphocreatine, creatine and 
NAD
+
) and histidine-containing moieties (anserine and carnosine) were reduced by up to 
3-fold with cerivastatin (1 mg/kg) treatment (Table 4.1). In contrast, resonances of two 
unknown metabolites (1.27 and 1.77 ppm) and glutamine were significantly increased 
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with cerivastatin (1 mg/kg) treatment (Table 4.1). Changes in nucleotides (AMP, ADP, 
ATP) were also observed with cerivastatin treatment. However, since ATP is labile and 
tissues were not freeze clamped, these metabolites were not quantitated. In contrast to the 
high dose, a reduction in NAD
+
 was the only change observed at the low dose of 
cerivastatin (0.5 mg/kg) in the aqueous extracts of the psoas from female rats (Table 4.1; 
spectra not shown).  
 
Since cerivastatin modulates cholesterol synthesis, lipophilic extracts of skeletal muscles 
were evaluated to determine the effects on sterols. Representative NMR spectra of the 
lipophilic extracts of the psoas from female rats indicated a dose dependent increase in 
cholesterol, phosphatidylcholine and an unknown metabolite at 3.15 ppm (Figure 4.9; 
Table 4.2). Further evaluation of the spectra indicated that the increase in cholesterol was 
specific to the free and not the esterified form. Specificity of this change in free 
cholesterol was determined based on an increase in the resonance at 3.55 ppm, 
representing the proton on the carbon for the CHOH group which is absent in esterified 
cholesterol (Figure 4.9; Table 4.2). 
 
The metabolomic profile of the aqueous extracts of the psoas from cerivastatin (1 mg/kg) 
treated male rats was similar to control, with one exception phosphocreatine showed a 
significant increase (Figure 4.10 and 4.11; Table 4.1). Similarly, the lipophilic extracts of 
the psoas from cerivastatin (1 mg/kg) treated male rats were similar to control, with only 
phosphatidylcholine showing an increase (Table 4.2; spectra not shown).  
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The metabolomic profile of the aqueous extracts of the soleus from cerivastatin (1 mg/kg) 
treated female rats was similar to control (Figures 4.12, 4.13 and Table 4.1). However 
anserine and phosphocreatine were reduced by almost 2-fold, whereas a significant 
increase in the nucleotide region was observed. In the lipophilic soleus extracts from 
cerivastatin (1 mg/kg) treated female rats there were no changes observed in cholesterol, 
phosphatidylcholine or phospholipids (Table 4.2; spectra not shown). Additionally, no 
changes were observed in either the aqueous or lipophilic soleus extracts from rats 
receiving 0.5 mg/kg cerivastatin (Table 4.2; spectra not shown).    
 
To further investigate the effects of cerivastatin treatment, a panel of sterols was 
measured in lipophilic extracts of the psoas from cerivastatin treated female rats (Table 
4.3). The LC-MS results corroborated the NMR findings demonstrating an increase in 
total cholesterol. Furthermore, the LC-MS results indicated a marked increase in the 
cholesterol precursors, desmosterol and 7-dehydrocholesterol and the downstream 
product 7α-hydroxycholesterol in the psoas from cerivastatin (1 mg/kg) treated rats. In 
contrast, cholesterol precursors including lanosterol and lathosterol as well as the 
phytosterols β-sitosterol, campesterol, and stigmasterol were unchanged or reduced in 
skeletal muscles from cerivastatin treated rats compared to control. 
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4.4. Discussion  
The major goal of this work was to use metabolomic profiling to determine whether sex- 
and fiber-specific metabolite differences were present in skeletal muscles from naïve rats, 
and to determine metabolic changes associated with cerivastatin-induced myopathy. 
Accordingly, it was hypothesized that determining the metabolic changes in skeletal 
muscle following cerivastatin treatment may provide further insight into the specific 
biochemical targets and pathways involved with the development of myopathy. Although 
NMR metabolomics has the potential to provide an unbiased and comprehensive 
assessment of the total metabolite pool in skeletal muscle, the current investigation was 
limited to resonances which could be identified against standard spectra, and metabolites 
with concentrations above the limit of detection (>0.1 µM). Therefore, compounds like 
isoprenoids and mevalonate which may be important in the mechanism of toxicity were 
not measured as their concentrations were below the limit of detection. 
 
The current work demonstrates that metabolomic profiles of both aqueous and lipophilic 
extracts of fast-twitch skeletal muscles from naïve female and male rats were similar, 
with only creatine showing higher levels in the male. Although the biological implication 
of this difference is unknown, it is consistent with a higher gene expression of the 
enzyme that catalyzes creatine formation (guanidinoacetate methyltransferase) in the 
male rat psoas (Table 3.5). In general, the lack of sex-specific metabolite changes is 
consistent with the transcriptional data, indicating that there is no difference in the most 
abundant genes which define the muscle fiber phenotype (Chapter 3.3, Tables 3.5 and 
3.6).  
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Metabolomic profiling of fast- and slow-twitch skeletal muscles from naïve female rats 
was also generally similar with only a few changes noted. In particular, lactate was higher 
in the psoas whereas taurine, fumarate and cholesterol were higher in the soleus, and 
these changes have been previously reported by other methods (Froberg, 1967; Nikolaidis 
et al., 2006; Pierno et al., 2011; Stefanyk et al., 2010; Yoshioka et al., 2002). The higher 
level of lactate and fumarate is consistent with anaerobic glycolysis in the fast-twitch 
muscle and oxidative energy metabolism in the slow-twitch muscles, respectively. In 
contrast, taurine is present in most tissues at millimolar levels, and in slow-twitch 
muscles it has been proposed to have several roles including attenuation of the atrophy 
process by reducing expression of the atrophy genes (Pierno et al., 2011). It is important 
to note that while only a few metabolites changed in a fiber-dependent manner, the gene 
expression data indicated that several thousand transcripts were differentially expressed 
(Chapter 3.3). Together, these results demonstrate that transcriptional profiling is more 
sensitive at detecting both sex- and fiber-specific changes which are consistent with the 
muscle fiber phenotype, whereas metabolomic profiling is more useful for monitoring 
changes in metabolites which are highly concentrated in the skeletal muscle. 
 
Since cerivastatin inhibits cholesterol synthesis, metabolomic profiling was also 
conducted on lipophilic extracts from cerivastatin treated female rats. Metabolomic 
evaluation of lipophilic extracts is not a common practice because of poor resolution 
mediated by a reduction in the chemical shifts, leaving few distinct resonances for 
metabolite identification (Srivastava et al., 2010). Despite this limitation, the NMR data 
revealed dose-dependent increases in free cholesterol and phosphatidylcholine in the 
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psoas from female rats. This observation was unexpected given the pharmacology of 
statins and the hypothesis that statin-induced myopathy is mediated by a decrease in 
skeletal muscle cholesterol (London et al., 1991). However, the current results are 
consistent with transcriptional induction of genes in the mevalonate pathway and 
cholesterol regulation, including HMG-CoA reductase and the Ldl receptor (Table 3.13). 
A similar increase in cholesterol has also been observed clinically in the quadriceps of 
patients on simvastatin, in the absence of an increase in CK, suggesting this change may 
precede myopathy (Paiva et al., 2005; Phillips et al., 2010). The accumulation and 
abnormal localization of free cholesterol adversely effects cellular functions and can lead 
to cell death (Ridgway et al., 1999). Furthermore, an abnormal accumulation of free 
cholesterol, representing 2 to 3-fold increase is associated with the pathogenesis of other 
myopathies, like inclusion body myositis, muscular dystrophy, chloroquine-induced 
myopathy, statin-induced myopathy in mice and muscle atrophy (Jaworska-Wilczynska 
et al., 2002; Kuhn and Logan, 1990; Kumar and Sharma, 2009; Nilsson et al., 1981; 
Owens and Hughes, 1970; Williams and Smith, 1989; Yokoyama et al., 2007). However, 
an inflammatory response in non-muscle tissues increases cholesterol as well as 
desmosterol and 7-dehydrocholesterol which were both noted in the current investigation 
(Fon Tacer et al., 2010). Therefore, additional experiments are needed to determine 
whether these changes represent pathology or are causally related to statin-induced 
myopathy. 
 
Metabolomic profiling of aqueous skeletal muscle extracts from cerivastatin treated 
female rats revealed several metabolites which were mostly decreased. In the female 
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psoas, metabolites involved with energy metabolism (lactate, NAD
+
, creatine, and 
phosphocreatine) were significantly decreased, and NAD
+
 was the only metabolite which 
was reduced in a dose-dependent manner. Similar metabolite changes have been reported 
in skeletal muscle and myotubes during conditions of physiological stress and myopathy 
(Brault et al., 2003; Gupta et al., 2000; Sharma et al., 2003a, 2003b; Straadt et al., 2010a, 
2010b). Accordingly, the current findings are consistent with alterations in energy 
homeostasis related to myopathy, and this conclusion is consistent with the gene 
expression data indicating a reduction in transcripts involved with energy metabolism 
(Table 3.8). In contrast, glutamine was significantly increased, and a similar response has 
been observed with other catabolic conditions in skeletal muscle (Huang et al., 2007; 
Salehian et al., 2006). Additionally, there was a significant reduction in histidine-
containing dipeptides, including both carnosine and anserine. These dipeptides are highly 
concentrated in skeletal muscle (1 – 50 mM) and play a role in pH-buffering and 
antioxidant activity (Aldini et al., 2004; Chan et al., 1994; Penafiel et al., 2004). The 
decrease in these metabolites is consistent with skeletal muscle degeneration.  
 
There were several unexpected findings in the aqueous extracts, including a decrease in 
anserine and phosphocreatine in the soleus from cerivastatin treated female rats, in the 
absence of histological evidence of toxicity (Table 2.2). Although the biological basis for 
these changes is unknown, they may be indicative of oxidative stress which would be 
consistent with transcriptional induction of Mt1a noted in the soleus (Table 3.16). 
Furthermore, a decrease in phosphocreatine may suggest a perturbation in energy 
homeostasis, and this conclusion is corroborated by transcriptional changes in several 
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genes involved with alterations in energy metabolism (Tables 3.15 and 3.16). Together, 
these results suggest that cerivastatin also affects the slow-twitch muscle, albeit in the 
absence of myopathy. However, it is also possible that changes observed in the slow-
twitch muscle are secondary to the observation that some of the rats were moribund.   
 
An additional unexpected finding in this study was that phosphocreatine increased in the 
psoas from male rats treated with cerivastatin. Given that constitutive levels of creatine 
were higher in the psoas from naïve male rats, these data may indicate that sex-specific 
differences in creatine metabolism are mechanistically important. Clinical evidence 
indicates phosphocreatine recovery time is prolonged in skeletal muscles of statin treated 
patients while exercising, thereby indicating an impairment in mitochondrial oxidative 
phosphorylation (Wu et al., 2011). Furthermore, in a separate clinical study, creatine 
supplementation prevented statin-induced myopathy (Shewmon and Craig, 2010). 
Together, these results may suggest that statins impair energy metabolism in the skeletal 
muscle. However, additional experiments are needed to determine whether these changes 
represent pathology or are causally related to statin-induced myopathy. 
 
In summary, metabolomic profiling of skeletal muscles from cerivastatin treated rats 
revealed alterations in cholesterol homeostasis and energy metabolism, and these findings 
were consistent with transcriptional changes noted in skeletal muscles (Chapter 3). To 
determine whether these changes are associated with pathology or causally related to 
cerivastatin-induced myopathy, additional experiments were conducted in Chapters 5 and 
6. Furthermore, in Chapter 7 metabolomic profiling was conducted on urine collected 
166 
 
from cerivastatin treated rats to determine whether specific skeletal muscle metabolites 
can be identified which would be useful as biomarkers of myopathy. 
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Figure 4.1. 
1
H NMR spectra of aqueous extracts of the psoas from female and male 
rats (aliphatic region: 0.5-4.5 ppm). Representative spectra of the psoas from A) female 
and B) male rats showing similar metabolomic profiles. However, creatine (↓) was 
increased in the male relative to the female rats. 
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Figure 4.2. 
1
H NMR spectra of aqueous extracts of the psoas from female and male 
rats (aromatic region: 5.7-9.5 ppm). Typical spectra of the psoas from A) female and 
B) male rats showing similar metabolomic profiles.  
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Figure 4.3. 
1
H NMR spectra of lipophilic extracts of the psoas from female and male 
rats. Representative spectra of the psoas from A) female and B) male rats showing 
similar metabolomic profiles including sharp resonances for cholesterol (↓) and 
phosphatidylcholine (↓) and broad resonances for the CH2 groups from phospholipids 
(PL). In general, resonances in the lipophilic extracts were broad which reduced 
resolution and limited metabolite identification. 
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Figure 4.4. 
1
H NMR spectra of aqueous extracts of the psoas and soleus from female 
rats (aliphatic region: 0.5-4.5 ppm). Representative spectra of the A) psoas and B) 
soleus from female rats. Fiber differences in several metabolites was observed including 
higher levels of lactate (↓)  in the psoas, whereas higher levels of taurine (↓) and an 
unknown metabolite at 1.25 ppm (↓) were noted in the  soleus.  
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Figure 4.5. 
1
H NMR spectra of aqueous extracts of the psoas and soleus from female 
rats (aromatic region: 5.7-9.5 ppm). Representative spectra of the A) psoas and B) 
soleus from female rats illustrating a similar distribution of metabolites in both muscle 
fiber types with one noted exception, higher levels of fumarate (↓) were noted in the 
soleus. 
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Figure 4.6. 
1
H NMR spectra of lipophilic extracts of the psoas and soleus from 
female rats. Typical spectra of the A) psoas and B) soleus from female rats showing 
sharp resonances for cholesterol (↓) and phosphatidylcholine (↓) and broad resonances 
for the CH2 groups from phospholipids (PL). Several PL resonances showed better 
resolution in the soleus which was likely the result of less tissue comapred to the psoas. 
Cholesterol levels were higher in the soleus relative to the psoas. 
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Figure 4.7. 
1
H NMR spectra of aqueous extracts of the psoas from cerivastatin 
treated female rats (aliphatic region: 0.5-4.5 ppm). Representative spectra of the psoas 
from A) control and B) cerivastatin (1 mg/kg) treated female rats showing the major 
metabolic changes including a decrease in anserine (↓), carnosine (↓), lactate (↓), 
phosphocreatine (↓), creatine (↓) and two unknown metabolites at 1.27 and 1.77 ppm (↓). 
In contrast, glutamine increased (↓) in the psoas following cerivastatin treatment. 
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Figure 4.8. 
1
H NMR spectra of aqueous extracts of the psoas from cerivastatin 
treated female rats (aromatic region: 5.7-9.5 ppm). Typical spectra of the psoas from 
A) control and B) cerivastatin (1 mg/kg) treated female rats illustrating the major 
metabolic changes including a reduction in NAD
+
 (↓) and histidine-containing moities 
(↓).  
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Figure 4.9. 
1
H NMR spectra of lipophilic extracts of the psoas from cerivastatin 
treated female rats. Representative spectra of the psoas from A) control and B) 
cerivastatin (1 mg/kg) treated female rats showing the major metabolic changes including 
an increase in cholesterol (↓), phosphatidylcholine (PC) (↓), phospholipids (PL) and an 
unknown metabolite at 3.15 ppm (↓). The increase in cholesterol was confirmed as the 
free and not the esterified form based on the resonance at 3.55 ppm (↓) representing the 
proton on the carbon for the CHOH group which is absent in esterified cholesterol. 
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Figure 4.10. 
1
H NMR spectra of aqueous extracts of the psoas from cerivastatin 
treated male rats (aliphatic region: 0.5-4.5 ppm). Representative spectra of the psoas 
from A) control and B) cerivastatin (1 mg/kg) treated male rats were generally similar but 
phosphocreatine (↓) was significantly higher following cerivastatin treatment.   
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Figure 4.11. 
1
H NMR spectra of aqueous extracts of the psoas from cerivastatin 
treated male rats (aromatic region: 5.7-9.5 ppm). Representative spectra of the psoas 
from A) control and B) cerivastatin (1 mg/kg) treated male rats illustrating similar 
metabolomic profiles.  
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Figure 4.12. 
1
H NMR spectra of aqueous extracts of the soleus from cerivastatin 
treated female rats (aliphatic region: 0.5-4.5 ppm). Representative spectra of the 
soleus from A) control and B) cerivastatin (1 mg/kg) treated female rats illustrating a 
decrease in anserine (↓)  and phosphocreatine (↓). Anserine was quantitated based on a 
unique resonance at 3.79 ppm and a pH chemical shift at 4.6 ppm. 
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Figure 4.13. 
1
H NMR spectra of aqueous extracts of the soleus from cerivastatin 
treated female rats (aromatic region: 5.7-9.5 ppm). Representative spectra of the 
soleus from A) control and B) cerivastatin (1 mg/kg) treated female rats shows an 
increase in several of the nucleotides (↓).  
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Table 4.1. Relative metabolite changes in aqueous skeletal muscle extracts 
following cerivastatin treatment
a
 
 
Metabolite 
Chemical shift (ppm) 
and assignment  
Female Psoas Male Psoas Female Soleus 
0.5 mg/kg 1 mg/kg 1 mg/kg 0.5 mg/kg 1 mg/kg 
Metabolites involved with energy metabolism 
Glucose 4.64 (H‟) - - - - - 
Lactate 1.33 (CH3), 4.11 (CH) - -1.7 ± 0.1* - - - 
NAD+ 
6.04 (H1‟), 8.84, 9.15, 9.34 
(nicotinamide and base) 
-1.4 ± 0.1* -2.5 ± 0.1* - - - 
Creatine 3.02 (CH3), 3.93 (CH2) - -3.3 ± 0.1* - -  
Phosphocreatine 3.04 (CH3), 3.95 (CH2) - -2.5 ± 0.1* 1.3 ± 0.1*  -1.7 ± 0.1* 
Fumarate 6.53 (CH=CH) - - - - - 
Amino acids 
Alanine 1.47 (β-CH3), 3.75 (α-CH) - - - - - 
Glutamic acid 
2.04 (β-CH2), 2.31 (γ-CH2), 
3.65 (α-CH2) 
- - - - - 
Glutamine 
2.08 (β-CH2), 2.34 (γ-CH2), 
3.66 (α-CH2) 
- 1.5 ± 0.1* - - - 
Leucine 
0.94, 0.95 (δ-CH3), 1.69 (γ-
CH2), 1.72 (β-CH), 3.64 (α-
CH)  
- - - - - 
Phenylalanine 
7.32 (2,6 H), 7.36 (4 H), 
7.42 (3,5 H) 
- - - - - 
Tyrosine 6.88 (3,5 H), 7.16 (2,6 H) - - - - - 
Valine 1.00 (γ-CH2), 2.20 (β-CH) - - - - - 
Other compounds 
Acetate 1.92 (CH3) - - - - - 
Carnosine  
Histidine: 2.95, 3.12 (β-
CH), 4.46 (α-CH), 6.94 
(4H), 7.68 (2H); β-alanine: 
2.61 (β-CH3), 3.12 (α-CH) 
- -2.5 ± 0.1* - - - 
Anserineb  - -2.5 ± 0.1* - - -1.7 ± 0.1* 
Taurine 
3.25 (CH2NH), 3.41 
(CH2SO3) 
- - - - - 
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a
Results represent the mean fold change ± SE for each metabolite in aqueous skeletal 
muscle extracts from cerivastatin treated compared to control rats measured by NMR. 
b
The 1H NMR spectra for anserine and carnosine are similar with one noted exception, 
anserine has a resonance at 3.79 ppm representing the NCH3 group. Additionally, the two 
spectra show a chemical and pH shift at 4.6 ppm which enabled quantitation. 
 (-) = no change relative to control. 
*Statistically significant at p<0.05. 
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Table 4.2. Relative metabolite changes in lipophilic skeletal muscle extracts 
following cerivastatin treatment
a
 
 
Metabolite 
Chemical shift and 
assignment  
Female Psoas 
Male 
Psoas 
Female Soleus 
0.5 mg/kg 1 mg/kg 1 mg/kg 0.5 mg/kg 1 mg/kg 
Cholesterolb 0.68, 0.90, 1.01(CH3), 1.64, 
1.96, 2.26 (CH2), 3.55 
(CHOH) 
1.4 ± 0.1* 1.8 ± 0.2* - - - 
Phosphatidylcholine  
(PC) 
3.30 (CH3)3-N 5.0 ± 0.6* 5.5 ± 0.6* 1.8 ± 0.1* - - 
Phospholipidsc 
(PL) 
0.90 (CH3), 3.74 (CH2-N), 
1.3, 1.7, 2.1, 2.35, 2.8, 3.7, 
3.98, 4.14, 4.29 (CH2), 5.4 
(CH=CH)  
 
a
Results represent the mean fold change ± SE of lipophilic skeletal muscle extracts from 
cerivastatin treated compared to control rats measured by NMR. 
b
There were two distinct resonances at 0.68 and 1.01 ppm which originate from C18 and 
C19 methyl groups of cholesterol (free + esterified forms), respectively. Specificity of the 
change in free cholesterol was determined based on an increase in the resonance at 3.55 
ppm representing the proton on the carbon for the CHOH group which is absent in 
esterified cholesterol. 
c
Phospholipids as a class were identified but specific changes were not determined. 
(-) = no change relative to control. 
*Statistically significant at p<0.05. 
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Table 4.3. Concentration of sterols in the psoas
a
 
Sterol   
Control 
Cerivastatin 
(0.5 mg/kg) 
Cerivastatin 
(1 mg/kg) 
nmol/g tissue
b
 
Total cholesterol
b
 1.6 ± 0.7 1.9 ± 0.1 2.8 ± 0.5* 
7-Dehydrocholesterol 2.2 ± 0.3 2.8 ± 0.3 4.4 ± 0.9* 
Desmosterol 1.4 ± 0.1 1.5 ± 0.2 5.4 ± 1.7* 
7α-Hydroxycholesterol 1.1 ± 0.1 1.2 ± 0.1 2.9 ± 1.0* 
Lanosterol 0.6 ± 0.1 0.7 ± 0.1 1.0 ± 0.2 
Lathasterol 8.6 ± 1.9 9.5 ± 2.3 10.3 ± 1.8 
β-Sitosterol 82.2 ± 8.1 52.7 ± 4.6* 58.7 ± 15.0 
Campesterol 18.0 ± 1.4 12.1 ± 0.9* 13.7 ± 3.8 
Stigmasterol 1.2 ± 0.1 1.0 ± 0.1 1.2 ± 0.5 
a
Results represent the mean ± SE of sterols in extracts of the female psoas from 
cerivastatin treated and control rats measured by LC-MS. 
b
Cholesterol, representing free and esterified is presented as µmol/g tissue.  
*Statistically significant at p<0.05. 
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Chapter 5 
 
 
Cerivastatin-induced myopathy is associated with alterations 
in cholesterol homeostasis and upregulation of the 25-
hydroxycholesterol pathway 
 
 
5.1. Introduction 
Transcriptomic and metabolomic profiling of fast-twitch muscles in the rat indicated 
cerivastatin-induced myopathy is associated with alterations in cholesterol homeostasis 
(Tables 3.13 and 4.2). Specifically, these changes were characterized by a 2-fold increase 
in cholesterol and transcriptional upregulation of HMG-CoA reductase and the LDL 
receptor. Furthermore, transcriptional induction was also noted for genes involved with 
removing excess cholesterol through esterification (acyl-CoA: cholesterol 
acyltransferase), efflux (ABCG1 and ABCA1) and synthesis to 25-hydroxycholesterol 
(cholesterol 25-hydroxylase) (Table 3.13).  
 
Given that the pharmacology of cerivastatin is inhibition of HMG-CoA reductase (IC50=1 
nM), and the plasma Cmax associated with myopathy is 221 nM (Reinoso et al., 2002; 
Steinke et al., 1996), an increase in skeletal muscle cholesterol was unexpected. 
However, the increase in cholesterol may in fact be mediated by the pharmacology, as 
statins cause a compensatory upregulation of cholesterol biosynthesis in the rat liver 
(Fujioka et al., 1995). Likewise, cerivastatin may also cause a pharmacological 
upregulation of cholesterol biosynthesis in the muscle and this could lead to pathological 
185 
 
consequences as accumulation and abnormal localization of cholesterol adversely affects 
cellular functions and promotes necrosis (Ikonen, 2006, 2008; Ridgway et al., 1999; 
Warner et al., 1995). Furthermore, accumulation of cholesterol in fast-twitch muscles has 
been associated with the pathogenesis of myopathies like inclusion body myositis, 
muscular dystrophy, chloroquine-induced myopathy, and muscle atrophy indicating this 
fiber type may be sensitive to changes in cholesterol homeostasis (Jaworska-Wilczynska 
et al., 2002; Kuhn and Logan, 1990; Kumar and Sharma, 2009; Nilsson et al., 1981; 
Williams and Smith, 1989). Accordingly, it was hypothesized that alterations in 
cholesterol homeostasis are causally related to the mechanism of statin-induced 
myopathy in rats.  
 
The goal of this work was to determine whether alterations in cholesterol homeostasis 
occur prior to, or as a consequence of the myopathy. To determine the relationship 
between alterations in cholesterol homeostasis and toxicity a time course of cerivastatin-
induced myopathy was conducted and alterations in cholesterol homeostasis were 
monitored in the sensitive fast-twitch muscle, the unaffected slow-twitch muscle and in 
the liver. 
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5.2. Methods 
Chemicals. Cerivastatin (Na salt) was purchased from Sequoia Research Products 
(Pangbourne, United Kingdom). Methylcellulose A15C premium was purchased from the 
Dow Chemical Company (West Point, PA). Nondeuterated sterols including 7-
Dehydrocholesterol 7α-hydroxycholesterol, 7α, 25-dihydrocholesterol, 7α,25-dihydro-4-
cholesten-3-one were purchased from Avanti Polar Lipids (Alabaster, Alabama) and 
24(S)-hydroxycholesterol was purchased from Enzo Life Sciences (Plymouth Meeting, 
PA) (Figure 6.1). Deuterated (D) sterols with the number of hydrogens replaced with 
deuterium (D3-7), including cholesterol (D7), desmosterol (D6), 7β-hydroxycholesterol 
(D7), 25-hydroxycholesterol (D3 and D6), 27-hydroxycholesterol (D6) were purchased 
from Avanti Polar Lipids (Figure 6.1).  
 
Study design. This investigation was conducted on samples obtained from study 1 and 2 
described in Chapter 2. Skeletal muscle muscles representing slow-twitch (soleus) and 
fast-twitch (quadriceps femoris and psoas) twitch fiber composition (Table 2.1) and the 
left lateral lobe of the liver were fixed in 10% neutral buffered formalin for 
histopathological assessment whereas the same skeletal muscles on the right side of the 
animal, including the right lateral lobe of the liver were flash frozen and used for sterol 
analysis and RNA isolation.  
 
Histopathology. Tissues were processed for histopathologic evaluation as described in 
Chapter 2.2.  
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Evaluation of sterols in skeletal muscle and liver. A pilot study was initially conducted 
on the quadriceps from control and cerivastatin treated rats treated for 14 days (study 1; 1 
mg/kg) to determine the relative changes in sterols and hydroxycholesterols. Based on 
these results, a panel of sterols and hydroxycholesterols were selected and quantitated in 
the psoas across the time course, and soleus and liver after 14 days of treatment (study 2). 
Frozen muscle tissues (quadriceps, psoas and soleus) and the right lateral lobe of the liver 
were individually pulverized in liquid nitrogen and a portion (100 mg psoas and liver, 
and 50 mg of soleus) was extracted according to the method of Folch (1957). Metabolite 
extraction was performed by homogenizing the tissue in a bead mill (Retsch MM 300, 
Haan Germany) for 4 minutes (30 Hz) with 10 volumes of ice-cold methanol. To each 
sample, 5 µl (60 ng/µl) of deuterated 25-hydroxycholesterol (D6) (internal standard) was 
added. Following centrifugation (8000g, 4˚C) for 15 minutes, the supernatant (0.6 ml for 
psoas and liver; 0.3 ml for soleus) was transferred to water/chloroform (0.4 ml / 1 ml for 
psoas and liver; 0.2 ml / 0.6 ml for soleus) and vortexed for 10 seconds and then shaken 
in a bead mill (30 Hz) for 10 minutes at room temperature. Samples were centrifuged 
(6000g, 4˚C) for 25 minutes and the chloroform (lipophilic phase) was collected and 
dried under nitrogen at room temperature and reconstituted in 200 µl of methanol, 
vortexed and centrifuged for 10 minutes at 12,000g. The supernatant was transferred to a 
new tube and sterols were measured by LC/MS. 
 
Sterol standard curves. For the pilot study, standards representing a panel of relevant 
sterols and hydroxycholesterols were prepared, including cholesterol (D7), 7-
dehydrocholesterol, desmosterol (D6), 7α-hydroxycholesterol, 7β-hydroxycholesterol 
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(D7), 24(S)-hydroxycholesterol, 25-hydroxycholesterol (D3), 7α, 25-dihydrocholesterol, 
7α,25-dihydro-4-cholesten-3-one, and 27-hydroxycholesterol (D6) (Figure 5.1). For 
quantitation of sterols in the psoas, soleus and liver standard curves were prepared for 
cholesterol (D7; 1-500 µg/ml), 7-dehydrocholesterol (5-5000 ng/ml), desmosterol (D6; 5-
50,000 ng/ml), 7β-hydroxycholesterol (D7; 5-5000 ng/ml), 25-hydroxycholesterol (D3; 
5-5000 ng/ml). Each sterol standard was prepared in 200 µl of methanol containing 300 
ng of the internal standard 25-hydroxycholesterol (D6) with a final concentration of 1.5 
µg/ml. 
 
LC/MS: Sterols were separated by a Thermo-Fisher Accela reversed-phase UPLC with a 
Waters Acquity UPLC BEH C18 analytical column (2.1×100 mm, 1.7 µm) at 65˚C. A 
gradient mobile phase was used consisting of (Mobile Phase A) 0.1% formic acid in 
water and (Mobile Phase B) methanol with 0.1% formic acid with a flow rate of 0.6 
ml/min and an injection volume of 5 µl. Initial mobile phase conditions were 60% A and 
40% B for 0.2 minutes, followed by a linear gradient to 25% A and 75% B over 0.3 
minutes and a linear gradient to 100% B over 8.5 minutes. Initial mobile phase conditions 
for system equilibration were established after 9 minutes for a total sample analysis time 
of 10 minutes. Between each sample analysis the needle was washed in 0.1% formic acid 
in acetonitrile and then with 0.1% formic acid in 80:20 (methanol:water). A Thermo-
Fisher Oribtrap Exactive MS with APCI positive mode was used for sterol detection. 
Identification of each sterol was based on an external standard curve, elution time and 
accurate m/z. Although sensitivity for each sterol was not determined the concentration 
189 
 
of all the sterols but 25-hydroxycholesterol was within the range of the standard curve. 
The LOQ for 25-hydroxycholesterol was 0.01 µg/g of wet tissue weight. 
 
RNA isolation. Frozen tissues from study 2 were pulverized and 50 mg of muscle (psoas 
and soleus) and liver was used for RNA isolation. RNA was isolated with TRIzol 
(Invitrogen Corporation, Carlsbad, CA) and an RNeasy spin column (Qiagen, Valencia, 
CA) according to the manufacturers' instructions. Removal of DNA was achieved by 
using Qiagen's RNase-Free DNase. The quantity (260 nm absorbance) and quality (260 / 
280 nm absorbance ratio) of total RNA was determined on a ND-1000 spectrophotometer 
(NanoDrop Technologies, Inc., Wilmington, DE). 
 
Quantitative RT-PCR. RNA (2 μg) was reverse transcribed to cDNA using a High 
Capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA). 
Quantitative RT-PCR was performed on the ABI Prism 7900HT Sequence Detection 
System (Applied Biosystems) using 2X Power SYBR® Green PCR master mix (Applied 
Biosystems). Primer Express (v2.0, Applied Biosystems) was used to design primers 
which were synthesized by Invitrogen (Table 5.1) (Invitrogen Corporation, Carlsbad, 
CA). The 18S rRNA primers from Applied Biosystems were used as an endogenous 
control. Primer specificity was confirmed by BLAST searches and melting curve analysis 
demonstrated that primers only generated a single amplicon. The amplification conditions 
used were 2 min at 50°C, 10 min at 95°C, followed by 40 cycles at 95°C for 15 s and 
60°C for 30 s. To create dissociation curves, additional steps were added to the end of the 
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amplification reaction: 95°C for 15 s, 60°C for 15 s and then gradually increasing to 95°C 
for 20 min. 
 
Isolation of rat fast-twitch myofibers. Isolation of rat fast-twitch myofibers is described 
in Chapter 2.2. To each well, 30 µl of vehicle (maintenance medium) or cerivastatin 
(final concentration was 300 nM) was added to the myofibers. This concentration was 
selected because a toxic dose of cerivastatin in female rats is associated with a Cmax of 
221 nM (Reinoso et al., 2002; Steinke et al., 1996). Therefore, for the current work a 
slightly higher concentration was selected for testing. Furthermore, 3-4 days of 
cerivastatin (300 nM) treatment is associated with morphological changes characteristic 
of a stressed and dying cell and reduced viability (Figure 2.5). On days, 1, 2, 3, and 4 the 
medium from one plate was gently removed with a pipette and the myofibers were 
washed twice with pre-warmed PBS (100 l).  
  
Myofiber sterol extraction. Ice-cold methanol (200 µl) was added to 24 control and 24 
treated wells. The bottom of the wells was scrapped with a pipette tip to remove the 
myofibers. The methanol was also pipetted up and down several times to remove 
myofibers. The methanol was removed and pooled together giving two samples (control 
and treated) for each of the four days. Following collection, these samples were frozen at 
-80˚C. To each sample (approximately 5 ml of methanol) one volume of chloroform and 
0.4 volumes of water was added. The samples were vortexed and centrifuged at 12,000g 
for 25 minutes. The bottom layer was transferred to a new glass vial and dried. For 
LC/MS analysis, samples were reconstituted in 200 µl of methanol, vortexed and 
centrifuged for 10 minutes at 12,000g. The supernatant was transferred to a new tube and 
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cholesterol, 7-dehydrocholesterol, desmosterol and 25-hydroxycholesterol were measured 
by LC/MS as described above for tissues. 
 
Myofiber RNA isolation. Lysis buffer (50 µl) (Qiagen RLT buffer) was added to 24 
control and 24 treated wells. The bottom of the wells were scrapped with a pipette tip to 
remove myofibers. The buffer was also pipetted up and down several times to remove the 
cells. The buffer was removed from 24 control and 24 treated wells and pooled together 
giving two samples (control and treated) for each of the four days. The lysis buffer was 
pipetted up and down with a 20 gauge needle on a syringe to lyse the cells. Following 
collection, these samples were frozen at -80˚C. RNA was isolated with an RNeasy spin 
column according to the manufacturers' instructions. The quantity and quality of RNA as 
well as the RT-PCR conditions were was conducted as described above. 
 
Cholesterol 25-hydroxylase immunohistochemistry. The quadriceps from control and 
cerivastatin (study 1; 1 mg/kg; 14 days) treated rats were sectioned at 4 µm, mounted on 
slides, deparaffinized, rehydrated and treated with cell conditioning 1 antigen retrieval 
buffer at 100˚C for 30 minutes (Ventana, Medical Inc., Tucson, AZ). Sections were 
incubated separately with CH25H mouse monoclonal antibody (Abcam, Cambridge, 
MA) at 1:50 or CD68 (ED1) mouse monoclonal antibody (AbD Serotec, Oxford, UK) at 
1:500 for one hour at room temperature. Following incubation, tissues were incubated 
with anti-mouse IgG biotin and streptavidin-HRP and developed in DAB substrate. 
Positive expression (brown signal) was confirmed by observation of distinct granular 
deposits by light microscopy. For double staining, DABMAP and REDMAP detection 
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kits were used (Ventana Medical Inc.). CH25H signals were developed with DAB 
chromagen (brown signal) and CD68 signals were developed with fast red substrate 
(red/purple signal). Colocalization of CH25H with CD68 shows a double positive orange 
signal.  
 
Data analysis. Sterol identification and relative changes following cerivastatin treatment 
were assessed based on a single standard in the pilot study (study 1) and in myofibers. 
Quantitation of sterols in muscle and liver were determined in study 2 with standard 
curves (correlation coefficient>0.99). For quantitative RT-PCR, relative changes in gene 
expression were determined by the ΔΔCt method. The Ct values for each gene were 
normalized to 18S Ct values and the fold change in treated muscles was determined 
relative to control. Group means for all analyses were compared with a Student‟s t-test or 
ANOVA using StatView (SAS Institute, Cary, NC) at p<0.05. However, statistics for the 
RT-PCR results were conducted on the values following normalization to 18S.  
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5.3. Results 
Cerivastatin caused fast-twitch specific myofiber degeneration in the quadriceps and 
psoas in female rats after 14 days of dosing whereas the slow-twitch fibers of the soleus 
were unaffected as previously described (Study 1; Figure 2.2; Table 2.2). In the 
cerivastatin time course, skeletal muscle toxicity was initially observed in the fast-twitch 
muscles (quadriceps and psoas) after 8 days of dosing and increased in severity after 10 
and 14 days of dosing as previously described (Study 2; Figure 2.3; Table 2.3). In 
contrast, no myopathy was observed in the soleus at any time. Furthermore, no evidence 
of hepatotoxicity was observed in either of these studies. (Tables 2.2 and 2.3).  
 
Cerivastatin-induced myopathy was associated with alterations in cholesterol homeostasis 
in the quadriceps, including an increase in cholesterol, 7-dehydrocholesterol,  
desmosterol and 7α/β-hydroxycholesterol as previously observed in the psoas (Study 1; 
Table 4.3; Table 5.2). Furthermore, 25-hydroxycholesterol was increased 31-fold relative 
to control and the downstream sterol in the 25-hydroxylation pathway, 7α,25-dihydro-4-
cholesten-3-one was also increased 14-fold (Study 1; Table 5.2; Figure 5.2). In contrast, 
24- and 27-hydroxycholesterol were non-detectable in the quadriceps showing myopathy 
(Study 1; Table 5.2). Accordingly, these results demonstrate that upregulation of the 25-
hydroxylation pathway is a specific response associated with cerivastatin-induced 
myopathy (Figure 5.2). 
 
To determine whether alterations in cholesterol homeostasis are causally related to 
toxicity the concentration of sterols was determined in a time course of cerivastatin-
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induced myopathy (Study 2). In the psoas, cholesterol, 7-dehydrocholesterol, desmosterol 
and 25-hydroxycholesterol were all increased but only in the presence of myopathy (≥ 
day 11), indicating these changes are not causally related to toxicity (Table 5.3). In 
contrast, these sterols were unchanged in the soleus, consistent with the absence of 
myopathy. In the liver, sterol increases were noted on day 15, indicating increased 
hepatic cholesterol synthesis and uptake (Table 5.3).  
 
To further investigate alterations in cholesterol homeostasis, transcriptional changes in a 
subset of genes induced with cerivastatin-induced myopathy, and involved with 
cholesterol regulation, were evaluated in tissues from the time course (Study 2; Table 
3.13). In the psoas, transcriptional induction of these genes was associated with the 
manifestation of myopathy whereas similar changes were not observed in the soleus 
(Figure 5.3). The expression of these genes in the time course after 14 days of dosing 
cerivastatin (1 mg/kg) were similar to the microarray results for skeletal muscles 
observed in the cerivastatin (1 mg/kg) dose response study 1 (Table 3.13). In the liver, 
HMG-CoA reductase showed an immediate and sustained transcriptional induction 
across the time course, suggesting this response is likely mediated by cerivastatin 
pharmacology (Figure 5.3). In contrast, cholesterol 25-hydroxylase, Acyl-CoA: 
cholesterol acyltransferase and ABCG1 were only minimally increased or unchanged 
(Figure 5.3). 
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To determine whether alterations in cholesterol homeostasis are muscle specific, fast-
twitch myofibers were isolated and treated with cerivastatin (300 nM) for up to 4 days. 
After 3-4 days, light microscopy revealed that the myofibers developed blebs on the 
plasma membrane consistent with a stressed / dying cell (Table 2.4; Figures 2.5 and 2.6). 
However, unlike the in vivo psoas response, cholesterol, 7-dehydrocholesterol, and 
desmosterol were not increased relative to control and 25-hydroxycholesterol was below 
the limit of detection following cerivastatin treatment (Figure 6.4). The transcriptional 
profile was also different in the myofibers compared to the psoas but similar to the liver, 
with HMG-CoA reductase showing a sustained transcriptional induction across the 4-day 
time course whereas cholesterol 25-hydroxylase, ABCG1 and Acyl-CoA: cholesterol 
acyltransferase showed no change or a reduction relative to control (Figure 5.5). 
Together, the sterol and transcriptional profile in the treated myofibers did not 
recapitulate changes observed in the psoas, suggesting alterations in cholesterol 
homeostasis are mediated in part by in vivo factors.  
 
Transcriptional induction of cholesterol 25-hydroxylase has not been reported in models 
of myopathy. Therefore, to determine whether the increase in cholesterol 25-hydroxylase 
is specific to the muscle, immunohistochemical staining of the quadriceps following 
cerivastatin treatment was conducted (Study 1). In the quadriceps from control rats, there 
was no expression of cholesterol 25-hydroxylase or CD68 (constitutive marker of 
macrophages) (Figure 5.6A). However, cholesterol 25-hydroxylase (Figure 5.6B) and 
CD68 (Figure 5.6C) were both readily detectable in muscle cells and macrophages, 
respectively with cerivastatin-induced myopathy. Furthermore, no double staining of 
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these proteins was observed indicating that the cholesterol 25-hydroxylase response is 
specific to the muscle cell (Figure 5.6D). 
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5.4. Discussion 
All nucleated cells can synthesize cholesterol from acetyl-CoA through the mevalonate 
pathway. However during normal physiological conditions the rate of cholesterol 
biosynthesis in rat skeletal muscle is less than 1% of the liver and significantly less than 
other major organs (Spady and Dietschy, 1983). Furthermore, skeletal muscle shows the 
lowest uptake of LDL-C compared to other major organs (Stange and Dietschy, 1984; 
Turley et al., 1981). The reduced need for cholesterol synthesis in skeletal muscle is 
likely related to the fact that under normal physiological conditions differentiated skeletal 
muscle is comprised of predominately post-mitotic cells and there is a minimal need for 
membrane synthesis. However, increases in skeletal muscle cholesterol synthesis and 
uptake are associated with processes involving membrane synthesis like myogenesis, 
hypertrophy and injury repair (Martini et al., 2009; Riechman et al., 2009; Trapani et al., 
2010; Vinagre et al., 2007). This tight regulation of cholesterol homeostasis is important 
because abnormal accumulation of cholesterol adversely affects cellular functions, 
promotes necrosis and has been associated with the pathophysiology of various 
myopathies (Cui et al., 2002; Ikonen, 2006, 2008; Jaworska-Wilczynska et al., 2002; 
Kuhn and Logan, 1990; Kumar and Sharma, 2009; Nilsson et al., 1981; Ridgway et al., 
1999; Warner et al., 1995; Williams and Smith, 1989).  
 
In humans, statins inhibit hepatic HMG-CoA reductase resulting in transcriptional 
induction of the LDL receptor, increased hepatic uptake and reduction in serum 
cholesterol. In rats, there is a compensatory response in which HMG-CoA reductase is 
transcriptionally induced resulting in increased liver and serum cholesterol levels 
(Fujioka et al., 1995). However, serum cholesterol was unchanged with cerivastatin 
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treatment in the current study (results not shown). Instead, cerivastatin was shown to 
increase cholesterol levels in fast-twitch muscles in association with myopathy, 
suggesting this tissue may respond similar to the liver (Chapters 3 and 4). Since abnormal 
accumulation of cholesterol is potentially toxic it was hypothesized that alterations in 
skeletal muscle cholesterol homeostasis are causally related to the development of 
cerivastatin-induced myopathy. (Ikonen, 2006, 2008; Ridgway et al., 1999; Warner et al., 
1995). Therefore, the goal of this work was to determine the temporal relationship 
between alterations in skeletal muscle cholesterol homeostasis and the development of 
cerivastatin-induced myopathy. 
 
In the cerivastatin time course the sterol and transcriptional profile of the fast-twitch 
muscle demonstrated that altered cholesterol homeostasis is a manifestation of the 
myopathy and unrelated to the mechanism of toxicity. Importantly, this profile was 
different from the soleus in which there was no evidence of toxicity or changes in 
cholesterol homeostasis. Furthermore, the profile was also different from the liver which 
showed an immediate and sustained compensatory transcriptional induction in HMG-
CoA reductase consistent with the pharmacology.  
 
Although the mechanism of increased cholesterol and transcriptional induction of HMG-
CoA reductase was not directly probed in this work, this response may be mediated by 
the need to repair damaged skeletal muscle and remove excess cholesterol (Figure 6.7). 
Similarly, transcriptional induction of HMG-CoA reductase was also observed in vitro 
although cholesterol concentrations were unchanged indicating that the in vitro model did 
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not recapitulate changes observed in vivo. The disparity between the in vivo and in vitro 
results may be related to undefined in vivo factors or the fact that the myofiber medium 
did not contain serum or cholesterol. Accordingly, the myofibers may not have been able 
to synthesize or acquire cholesterol from the medium. Importantly, cerivastatin caused 
toxicity in vitro in the absence of alterations in cholesterol homeostasis. Therefore, this 
work further demonstrates that an increase in cholesterol is a response to myofiber 
damage and  unrelated to the mechanism of toxicity. 
 
One limitation of this study was that the location of the increased cholesterol in the 
muscle was not directly determined. Specifically, the increase in cholesterol could be 
occurring intracellularly or extracellularly in the muscle as a consequence of necrosis. 
However, transcriptional induction of genes involved with cholesterol esterification 
(acyl-CoA: cholesterol acyltransferase), efflux (ABCG1 and ABCA1) and conversion 
(cholesterol 25-hydroxylase) to 25-hydroxycholesterol represent a profile consistent with 
a response involving removal of excess intracellular cholesterol (Bjorkhem et al., 2009). 
Furthermore, since cholesterol 25-hydroxylase protein was specifically expressed in 
muscle cells it is reasonable to conclude that alterations in cholesterol homeostasis 
occurred within the skeletal muscle and not in macrophages or extracellularly.  
 
Activation of the 25-hydroxylation pathway has not been previously reported with 
skeletal muscle necrosis. Therefore, it is unknown whether this response is specific to 
statin myopathy or commonly associated with other muscle pathologies. However, 
various biological roles for 25-hydroxycholesterol have been previously identified. 
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Specifically, this oxysterol is more hydrophilic than cholesterol and is able to passively 
diffuse across the membrane and is reverse transported to the liver where it is converted 
to bile acids (Bjorkhem et al., 2009). Moreover, 25-hydroxycholesterol is a ligand for 
LXR which activates the efflux transporters and further increases removal of cholesterol 
(Bjorkhem et al., 2009). At the same time, 25-hydroxycholesterol suppresses cholesterol 
synthesis when levels are in excess (Figure 1.3). Additionally, a pro-inflammatory role 
has also been described in which cholesterol 25-hydroxylase is transcriptionally induced 
through Toll-like receptor signaling and 25-hydroxycholesterol stimulates IL-8 
production and recruits inflammatory cells (Bauman et al., 2009; Vejux et al., 2008). 
Similar hydroxylation pathways have also been identified, which are induced in a tissue 
specific manner, and regulate cholesterol homeostasis including, 27-hydroxycholesterol 
in macrophages, 24S-hydroxycholesterol in the brain and 7α-hydroxycholesterol in the 
liver (Bjorkhem, 2009; Vejux et al., 2008). Accordingly, the current results suggest that 
25-hydroxylation of cholesterol is an important pathway in skeletal muscle which 
regulates cholesterol homeostasis with statin-induced myopathy (Figure 5.7). 
 
In summary, the current work demonstrates that cerivastatin increases skeletal muscle 
cholesterol levels but these alterations are not causally related to the mechanism of 
cerivastatin-induced toxicity. Instead, the increase in cholesterol is likely associated with 
the tissue repair process triggered by muscle injury (Figure 6.7). Furthermore, in the face 
of ongoing toxicity, the muscle is unable to repair itself, resulting in cholesterol 
accumulation and triggering pathways, including esterification, efflux and conversion to 
25-hydroxycholesterol which facilitate removal of excess cholesterol (Figure 5.7). 
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Figure 5.1. Chemical structures of sterols measured in tissues. For several sterols, 
hydrogens on carbons 25, 26 and 27 were replaced with deuterium. 
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Figure 5.2. Cerivastatin-induced myopathy upregulates the cholesterol 25-
hydroxylase pathway. Cholesterol 25-hydroxylase was transcriptionally induced with 
cerivastatin-induced myopathy and this was accompanied by an increase in 25-
hydroxycholesterol and 7α, 25-dihydroxy-4-cholesten-3-one. Although not evaluated in 
the current work, both CYP7B1 and 7α-diol-3β-dehydrogenase were also 
transcriptionally induced with cerivastatin (1 mg/kg) myopathy after 14 days of dosing 
(Table 3.13). In contrast, levels of 7α-, 24- and 27-hydroxycholesterol were minimally 
increased or unchanged and this is consistent with the previous observation indicating 
that CYP7A1 and CYP46A1 are not transcriptionally induced and CYP27A1 is 
downregulated with cerivastatin (Table 3.13). Accordingly, these results demonstrate that 
cerivastatin-induced myopathy is associated with a specific upregulation of the 
cholesterol 25-hydroxylase pathway. 
CYP7B1
7α, 25-dihydrocholesterol
7α-diol-3β-dehydrogenase
7α,25-dihydroxy-4-cholesten-3-one Bile acids
Cholesterol
Cholesterol 25-hydroxylase CYP7A1 CYP46A1 CYP27A1
25-hydroxycholesterol 7α-hydroxycholesterol 27-hydroxycholesterol24-hydroxycholesterol
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Figure 5.3. Genes involved with cholesterol homoeostasis are transcriptionally induced with 
cerivastatin-induced myopathy. A subset of genes involved with cholesterol regulation, and 
induced with myopathy after dosing cerivastatin (1 mg/kg) for 14 days (Table 3.13), were 
evaluated in a time course to determine whether these changes are causally related to toxicity. In 
the psoas, these genes were transcriptionally induced as a manifestation of myopathy (≥ 8 days of 
cerivastatin) whereas in the soleus these genes were unchanged. In the liver, HMG-CoA 
reductase was transcriptionally induced as expected in response to the pharmacological activity of 
cerivastatin. 
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Figure 5.4. Sterol changes in cerivastatin treated isolated myofibers. Myofibers cultured in  
 
medium without serum were treated with cerivastatin (300 nM) for up to four days and sterol  
 
levels were measured by LC/MS. The concentration of these sterols was either unchanged or  
 
decreased with cerivastatin treatment. These results do not recapitulate the in vivo findings  
 
suggesting other in vivo factors contribute to an increase in these sterols. 
 
Results represent the mean fold change relative to control ± SE of three separate experiments. 
 
25-Hydroxycholesterol was non-detectable. 
 
Statistically significant at p<0.05. 
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Figure 5.5. Myofiber transcriptional changes in genes involved with cholesterol 
homeostasis following cerivastatin treatment. Myofibers cultured in medium without 
serum were treated with cerivastatin (300 nM) for up to four days and a subset of genes 
involved with cholesterol homeostasis were evaluated by RT-PCR. HMG-CoA reductase  
showed a sustained transcriptional induction indicating cholesterol deficiency (A). In 
contrast, the other genes were either reduced or unchanged across the time course (A and 
B). This transcriptional profile is different than the psoas following cerivastatin treatment 
suggesting in vivo factors mediate alterations in cholesterol homeostasis.  
Results represent the mean fold change relative to control ± SE of three separate 
experiments. 
*Statistically significant at p<0.05. 
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Figure 5.6. Cholesterol 25-hydroxylase expression in rat skeletal muscle from 
cerivastatin treated rats. CH25H and CD68 (macrophage marker) expression were not 
detected in the quadriceps from control rats (A), whereas a brown signal ( ) for 
CH25H in skeletal muscle (B), and CD68 in macrophages (C) was observed in the 
quadriceps from cerivastatin (1 mg/kg; 15 days) treated rats. Double staining with 
CH25H ( ; showing a brown signal) and CD68 ( ; showing a red/purple signal) in the 
quadriceps from cerivastatin (1 mg/kg; 15 days) treated rats demonstrates expression in 
skeletal muscle and macrophages, respectively with no colocalization of these positive 
signals (D; magnified to illustrate expression). Similar results were observed in muscles 
from other rats (n = 3 control and 3 treated). 
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Figure 5.7. Proposed mechanism of cerivastatin-induced alterations in cholesterol 
homeostasis. Cerivastatin-induced myopathy triggers a tissue repair response 
characterized by inflammation, transcriptional induction of HMG-CoA reductase and the 
LDL receptor as well as an increase in free cholesterol (yellow boxes). However, in the 
face of ongoing toxicity, excess cholesterol accumulates in the muscle causing an 
increase in esterification, efflux and conversion to 25-hydroxycholesterol (green boxes). 
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transporters↑ 
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↑
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Table 5.1. Quantitative RT-PCR primers 
 
 
  
Gene Description Forward Primer Reverse Primer
18srRNA 18s Ribosomal RNA CGGCTACCACATCCAAGGAA GCTGGAATTACCGCGGCT
HMGCR 3-hydroxy-3-methylglutaryl-Coenzyme CGACATCATCATCCTCACGATAA AGCTGACGCAGGTTCTGGAA
CH25H Cholesterol 25-hydroxylase CCAGAAGAAGAAACAGACTTGAGTTATTT CGGGCTGCAGAAACACATTA
SOAT1 Acyl-CoA: Cholesterol acyltransferase AGGTGTGCTGATGCTGTTCCT AACATTTCAGCAAAGGCATTGA
ABCG1
ATP binding cassette subfamily G 
member 1 (Efflux transporter) TACCTTGGGATTGGGAACGA AGGGCGGCGAACATGAG
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a
Results represent the mean fold change relative to control ± SE in the quadriceps from 
cerivastatin (study 1; 1 mg/kg; day 15) treated rats (n = 6 control and 9 treated rats / 
group).  
b7α- and 7β-hydroxycholesterol were not resolved under these conditions. 
(-) indicates no change. 
*Statistically significant at p<0.05. 
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a
Results represent the mean concentration ± SE of sterols per wet tissue weight from 
control (n=4) and cerivastatin (1 mg/kg; n=8) treated rats.  
LOQ for 25-hydroxycholesterol was 0.01 µg/g of wet tissue weight. 
*Statistically significant at p<0.05.
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Chapter 6 
 
 
Cerivastatin-induced myopathy is associated with alterations 
in energy metabolism 
 
6.1. Introduction  
Skeletal muscle energy metabolism relies on oxidative phosphorylation, and a critical 
step in this process is glucose oxidation followed by conversion of pyruvate to acetyl-
CoA, in a reaction catalyzed by the pyruvate dehydrogenase complex (PDC) (Pilegaard 
and Neufer, 2004). This irreversible process plays a major role in energy metabolism, 
particularly in fast-twitch skeletal muscles, as it represents the only entry point for 
glucose derived from uptake or glycogen degradation into the mitochondria for oxidation 
and ATP synthesis. However, under certain conditions like fasting, diabetes and exercise, 
glucose availability becomes limited and the skeletal muscle is required to adapt via 
metabolic switch to fatty acids or amino acids for energy metabolism (Pilegaard and 
Neufer, 2004). The metabolic switch to alternative fuel substrates occurs with 
transcriptional induction of pyruvate dehydrogenase kinase 4 (PDK4) followed by 
phosphorylation of serine residues in PDC which inactivates the enzyme thereby limiting 
glucose oxidation. 
 
In Chapter 3, PDK4 was transcriptionally induced by 2-fold in fast-twitch muscles prior 
to the onset of cerivastatin-induced myopathy and this change has been shown to 
significantly reduce PDC activity (Table 3.7; Sidaway et al., 2010). Furthermore, PDK4 
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was transcriptionally induced by more than 10-fold in fast-twitch muscles from rats 
treated with simvastatin and this effect was accompanied by impaired glucose oxidation 
(Mallinson et al., 2009). Similar effects of PDK4 induction have also been demonstrated 
in skeletal muscles from mice treated with various statins (Motojima, 2002; Motojima 
and Seto, 2003). Together, these studies suggest statin therapy may impair normal 
glucose metabolism in fast-twitch muscles.  
 
Biochemical abnormalities reflecting deficiencies in fatty acid metabolism and impaired 
muscle energetics are also commonly observed in patients sensitive to statin-induced 
myopathy (Hubal et al., 2011; Phillips and Haas, 2008; Phillips et al., 2009). In the 
absence of normal glucose and fatty acid oxidation, fast-twitch muscles rely on amino 
acids from myofibrillar protein degradation for energy. Recent evidence in several 
species, including humans, has demonstrated that transcriptional induction of the muscle 
specific ubiquitin ligases atrogin-1 and MuRF-1 are causally related to statin-induced 
myopathy (Hanai et al., 2007; Mallinson et al., 2009). Transcriptional induction of these 
muscle specific ubiquitin ligases are considered hallmark changes associated with 
myofibrillar protein degradation, and abnormal activation of this process during impaired 
energy metabolism can lead to myopathy (Hanai et al., 2007; Mallinson et al., 2009; 
Motojima, 2002; Motojima and Seto, 2003). However, transcriptional profiling in 
Chapter 3 indicated that these genes were not transcriptionally induced. However, RT-
PCR results demonstrated that these genes were transcriptionally induced in the 
cerivastatin time course study described in Chapter 2.2 (study 2), but expression was 
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significantly lower after 14 days of dosing relative to 8 and 10 days, which may reflect 
severe myopathy (Table 8.2).  
 
In Chapter 3, PGC-1α was transcriptionally induced in the slow-twitch muscles following 
cerivastatin treatment, and this may represent an adaptive response in this fiber type as 
overexpression of this gene mediates the oxidative phenotype, prevents myofibrillar 
protein degradation and statin-induced myopathy (Table 3.15; Brault et al., 2010; Hanai 
et al., 2007; Lin et al., 2002). Specifically, physiological stress and altered energy 
metabolism cause transcriptional induction of PGC-1α which induces the estrogen 
receptor α (ERRα) and together they bind the PDK4 promoter and induce gene 
expression which increases mitochondrial biogenesis and represses the muscle specific 
ubiquitin ligases (Figure 6.1; Brault et al., 2010; Hanai et al., 2007; Zhang et al., 2006; 
Wende et al., 2005). Accordingly, these results suggest a specific transcriptional program 
related to impaired energy metabolism may occur in a fiber dependent manner following 
statin treatment. 
 
Together, these studies suggest fiber specific differences in energy metabolism may be 
important in the mechanism of statin-induced myopathy. Therefore, it was hypothesized 
that cerivastatin-induced myopathy is mediated by alterations in energy metabolism 
which occur in a fiber dependent manner. The major goal of this work was to determine 
whether PDK4 inhibition in fast-twitch skeletal muscles is causally related to 
cerivastatin-induced myopathy. An additional goal of this work was to determine the 
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temporal relationship between transcriptional induction of PDK4, PGC-1α and the 
muscle specific ubiqutin ligases with the development of cerivastatin-induced myopathy.  
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6.2. Methods  
Study design. This investigation was conducted on skeletal muscles obtained from study 
2 described in Chapter 2. Study 2: For this study, muscles representing slow-twitch 
(soleus) and fast-twitch (psoas) fiber composition (Table 2.1) were collected from the left 
side and fixed in 10% neutral buffered formalin for histopathological assessment whereas 
the same tissues on the right side were flash frozen and used for RNA isolation.  
 
Histopathology. Tissues were processed for histopathologic assessment as described in 
Chapter 2.2 (study 2).  
 
Gene expression analysis. Constitutive PGC-1α expression in fast- and slow-twitch 
muscles from naïve rats was determined based on microarray data as described in 
Chapter 3. 
 
Determination of transcriptional changes in cerivastatin treated rat fast-twitch FDB 
myofibers Female rat fast-twitch FDB myofibers were isolated and cultured as previously 
described in Chapter 2.2. To each well, 30 l of vehicle (maintenance medium) or 
cerivastatin (final concentration was 300 nM) was added to the myofibers. This 
concentration was selected because a toxic dose of cerivastatin in female rats is 
associated with a Cmax of 221 nM (Reinoso et al., 2002; Steinke et al., 1996). Therefore, 
for the current work a slightly higher concentration was selected for testing. Furthermore, 
3-4 days of cerivastatin (300 nM) treatment is associated with morphological changes 
characteristic of a stressed / dying cell and reduced viability (Figure 2.4). On days 1, 2, 3, 
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and 4 the media was gently removed with a pipette and the myofibers were washed twice 
with pre-warmed PBS (100 l). This incubation time was selected because 4 days of 
cerivastatin treatment was required to cause a significant reduction in viability as 
measured by ATP (Figure 2.4). This experiment was conducted in triplicate with 24 wells 
per treatment on three separate days. 
 
Determination of cerivastatin treated rat fast-twitch FDB myofiber viability with 
dichloroacetate. Female rat fast-twitch FDB myofibers were isolated and cultured as 
previously described in Chapter 2.2. To each well, 30 l of vehicle (maintenance 
medium), cerivastatin (final concentration was 300 nM), dichloroacetate (DCA; an 
inhibitor of PDK4; final concentration was 5 mM) or cerivastatin (300 nM) and 
dichloroacetate (5 mM) were added to the myofibers. This concentration of 
dichloroacetate was selected because the Ki for PDK4 is 0.5 mM (Bowker-Kinley et al., 
1998; Philp et al., 2010). On a daily basis, the media was removed and replenished with 
the treatments described above. After 4 days of treatment, viability (ATP) was 
determined. Myofibers were treated for 4 days because previous experiments indicated 
this treatment time caused a marked reduction in viability (Figure 2.4). This experiment 
was conducted in triplicate with 24 wells per treatment on three separate days.  
 
Myofiber RNA isolation. Total RNA isolation was conducted as described in Chapter 
5.2. 
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RNA isolation from skeletal muscles. Total RNA was isolated from flash-frozen skeletal 
muscle as described in Chapter 5.2.  
 
RT-PCR. RT-PCR experiments were conducted as described in Chapter 5.2. The forward 
and reverse primer sequences are given in Table 6.1.  
 
Data analysis. The mean mRNA fold change ± SE of PDK4, PGC-1α, atrogin-1 and 
MuRF1 was determined in fast- and slow-twitch muscles following cerivastatin treatment 
and in myofiber cultures representing three separate experiments. For the dichloroacetate 
experiment, the mean viability ± SE representing three separate experiments was 
determined. Group means were determined and compared with a Student‟s t-test or 
ANOVA using StatView (SAS Institute, Cary, NC) at p<0.05. However, statistics for the 
RT-PCR results were conducted on the values following normalization to 18S.  
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6.3. Results 
Cerivastatin (1 mg/kg) caused a time dependent, fast-twitch specific myofiber 
degeneration in female rats whereas no evidence of myopathy was observed in the slow-
twitch muscle (Figure 2.2; Table 2.3). These changes were first noted in 25% of the 
animals after 8 days of cerivastatin treatment and the incidence of myopathy increased to 
75% and 100% of the animals after 10 and 14 days, respectively (Table 2.3). The severity 
of cerivastatin-induced myotoxicity also increased with time from a minimal injury after 
8 days (Figure 2.2, panel B) to a severe myopathy after 14 days of cerivastatin treatment 
(Figure 2.2, panel D).  
 
In fast-twitch muscles, transcriptional induction of PDK4 was first observed prior to 
evidence of myopathy after 6 days of cerivastatin (1 mg/kg) treatment and continued to 
show a sustained increase throughout the time course (Table 6.2). Similarly, PGC-1α was 
transcriptionally induced after 6 and 8 days but was unchanged after 10 days and reduced 
after 14 days of cerivastatin treatment (Table 6.2). In contrast, transcriptional induction of 
atrogin-1 and MuRF1 was only observed from days 8 to 10 when myopathy was present 
(Table 6.2). However, transcriptional induction of 2-fold or greater was observed in all 
rats on days 8 and 10. These results are consistent with an early metabolic switch in the 
fast-twitch muscle followed by impaired energy metabolism and evidence of myofibrillar 
degradation.  
 
In the slow-twitch muscle, transcriptional induction of PDK4, atrogin-1 and MuRF1 were 
only observed after 14 days of cerivastatin treatment whereas PGC-1α was unchanged 
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across the time course (Table 6.3). To further probe skeletal muscle differences in PGC-
1α constitutive expression this gene was interrogated in the gene expression profiles 
(Chapter 3). The differential expression of PGC-1α was 4.4-times higher (p<0.0001) in 
the slow- compared to the fast-twitch muscle of naïve female rats. These results 
demonstrate that cerivastatin treatment results in a different metabolic response in the 
slow- compared to the fast-twitch muscle which may be related to transcriptional 
induction of PDK4 and the higher constitutive expression of PGC-1α resulting in an 
oxidative phenotype.  
 
To further examine the temporal relationship between these transcriptional changes, 
alterations in energy metabolism, and toxicity an in vitro culture of isolated FDB fast-
twitch myofibers was used. Following cerivastatin (300 nM) treatment, PDK4 was 
transcriptionally induced on all days indicating an early and sustained response consistent 
with a metabolic switch in energy metabolism (Table 6.4). In contrast, PGC-1α, atrogin-1 
and MuRF1 were only transcriptionally induced after 4 days, when viability was reduced 
(Table 6.4). For all transcripts evaluated, expression was unchanged across the time 
course in control myofibers. These data are generally consistent with the in vivo results 
indicating an early metabolic switch in the fast-twitch muscle followed by impaired 
energy metabolism and evidence of myofibrillar degradation.  
 
To test the hypothesis that impaired energy metabolism, mediated by PDK4 induction in 
the fast-twitch muscle was causally related to cerivastatin-induced myopathy FDB 
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myofibers were treated with dichloroacetate (PDK4 inhibitor) (Figure 6.2). However, 
dichloroacetate treatment did not prevent cerivastatin-induced toxicity (Figure 6.2).  
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6.4. Discussion 
Skeletal muscle is capable of rapidly adapting to different fuel substrates for energy 
metabolism in response to a variety of physiological conditions. To adapt to these ever 
changing energy demands muscle substrate utilization pathways are tightly controlled.  
Determining the gene expression changes and metabolic consequences associated with 
cerivastatin treatment is important in understanding the molecular pathogenesis of the 
myopathy in which substrate utilization for energy metabolism is impaired (Mallinson et 
al., 2009; Phillips and Haas, 2008).  
 
The current results demonstrate that cerivastatin triggers an early and sustained 
transcriptional induction of PDK4 in fast-twitch muscles which is consistent with a 
metabolic switch in energy metabolism to a more oxidative phenotype. However, 
inhibition of this metabolic switch by dichloroacetate was insufficient to protect the fast-
twitch muscle from cerivastatin-induced toxicity. Therefore, these results suggest that 
transcriptional induction of PDK4 may be necessary but insufficient to mediate 
cerivastatin-induced myopathy. Consistent with this observation, previous investigators 
have also demonstrated that statins transcriptionally induce PDK4 and reduce 
mitochondrial oxidative capacity resulting in impaired energy metabolism in fast-twitch 
muscles (Hubal et al., 2011; Mallinson et al., 2009; Motojima, 2002; Motojima and Seto, 
2003; Phillips and Haas, 2008; Phillips et al., 2009; Sidaway et al., 2010). Consistent 
with this hypothesis, transcriptional induction of PGC-1α expression was observed 
supporting a metabolic demand for a more oxidative phenotype. However, this metabolic 
adaptation was insufficient in protecting the muscle, as transcriptional markers of protein 
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degradation, indicative of impaired energy metabolism, were induced in association with 
myopathy.  
 
In contrast to the current work, it was recently demonstrated that DCA administered with 
simvastatin prevents myopathy in rats, thereby supporting a role for PDK4 in mediating 
toxicity (Sidaway et al., 2010). In that study, the authors demonstrated simvastatin (40 
mg/kg) caused a 2-fold transcriptional induction of PDK4 which was associated with a 
significant reduction in PDC activity, a 2-fold transcriptional induction of atrogin-1 and 
myopathy. All of these changes were prevented when simvastatin was administered with 
DCA (50 mg/kg/day). The fact that DCA did not protect against cerivastatin-induced 
myopathy in the current experiment may be related to the in vitro conditions. As noted in 
Chapter 5 the in vitro response did not recapitulate alterations in cholesterol homeostasis 
observed in vivo.  
 
There were several limitations of this work which make it difficult to completely interpret 
the results. Specifically, glycolytic and oxidative flux were not measured. Therefore, it is 
unknown whether there was a direct correlate between transcriptional changes and 
functional consequences in energy metabolism. This would have been particularly 
valuable for the dichloroacetate experiment by confirming that PDK4 was inhibited.  
 
Although slow-twitch muscles are generally considered insensitive to cerivastatin-
induced myopathy the current results suggest this fiber type simply shows a delayed 
response, as PDK4 and markers of protein degradation were transcriptionally induced 
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after 14 days of treatment (Obayashi et al., 2011; Westwood et al., 2005). However, 
unlike the fast-twitch muscle, PGC-1α was not transcriptionally induced in the slow-
twitch muscle following cerivastatin treatment. Instead, constitutive levels of PGC-1α 
were 4-times higher in the slow-twitch muscle which may offer protection against 
myofibrillar degradation in this fiber type (Brault et al., 2010). Furthermore, 14 days of 
cerivastatin (1 mg/kg) treatment led to a significant increase in metallothionein 1, 
indicating oxidative stress in addition to transcriptional evidence of altered energy 
metabolism along with a reduction in phosphocreatine (Tables 3.16 and 4.1). Together, 
these results suggest that additional cellular stress factors, which occur in a fiber 
dependent manner, may be important in mediating impaired energy metabolism 
associated with cerivastatin-induced myopathy. Alternatively, the effects in the slow-
twitch muscle may be related to physiological stress as these changes only occurred in 
animals with severe fast-twitch myopathy. 
 
Recent work by Bouitbir et al (2011), indicated significantly greater ROS formation in 
fast-twitch muscles along with reduced oxidative capacity, and collapse of PGC-1α 
expression compared to the heart following statin treatment. These authors also 
demonstrated attenuation of ROS formation with antioxidants and overexpression of 
PGC-1α which prevented statin-induced myopathy (Bouitbir et al., 2011). Accordingly, 
since the slow-twitch muscle phenotype is more similar to the heart in regard to energy 
metabolism than fast-twitch muscles, a similar mechanism involving less ROS formation 
and higher PGC-1α expression may delay oxidative stress, impaired energy metabolism 
and toxicity in this fiber type. In contrast to this hypothesis, cerivastatin also caused 
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cardiac toxicity suggesting these results may not fully explain the mechanism of fiber-
specific toxicity. However, the role of ROS in this mechanism was not pursued in the 
current work and it is unknown whether this is a cause or an effect. 
 
In summary, the current work demonstrates fundamental transcriptional differences in 
female rat fast- and slow-twitch muscles in response to cerivastatin treatment. In the fast-
twitch muscle, transcriptional changes were consistent with impaired energy metabolism 
as a mediator of myotoxicity whereas in the slow-twitch muscle alterations in energy 
metabolism were only observed after 14 days of cerivastatin treatment which did not 
result in myopathy. Furthermore, these results demonstrate that PDK4 inhibition in the 
fast-twitch muscle was insufficient to prevent cerivastatin-induced myotoxicity, thereby 
implicating additional factors in mediating toxicity. Alternatively, the lack of protection 
by DCA may be related to the in vitro culture conditions as rats treated with a toxic dose 
of simvastatin and DCA prevents myopathy (Sidaway et al., 2010). The current in vitro 
results, in addition to those presented in Chapter 6, indicate that this model does not 
always recapitulate the in vivo findings.  
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Figure 6.1. Proposed mechanism for the regulation of glucose metabolism involving 
PGC-1α / ERRα and PDK4 (Wende et al., 2005). Physiological stress increases energy 
demands causing induction of skeletal muscle PGC-1α, which in turn induces ERRα and 
together bind to the PDK4 promoter to activate gene expression. PDK4 activation results 
in a negative regulation of PDC and reduced glucose oxidation coincident with increased 
mitochondrial biogenesis and fatty acid oxidation mediated by PGC-1α in the slow-twitch 
muscle. 
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Figure 6.2. Dichloroacetate inhibition of PDK4 does not prevent cerivastatin-
induced toxicity in isolated FDB fast-twitch myofibers. FDB myofibers were isolated 
from female rats and treated with cerivastatin (ceriva; 300 nM), dichloroacetate (DCA; 5 
mM) or cerivastatin and dichloroacetate for 5 days and viability (ATP) was determined. 
Results represent the mean ± SE of three separate experiments. 
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a
Results represent the mean mRNA expression ± SE normalized to 18s and relative to 
control following cerivastatin (1 mg/kg) treatment. Results for all control rats (n = 20) 
were pooled together. 
NC = no change relative to control.  
b
Results represent the number of animals with skeletal myofiber necrosis and 
degeneration / number of animals per group. The mean severity score in () is based on an 
arbitrary score of 1 to 4 (most severe). (-) Denotes no significant findings observed.  
*Significantly different from control (p<0.05). 
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a
Results represent the mean mRNA expression ± SE normalized to 18s and relative to 
control following cerivastatin (1 mg/kg) treatment. Results for all control rats (n = 20) 
were pooled together. 
NC = no change relative to control.  
b
No adverse histological effects were observed in the soleus. (-) Denotes no significant 
findings observed. 
*Significantly different from control (p<0.05). 
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a
Results represent the mean mRNA expression ± SE normalized to 18s and relative to 
control following cerivastatin (300 nM) treatment for three separate experiments. 
NC = no change relative to control.  
*Significantly different from control (p<0.05). 
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Chapter 7 
 
 
Identification of 1- and 3-methylhistidine as biomarkers of 
skeletal muscle toxicity by nuclear magnetic resonance-based 
metabolic profiling (Anal. Biochem. 2011 Mar 1;410(1):84-91) 
 
This work was conducted in collaboration with Dr. Nelly Aranibar. Specifically, I was 
responsible for designing and conducting all in vivo portions of this work, whereas Dr. 
Nelly Aranibar conducted all NMR analysis, including identification of 1- and 3-MH. 
 
7.1. Introduction 
Drug-induced skeletal muscle injury is commonly associated with the use of a variety of 
medications including statins, fibrates and glucocorticoids (Singh et al., 2005). The 
potential severity of this adverse effect is illustrated by withdrawal of cerivastatin from 
the market after more than 100 rhabdomyolysis-related deaths were associated with this 
drug (Thompson et al., 2003). Early evaluation of myotoxic potential is important in drug 
development, and preclinically has relied mainly on serological biomarkers, such as 
creatine kinase (CK) and aspartate aminotransferase (AST). Unfortunately, the diagnostic 
utility of these analytes is limited by their lack of sensitivity and specificity, particularly 
in rats (Bohlmeyer et al., 1994; Sorichter et al., 1999). As a result, histopathologic 
assessments are most often used to confirm drug-induced myotoxicity. Consequently, the 
need for specific biomarkers of myopathy from peripheral biological fluids has been 
recognized, and several new potential serum biomarkers of drug-induced myotoxicity, 
including skeletal muscle troponin I (sTnI), myosin light chain 3 (Myl3) and fatty acid 
binding protein 3 (fabp3), have recently been reported (Berna et al., 2007; Pritt et al., 
2008; Tonomura et al., 2009; Vassallo et al., 2009).  
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Transcriptional profiling of skeletal muscles has been used to develop insight into the 
etiology of idiopathic or disease-related myopathies in humans and rats and has helped to 
identify gene expression profiles that suggest possible new biomarkers of myotoxicity 
(Casey et al., 2008; De Souza et al., 2006; Jagoe et al., 2002; Laaksonen et al., 2006; 
Morikawa et al., 2005; Yu et al., 2009). However, transcriptional profiling is not an ideal 
platform for routine monitoring of drug-induced myotoxicity in the preclinical setting.  
 
In direct contrast to global transcriptional profiling, metabolomic evaluation of biological 
fluids affords the opportunity to assess systemic metabolic changes that may be directly 
related to myotoxicity. Metabolomics has been widely used in the last decade to define 
tissue metabolic profiles, investigate mechanisms of toxicity and to identify biomarkers 
of pharmacologic or adverse effect, with nuclear magnetic resonance (NMR) and mass 
spectrometry representing the commonly used analytical platforms (Xu et al., 2011). 
However, there is presently very little information available on the global metabolic 
effects observed with drug-induced myopathy in laboratory animals. In Chapter 4, 
metabolomic profiling of fast-twitch muscles identified several metabolites which 
decreased in association with cerivastatin-induced myopathy. Therefore, it was 
hypothesized that metabolomic profiling of urine from that study would show an increase 
in skeletal muscle specific metabolites which may represent biomarkers of myopathy. 
 
In the present research, the urinary NMR metabolomic profile of cerivastatin-induced 
myopathy in rats was evaluated. Changes in relevant endogenous metabolites including 
creatine were noted. However, a predominant but unknown moiety was also detected that 
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directly correlated with the sex-, dose-, and time-dependent development of myopathy.  
The work described herein summarizes the analytical effort to identify these unknown 
analytical signals as 1- and 3-methylhistidine and to characterize their relevance to 
muscle biology and function with respect to their potential utility as biomarkers of 
muscle toxicity.  
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7.2. Methods 
Chemicals. Cerivastatin (Na salt) was purchased from Sequoia Research Products 
(Pangbourne, United Kingdom). Isoproterenol hydrochloride, anserine, 1-methylhistidine 
(1-MH), 3-methylhistidine (3-MH), and corn oil were purchased from the Sigma-Aldrich 
Company (St Louis, MO). Methylcellulose A15C premium was purchased from the Dow 
Chemical Company (West Point, PA); HPLC grade methanol from Mallinckrodt Baker 
(Phillipsburg NJ, USA); ammonium acetate and formic acid from Aldrich (Milwaukee, 
WI). TSP (trimethylsilyl-2,2,3,3-tetradeuteropropionic acid) was purchased from 
ISOTEC (Miamisburg, Ohio). 
 
Animals. Male (250-300 g) and female (175-225 g) Sprague-Dawley rats (8-9 weeks old; 
Charles River Laboratories, Portage, MI) were individually housed in temperature and 
humidity controlled rooms with a 12-h light/dark cycle. Animals were allowed free 
access to water and a standard lab diet (Harlan Teklad 2018C, Madison, WI) and were 
acclimated for one week prior to dosing. The conduct of all animal studies was approved 
by the Bristol-Myers Squibb Animal Care and Use Committee. 
 
Treatment and sample collection. The metabolomic investigation was conducted on 
urine samples obtained from a previously published study in which male and female rats 
were dosed orally with cerivastatin (0.5 and 1 mg/kg; 5 mL/kg) or methylcellulose 
vehicle (n = 6 - 9 animals / group / sex) for 14 days (Vassallo et al., 2009). Cerivastatin 
dosages were selected based on the literature indicating that 0.5 mg/kg was associated 
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with a minimal and variable myopathy whereas 1 mg/kg caused a mild to severe 
myotoxicity (Westwood et al., 2005).  
 
In a second study, female rats (n = 4 – 8 animals / group) were dosed orally with a 
myotoxic dose of cerivastatin (1 mg/kg) for 14 days. Only female rats were used for this 
study because the initial results indicated this sex was more sensitive to cerivastatin-
induced myotoxicity than male rats. Isoproterenol (0.5 mg/kg; 1 mL/kg) was 
administered (sc) as a single dose to male rats (n = 5 – 6 animals per group) as previously 
described (Vassallo et al., 2009). This dosing paradigm was selected because it was 
associated with mild to severe cardiac myopathy with no skeletal muscle toxicity. Only 
male rats were used for this study because previous research indicated that isoproterenol 
caused skeletal muscle hypertrophy in this sex (Agrawal et al., 2003) 
 
Urine was collected over 24 hours from cerivastatin-treated rats housed in metabolism 
cages immediately after dosing on days 7 and 14 or after dosing isoproterenol. Serum 
from cerivastatin-treated rats was collected as previously described after 14 doses of 
cerivastatin (Vassallo et al., 2009). Urine and serum samples were stored at -80 C 
pending analysis. 
 
NMR metabolomics. Rat urine samples were thawed on ice and 400 L aliquots were 
mixed with 200 L buffer: 0.2 M sodium phosphate, pH 7.2, containing 20% D2O for 
field-lock and 1 mM TSP (trimethylsilyl-2,2,3,3-tetradeuteropropionic acid) as an 
internal standard. Each sample was placed into a 5 mm NMR tube and data were acquired 
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on a 600 Avance III  Bruker NMR spectrometer (Bruker Analytic GmbH, Germany) 
equipped with a 5 mm TCI cryoprobe operating at 600.53 MHz for 
1
H. Samples were 
measured in batches of 20 at a probe temperature of 27 C using standard 1D proton 
parameters as follows:  256 transients following 8 dummy transients, 16 ppm spectral 
width, and a 90 pulse of 7.7 us. The water suppression was accomplished using the 
standard Bruker sequence „noesy1dpr‟, with irradiation during the 0.05 s mixing time and 
2 s relaxation delay. The size of the time domain data (free induction decay) was 32k 
points. The NMR spectra were Fourier transformed and phase and baseline corrected in a 
consistent manner. For principal component analysis (PCA) and region integration for 
metabolite quantification, AMIX software version 3.8 (Bruker Analytik) was used. For 
input, reduced NMR spectra were prepared by integrating 0.01 ppm wide regions from 10 
to -0.5 ppm, scaled to total intensity, excluding the water residual signal regions (4.7 to 5 
ppm) with a total of 525 regions considered for the analysis. Pareto scaling was used to 
calculate the three first principal components and loadings. For NMR-based metabolite 
quantitation, regions containing well isolated peaks were integrated across all relevant 
spectra, normalized to TSP and analyzed statistically (ANOVA, t-test and regression 
calculations) with Partek Pro (v. 6.0 Partek Inc. Missouri, USA).   
 
Evaluation of unknown urinary metabolites. To aid in the identification of unknown 
metabolites, preparative HPLC followed by NMR analyses was used to isolate individual 
urine fractions for more detailed analytical evaluation. Briefly, the preparative HPLC 
system (Varian Prostar, Palo Alto, CA, USA) was equipped with two solvent delivery 
modules, a UV-Vis detector, an autosampler, and fraction collector. Urinary metabolites 
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were separated on a Luna NH2 (Phenomenex, Torrance, CA, USA) column (100 mm  
21.2 mm I.D, 5 m) and eluted with a gradient of A: 20 mM NH4Ac and B: 100% 
methanol. Chromatographic preparative separation was made at a flow rate of 22 mL/min 
at ambient temperature. The elution solvent gradient started with 5% A/ 95% B, changing 
to 90% B/10% A in 15 minutes and held at this composition for 5 minutes. The column 
was then washed with 100% methanol with 0.02% formic acid for 2 minutes, followed by 
2 minutes washing with HPLC-grade water containing 0.02% formic acid. Urine from 
two female rats showing the greatest intensities of the unknown NMR signals were 
pooled and concentrated for HPLC analysis. After sample injection, fractions were 
collected at 0.5 minute fractions over the course of the gradient, and two additional 
fractions were collected during the wash period. 
 
After collection, all the chromatographic fractions were dried under nitrogen. To 
facilitate removal of any residual mobile phase, samples were rinsed and dried again 
overnight under nitrogen. After the last drying procedure, 250 L of 0.2 N phosphate 
buffer in D2O: H2O (20:80) with 1mM TSP and 500 L DI water were added to each 
sample. Reconstituted samples were mixed thoroughly and subjected to centrifugation at 
8000 rpm for 10 min to remove any particulates. Aliquots (600 L) were used for NMR 
spectroscopy in 5 mm tubes with the same pulse sequence and parameters as described 
above. Selected fractions containing the peaks of interest were analyzed by 2D proton-
carbon NMR, including one-bond and multiple-bond experiments.  The one bond 
(HMQC) experiments were recorded using a pulse sequence for proton-carbon 
correlation via heteronuclear zero and double quantum coherence with decoupling during 
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acquisition, using gradient pulses for selection (called „hmqcgpqf‟ in the Bruker pulse 
library) with 64 dummy transients, 112 transients, 400 T1 increments and 1k points in F2.  
The sweep width was 12 ppm for proton and 220 ppm for carbon. The 90 degree pulse 
for proton was 7.7 us and for carbon was 15.4 us. A 1.5 sec relaxation delay was used 
between scans. Decoupling was performed utilizing a GARP sequence, and a sine shape 
was used for the gradient selection. The evolution time was optimized for a one bond C-
H scalar coupling of 145 Hz. Multiple bond proton-carbon (HMBC) experiments were 
acquired with a pulse sequence for proton-carbon multiple bond correlation via 
heteronuclear zero and double quantum coherence, optimized on long range couplings 
with low-pass J-filter to suppress one-bond correlations, no decoupling during 
acquisition, using gradient pulses for selection ( identified as „hmbcgplpndqf‟ in the 
Bruker pulse library), with 64 dummy transients, 128 transients, 400 increments in T1 
and 4k points in F2.  The sweep width was 12 ppm for proton and 240 ppm for carbon. 
Pulses and delays used as for HMQC, except that the evolution time was optimized for a 
multiple C-H bond coupling of 10 Hz. 
 
Constitutive tissue concentrations of 1- and 3-methylhistidine in rats  The distribution 
and concentration of 1- and 3-MH were determined in select muscles and all other major 
organs from male and female Sprague Dawley rats (n=3). Tissues analyzed included 
skeletal muscles representing fast-twitch muscles (quadriceps, psoas, and gastrocnemius), 
slow-twitch muscles (soleus) and mixed muscle fibers (diaphragm), along with heart, 
stomach, duodenum, jejunum, ileum, colon, spleen and lung, kidney, liver, testes, 
ovaries, brain and serum (Ariano et al., 1973; Hamalainen and Pette, 1993; Koerker et al., 
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1990; Kumagai et al., 2001). Rats were anesthetized with isoflurane and exsanguinated, 
after which all tissues were flash-frozen and stored at -80 C pending analysis. The 
concentration of 1- and 3-MH was determined in each tissue by GC-MS. Briefly, the 
internal standards (20 nmol) 1-[methyl-
2
H3]methylhistidine (d3-1MH) (MSD Isotopes, 
Montreal, Canada) and 3-methyl-[methyl-
2
H3]-histidine (d3-3MH) (MassTrace, Woburn, 
MA), and 4 mL of 6 N HCl were added to approximately 50 mg of tissue. The tissue was 
homogenized with a Tissue Tearor™ (BioSpec Products, Inc.) and then hydrolyzed to 
free the methylhistidines from the acetylated form, by heating at 100° C for 20h. The 
resultant methylhistidine isomers in tissue hydrolysates were absorbed on a cation 
exchange column (Dowex-50W in the hydrogen form Sigma Chemical, St. Louis, MO), 
after which the column was washed with 0.01 N HCl (4x1mL) and deionized water 
(2x1ml). The methylhistidine isomers were eluted with 25% NH4OH and dried at 65°C 
under nitrogen. The samples were derivatized with acetonitrile and N-methyl-N-(t-
butyldimethylsilyl)-trifluoroacetamide (MTBSTFA, Regis Technologies, Inc., Morton 
Grove, IL) and analyzed by GC-MS (Rathmacher et al. 1992). Both 1- and 3-MH were 
quantified based on the isotope ratios of the unknowns compared to the internal standard 
curves. 
 
Urine and serum 1- and 3-MH were analyzed by a similar method. Urine and serum 
samples (75 µL) and 20 nmol of the internal standards were hydrolyzed in 100 µL 6 N 
HCl with heat (110 °C) for 15 h. Urine hydrolysates were subjected to cation exchange, 
derivatized and analyzed by GC-MS as described above. 
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Statistics. Urine from vehicle-treated male (n=15) and female (n=17) rats, representing 
samples collected across the cerivastatin and isoproterenol studies described herein, were 
used for determining the population mean concentration of 1- and 3-MH. The mean urine 
concentrations of 1- and 3-MH in treated rats were compared to respective experimental 
controls with a Student‟s t-test (p < 0.05).  
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7.3. Results 
Metabolomics. PCA scores plot of the reduced NMR spectra indicated that urine from 
female rats treated with cerivastatin (1 mg/kg) separated from control, low dose (0.5 
mg/kg) females and high dose (1 mg/kg) males after 14 (but not 7) days of dosing (results 
not shown). When the loadings were investigated, resonances contributing to the 
separation included the citrate and 2-oxoglutarate regions along with resonances 3.05 and 
3.95 ppm, which correspond to creatine. In addition, two unknown singlets at 3.83 (U1) 
and 2.01 ppm (U2) showed high discriminating power between the treatment and control 
groups (Figure 7.1A). The mean values and distributions of selected metabolites, 
including the two unknown peaks are shown in Figure 7.1B. The most notable changes 
were increased excretion of creatine, U1 and U2 in rats with myopathy.  
 
To identify the origin of the unknown resonances, 4 mL of urine from two female 
animals which showed the greatest intensities of the unknown NMR signals were pooled, 
concentrated 2-fold and chromatographically separated into fractions by preparative 
HPLC. Proton NMR revealed that the singlets of interest (2.01 and 3.83 ppm) appeared in 
four fractions (20 through 23). The 
1
H NMR spectra from two of these critical fractions, 
shown in Figure 7.2, showed significant enrichment of two similar molecules which carry 
the 2.01 ppm resonance. Key features in both spectra include an AMX-type spin system 
with multiplets at 4.49 or 4.45 ppm, 3.25 or 3.17 and 3.06 or 3.01 ppm, singlets at 3.83 or 
3.81 and 2.01 or 1.99 ppm for fractions 20 and 23, respectively. The singlets at low field 
are consistent with N-methyl groups whereas the singlets at high field are consistent with 
acetyl groups. Finally, there were two pairs of singlets in the aromatic region (7.19 or 
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7.13 ppm and 8.47 or 8.28 ppm) consistent with an imidazole moiety in fractions 20 and 
23, respectively. Based on the relative signal intensities between fractions 20 and 23, 
there was at least an order of magnitude more material in fraction 20. These fractions 
were pure enough to conduct rigorous multi-dimensional NMR assessment without 
further purification. The single and multiple bond proton-carbon correlations allowed 
confident assignment of the unknown resonances to N-acetylated 1- and N-acetylated 3-
methylhistidine for fractions 20 and 23, respectively. The HMBC spectrum for the N-
acetyl-1-methylhistidine is shown in Figure 7.3, along with key correlations indicated. 
 
The nomenclature of the positional isomers of methylhistidine in the literature has been 
inconsistent. To clarify the names associated with each of these molecules, the structures 
for the two isomers are shown in Figure 7.4. 1-Methylhistidine is also known as N -
methylhistidine, N- -methylhistidine, or pros-methylhistidine, and 3-methylhistidine has 
been identified as N methylhistidine or N- methylhistidine. The IUPAC names for 
these compounds are as follows: 1-MH is 2-amino-3-(1-methyl-1H-imidazol-5-yl) 
propanoic acid and 3-MH is 2-amino-3-(1-methyl-1H-imidazol-4-yl) propanoic acid. 1-
MH is a known component of anserine, a cytosolic dipeptide found in muscle of many 
species including the rat (Abe, 2000; Aldini et al., 2004, Crusch, 1970; Christman 1976; 
Tamaki et al., 1980) whereas 3-MH is a known post-translational modification of one 
histidine residue in actin of skeletal and smooth muscle and one residue in fast-twitch 
myosin of skeletal muscle (Johnson et al. 1967; Young and Munro, 1978).  
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In light of the relevance of the methylhistidines to skeletal muscle, the distribution and 
concentration of 1- and 3-MH in 18 tissues from female and male rats was determined. 
(Figure 7.5; Table 7.1). In the five skeletal muscles evaluated, the concentration of 1-MH 
was higher than 3-MH, and there were no sex differences observed for either 
methylhistidine isomer (Table 7.1). Across evaluated muscles, 1-MH was highest in the 
quadriceps with a concentration of approximately 7 μmol/g (or about 7 mM), whereas the 
concentration of 3-MH was about 1 mM across the 5 muscles evaluated (Figure 7.5A; 
Table 7.1). In the heart, both isomers were lower than in skeletal muscles with 3-MH 
somewhat higher than 1-MH. (Figure 7.5B; Table 7.1). In smooth muscle-containing 
tissues (stomach, duodenum, jejunum, ileum, colon, spleen and lung) 3-MH was more 
abundant than 1-MH, and both isomers were lower than skeletal muscle (Figure 7.5B; 
Table 7.1). Other organs (liver, ovaries, testes and brain) had low levels of 
methylhistidine isomers compared to skeletal muscles, with higher levels of 1-MH 
compared to 3-MH. No sex differences were observed for either methylhistidine isomer 
(Figure 7.5B; Table 7.1). Together, these data suggest that 1- and 3-MH are highly 
abundant in skeletal muscle relative to other tissues. The high concentration of 1-MH in 
skeletal muscles suggests that its excretion in urine may be diagnostic for skeletal muscle 
damage.  In contrast, excretion of 3-MH might reflect damage to skeletal, cardiac or 
smooth muscle, or a combination of these.  
 
In vehicle-treated rats, GC-MS determined urine 1-MH was  451  29 and 583  39 
nmol/mg creatinine, in males and females, respectively, while 3-MH was  253  13 and 
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257  12 nmol/mg creatinine, respectively (Tables 7.2 and 7.3). There did not appear to 
be any vehicle-related effects on 1- or 3-MH levels in urine. 
 
The absolute change in urinary concentrations of 1- and 3-MH following cerivastatin 
treatment was determined (Table 7.4). At 0.5 mg/kg, a dose that caused only minimal 
myotoxicity (Vassallo et al. 2009), 1-MH excretion was variable and not significantly 
increased in female rats and 3-MH was unchanged. In contrast, 1- and 3-MH increased by 
6- and 2-fold, respectively in female rats dosed at 1 mg/kg and showing a mild to severe 
myotoxicity (Table 2.1). In cerivastatin-treated male rats, urinary excretion of 1- and 3-
MH was unchanged consistent with the absence of histologic evidence of myopathy 
(Table 2.1).   
 
In serum, 1-MH was readily detected with concentrations of 6 and 16 M in female and 
male, rats respectively. Additionally, 3-MH was detected in serum with concentrations of 
2 and 3 M in female and male rats, respectively. For both methylhistidine isomers, the 
serum concentration was higher in male rats. Following a myotoxic dose of cerivastatin 
(1 mg/kg), serum levels of 1- and 3-MH increased significantly by 12- and 3-fold, 
respectively (Table 7.4). Similar to the urine data, serum levels of 1- and 3-MH were 
unchanged in cerivastatin-treated male rats. 
  
Urinary excretion of 1- and 3-MH was also evaluated in male rats dosed with 
isoproterenol (0.5 mg/kg), a dosing regimen known to cause frank cardiac necrosis (Ng et 
al. 2002). No increase in urinary levels of 1- and 3-MH was observed in isoproterenol-
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treated rats, suggesting specificity of these metabolites for skeletal muscle toxicity. 
Surprisingly however, isoproterenol decreased the excretion of 1- and 3-MH by 2-fold 
compared to vehicle-treated rats (Table 7.5). 
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7.4. Discussion 
The evaluation of skeletal muscle toxicity has long relied on serum markers such as AST 
and CK. Although CK is a useful diagnostic tool for assessing muscle toxicity in humans, 
its utility in preclinical species has been limited by its marked variability, and other 
preclinical markers like AST suffer from a lack of muscle specificity (Bohlmeyer et al., 
1994). With these limitations, there has been considerable effort invested over the past 
several years to identify more specific and sensitive biomarkers of skeletal muscle 
toxicity particularly in preclinical species. These efforts have focused primarily on 
proteins that are highly expressed in or unique to skeletal muscles such as sTnI, Myl3, 
fabp3 and myoglobin (Berna et al., 2007; Pritt et al., 2008; Tonomura et al., 2009; 
Vassallo et al., 2009). In contrast, minimal effort has been invested in pursuing 
endogenous small molecules or metabolites as potential markers of myotoxicity. Urinary 
excretion of creatine has been associated with a variety of myopathies and this metabolite 
was also observed to increase with cerivastatin-induced myotoxicity (Bohlmeyer et al., 
1994; Chung et al., 2003, 2005; Draper et al., 1994). However, creatine excretion is also 
known to increase with testicular damage and hepatotoxicity indicating that it may not be 
a specific biomarker of skeletal muscle damage despite the fact that it is highly abundant 
in this tissue (Clayton et al., 2004; Draper and Timbrell, 1996).  
 
In the present work, the urinary excretion of two metabolites, 1- and 3-MH were 
identified in female rats following the development of cerivastatin-induced myotoxicity. 
Moreover, this observation was extended to serum, indicating that either biological 
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matrix may be useful for monitoring changes in these biomarkers in association with 
drug-induced myotoxicity.  
 
Although this is the first report showing increased excretion of 1- and 3-MH in response 
to a muscle toxicant such as cerivastatin, these metabolites have been used for studying 
muscle protein turnover for more than 30 years Young et al. 1973, Elia et al. 1981). 1-
MH is a component of anserine (β-alanyl-1-MH), which is found in the cytoplasm of 
skeletal muscles in millimolar concentrations (Abe, 2000; Aldini et al., 2004; Christman, 
1976; Penafiel et al. 2004). Anserine can be synthesized either from β-alanine and 1-MH 
(Tamaki, 1980) or from the N-methylation of carnosine (β-alanyl-histidine) (McManus, 
1967). Either biosynthetic pathway occurs primarily in skeletal muscle but not in other 
organs including the liver (Bauer and Schulz, 1994). The present data show that in rats, 1-
MH is highly abundant in skeletal muscles, regardless of sex or fiber type, with 
substantially lower concentrations detected in cardiac muscle or in organs that have 
abundant smooth muscle (i.e. gastrointestinal tract). Constitutive levels of 1-MH ranged 
from 1 – 7 mol/g tissue in the skeletal muscles evaluated, results that are consistent with 
reported variability in anserine levels (Aldini et al., 2004; Christman, 1976; Penafiel et 
al., 2004).   
 
Anserine is stored in muscle cells and is hydrolyzed into its amino acid components, 1-
MH and -alanine, under the action of carnosinase. -alanine can be reused to synthesize 
anserine or other metabolites including dipeptides or molecules such as pantothenate (and 
subsequently Coenzyme A) and quinolinate. As such, -alanine would not be expected to 
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be a useful marker of skeletal muscle toxicity and in fact did not increase with 
cerivastatin-induced myotoxicity (results not shown). In contrast, the current data indicate 
that 1-MH excretion and serum levels increase with cerivastatin-induced skeletal muscle 
necrosis and thus may represent a potentially useful marker of toxicity.  
 
3-MH is a post-translational modification of myofibrillar actin and fast-twitch myosin in 
all species. Conditions that cause skeletal muscle atrophy result in degradation of these 
proteins and increased urinary excretion (Haverberg et al., 1975; Young and Munro, 
1978; Lowell et al., 1986, Segaud et al., 2007). In the present work, constitutive 
concentrations of 3-MH were lower than 1-MH in skeletal muscles, whereas 3-MH was 
typically higher than 1-MH in cardiac and smooth muscle. 1-MH increased to a much 
greater extent than 3-MH following cerivastatin treatment, a result that is consistent with 
the relative levels of these metabolites in skeletal muscles. 
 
The marked increase in excretion and serum levels of 1- and 3-MH in response to 
cerivastatin, coupled with their recognized relevance to skeletal muscle biology, suggests 
that these metabolites may be useful biomarkers of skeletal muscle toxicity. An important 
attribute of a useful biomarker for skeletal muscle toxicity is its ability to distinguish 
between cardiac and skeletal myofiber damage. Accordingly, excretion of 1- and 3-MH 
was evaluated in an acute model of cardiac necrosis with isoproterenol. If skeletal muscle 
specific, excretion of 1- and 3-MH should remain unchanged by isoproterenol treatment. 
Unexpectedly, a significant decrease in excretion of both 1- and 3-MH was observed in 
this model, despite evidence of marked cardiac necrosis. However, β-adrenergic agonists 
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are known to have a direct anabolic effect on skeletal muscle, and the action of building 
muscle will reduce urinary excretion of these metabolites. In support of this concept, 
there is evidence that clenbuterol (β2-adrenergic agonist) decreases 3-MH excretion in 
rats (Waterfield et al., 1995). These results suggest that serum or urine levels of 1- and 3-
MH may be useful markers for skeletal muscle necrosis and anabolic effects, thereby 
providing information on the totality of skeletal muscle protein turnover in rats.  
 
This is the first report showing an increase in urinary excretion and serum levels of 1- and 
3-MH in association with drug-induced skeletal muscle injury. As such, additional work 
will be required to extend analysis of these metabolites in response to other skeletal 
muscle toxicants, additional models of cardiac toxicity, particularly models devoid of 
skeletal muscle hypertrophy, and other general models of hepatic or renal toxicity. 
Furthermore, there is a need to consider the utility of these biomarkers across species. In 
this regard, anserine, which contains 1-MH, is most likely not present in human skeletal 
muscles (Abe, 2000; Christman, 1976), however basal urinary excretion of 1-MH in 
humans has been observed even in the absence of dietary meat intake (Sjolin et al., 1987). 
1-MH has the most potential utility in preclinical species such as rodents, dogs and non-
human primates (Abe, 2000, Christman, 1976, Harris et al., 1990; Penafiel et al.,, 2004). 
In contrast, 3-MH is highly conserved, and although its basal levels can be altered by 
diet, age or disease, it should translate across species such as rodents, dogs and non-
human primates (Asatoor and Armstrong, 1967; Johnson et al., 1967), under pre-clinical 
experimental conditions, in which diet and other conditions are highly controlled. In 
humans, its utility as a biomarker of drug-induced muscle toxicity would be restricted to 
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controlled diet and exercise, as well as in the absence of any other physiological or 
pathological conditions which would affect skeletal muscle. 
 
The present study has focused on the identification of 1- and 3-MH in rat urine and their 
potential significance in preclinical evaluation of myopathy, however the work also 
highlights the impact of urinary metabolomic profiling in toxicology. Although not as 
sensitive as liquid or gas chromatographic methods, the MH isomers were originally 
detected as unique, unknown moieties from NMR-based profiling. Several other 
endogenous metabolites, including intermediates in the Krebs cycle and creatine were 
also observed to change with cerivastatin-induced skeletal muscle injury. However, 
untargeted NMR profiling provided a rapid and reproducible method wherein global 
metabolite changes were noted, and in light of the extent of changes noted, the method 
enabled the targeted identification of these metabolites. Many research efforts have 
focused on applying NMR metabolomic profiling to assessing mechanisms of toxicity or 
developing signatures of metabolites that are associated with specific organ toxicity or 
adaptive responses (Griffin, 2003). In addition to these approaches, the present work 
provides a novel example in which metabolomic profiling can be directly applied to 
biomarker discovery. 
 
In summary, the present work illustrates the ability of untargeted metabolomics analysis 
to identify relevant biomarkers and describes the utility of 1- and 3-MH as putative 
biomarkers of drug-induced skeletal muscle necrosis and hypertrophy in the rat. 
Quantitative measurements of both methylated species are straightforward and can be 
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evaluated in a single sample by GC-MS. Evaluation of these metabolites in urine 
provides for non-invasive and repeated collection such that the onset, progress, and 
potential recovery of  skeletal muscle toxicity can be followed. Further investigation into 
the use and limitations of these metabolites as markers of muscle necrosis, hypertrophy 
and atrophy is warranted. However, given that 3-MH translates across species additional 
experiments will be conducted in Chapter 8 to further determine the utility of this 
biomarker for assessing preclinical drug-induced myopathy.   
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Figure 7.1.  Metabolic profiles of urine 
1
H NMR spectra. A. Representative spectra of 
urine from control (bottom trace) and cerivastatin (1 mg/kg/day; top trace) treated female 
rats, showing some of the major metabolic changes:  creatine (3.05, 3.93 ppm), citrate 
(2.55, 2.71 ppm), 2-oxoglutarate (2.45, 2.47 ppm), succinate (2.41 ppm), U1 = unknown 
peak at 3.82 ppm, U2 = unknown peak at 2.01 ppm. B: Mean peak areas with standard 
errors for selected metabolites in urine from control and cerivastatin (1 mg/kg) treated 
female rats. The y-axis is relative NMR peak intensity normalized to creatinine. 
  
A
B
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Figure 7.2.  
1
H NMR spectra of unknown metabolites. 600 MHz 
1
H NMR spectra of 
HPLC fractions 20 (bottom trace) and 23 (top trace, with vertical scale increased 32-fold 
relative to bottom trace) showing two well resolved sets of signals of different but 
structurally similar molecules, including the diagnostic singlets at 3.83 or 3.81 and 2.01 
or 1.99 ppm for fractions 20 and 23, respectively. 
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Figure 7.3. 2D NMR spectrum of N-acetyl-1-methylhistidine. Proton-carbon cross 
correlations observed in the HMBC 2D NMR spectrum of fraction 20.  Inset: key 
correlations that identified the compound as N-acetylated 1-methylhistidine.  Selected 
cross peaks crucial to the structural assignment are indicated. 
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Figure 7.4. Structures of 1- and 3-methylhistidine. The structures of 1- and 3-
methylhistidine were identified as the unknown metabolites from cerivastatin-treated rats. 
 
 
 
  
H2N CH C
CH2
OH
O
N
N
H3C
H2N CH C
CH2
OH
O
N
N
CH3
1-Methylhistidine 3-Methylhistidine 
257 
 
 
Figure 7.5. Tissue distribution and concentration of 1- and 3-methylhistidine in 
female rats.  The concentration of the methylhistidine isomers was determined by GC-
MS in A) five skeletal muscles, representing predominately fast- (quadriceps, psoas, 
gastrocnemius), slow- (soleus) and mixed- (diaphragm) twitch fibers. In panel B, the 
gastrocnemius muscle is presented for direct comparison to other tissues.  
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Table 7.1. Tissue distribution and concentration of 1- and 3-methylhistidine in male 
and female rats. 
 
 
  
1-Methylhistidine 
(µmol / g tissue)
SE
3-Methylhistidine 
(µmol / g tissue)
SE
Quadriceps Male 5.416 1.198 0.611 0.034
Quadriceps Female 6.892 0.822 0.701 0.046
Psoas Male 1.626 0.228 0.415 0.027
Psoas Female 1.611 0.399 0.474 0.026
Gastrocnemius Male 1.503 0.238 0.526 0.019
Gastrocnemius Female 1.609 0.161 0.544 0.017
Diaphram Male 0.787 0.212 0.488 0.037
Diaphram female 0.860 0.139 0.537 0.030
Soleus Male 1.344 0.124 0.539 0.031
Soleus Female 1.296 0.362 0.493 0.041
Heart Male 0.182 0.005 0.281 0.016
Heart female 0.211 0.023 0.345 0.045
Stomach Male 0.026 0.007 0.200 0.048
Stomach Female 0.072 0.019 0.209 0.036
Duodenum male 0.031 0.004 0.184 0.003
Duodenum female 0.048 0.030 0.207 0.033
Jejunum male 0.054 0.005 0.184 0.004
Jejunum female 0.060 0.007 0.190 0.010
Ileum male 0.067 0.014 0.232 0.012
Ileum female 0.044 0.002 0.195 0.016
Colon male 0.078 0.015 0.293 0.017
Colon female 0.059 0.009 0.306 0.049
Spleen Male 0.131 0.022 0.215 0.008
Spleen Female 0.134 0.028 0.248 0.016
Lung Male 0.128 0.014 0.154 0.005
Lung Female 0.116 0.023 0.137 0.007
Kidney Male 0.062 0.025 0.105 0.008
Kidney Female 0.060 0.014 0.092 0.009
Liver Male 0.196 0.040 0.067 0.005
Liver Female 0.245 0.016 0.062 0.010
Testes 0.230 0.024 0.050 0.002
Ovaries 0.276 0.037 0.052 0.005
Brain Male 0.100 0.024 0.038 0.006
Brain Female 0.094 0.018 0.050 0.007
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Table 7.2. 1- and 3-Methylhistidine urine concentrations in vehicle-treated male rats
a
 
 
Animal # Vehicle 
1-MH 
(nmol/mg creatinine) 
3-MH 
(nmol/mg creatinine) 
1 0.5% Methylcellulose
b
 438 268 
2 (Cerivastatin vehicle) 582 228 
3  412 232 
4  510 275 
5  430 222 
6  340 154 
7 Saline
c
 502 349 
8 (Isoproterenol vehicle) 337 257 
9  384 279 
10  445 333 
11  418 301 
12 Saline
c
 340 235 
13  672 242 
14  652 248 
15  305 173 
    
Mean concentration  SE  451  29 253  13 
a
The concentration of 1- and 3-MH in male rat urine collected for 24 hrs was determined 
across 3 studies. 
b
Rats were given 14 doses of 0.5 methylcellulose. 
c
Rats were given a single dose of saline.  
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Table 7.3. 1- and 3-methylhistidine urine concentrations in vehicle-treated female rats
a 
 
Animal # Vehicle 
1-MH 
(nmol/mg creatinine) 
3-MH 
(nmol/mg creatinine) 
1 0.5% Methylcelluloseb 504 321 
2 (Cerivastatin vehicle) 459 278 
3  456 262 
4  306 136 
5  535 257 
6  701 284 
7 Salinec 742 283 
8 (Isoproterenol vehicle) 672 286 
9  492 251 
10  430 162 
11  714 323 
12 Salinec 804 306 
13  808 272 
14  658 253 
15  752 261 
16  545 238 
17  334 202 
    
Mean concentration  SE  583  39 257  12 
a
The concentration of 1- and 3-MH in female rat urine collected for 24 hrs was 
determined across 3 studies.  
b
Rats were given 14 doses of 0.5% methylcellulose.  
c
Rats were given a single dose of saline. 
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Table 7.4. 1- and 3-Methylhistidine in urine and serum from cerivastatin treated 
female and male rats
a 
 
 1-Methylhistidine 3-Methylhistidine 
Treatment 
(mg/kg) 
Urine 
(nmol/mg creatinine) 
Serum 
( M) 
Urine 
(nmol/mg creatinine) 
Serum 
( M) 
Females 
Control 494  52 6.0  0.9 256  26 1.9  0.2 
     
0.5 829  199 nd 278  23 nd 
     
1.0 3142  966* 69.7  22.8* 512  98* 5.5  0.9* 
     
Males 
Control 452  34 15.8  2.1** 230  18 3.0  0.2** 
     
0.5 446  18 nd 230  8.5 nd 
     
1.0 381  45 14.0  0.8 252  36 2.8  0.1 
a
Results represent the mean and SE of 4 - 9 rats dosed daily with 
cerivastatin or vehicle for 14 consecutive days.  
(nd) not determined. 
*
Significantly different from control (p < 0.05). 
**Significantly different from female control (p < 0.05).
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Table 7.5. 1- and 3-Methylhistidine in urine from isoproterenol 
treated male rats
a
 
 
Treatment 
(mg/kg) 
1-MH 
(nmol/mg creatinine) 
3-MH 
(nmol/mg creatinine) 
Control 417  28 304  17 
   
0.5 170  28* 153  21* 
a
Results represent the mean and SE of 5 - 6 rats given a single dose of 
isoproterenol. 
*
Significantly different from control (p < 0.05). 
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Chapter 8 
 
 
Utility of 3-methylhistidine as a preclinical biomarker of drug-
induced myopathy 
 
 
8.1. Introduction 
Preclinical skeletal muscle injury is routinely evaluated by histopathology because 
commonly used serological proteins, including CK and AST lack sensitivity and 
specificity (Bohlmer et al., 2004; Loeb, 1999). Although histopathology is a definitive 
indicator of myopathy, it is invasive, labor intensive, and it is not feasible to assess all 
muscles from a rat. Thus, there is a significant need for more reliable preclinical 
biomarkers of skeletal muscle toxicity. This need is further underscored by the increased 
incidence of skeletal muscle injury in the preclinical evaluation of new therapeutic targets 
and the fact that drug-induced skeletal muscle toxicity is a serious clinical liability 
highlighted by cerivastatin, which was withdrawn from the market after it was associated 
with more than 100 rhabdomyolysis-related deaths (Thompson et al., 2003). 
 
NMR metabolomic profiling of urine from cerivastatin treated rats indicated that 3-
methylhistidine (3-MH), an endogenous metabolite originating from skeletal muscle, 
increased with the severity of myopathy in the rat (Chapter 7; Aranibar et al., 2011). 
Methylation of histidine at the 3-position represents a post-translational modification of 
actin and myosin heavy chain which is most abundant in skeletal muscle (Aranibar et al., 
2011; Johnson et al., 1967, 1970; Tomas et al., 1979; Young et al., 1972; Young and 
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Munro, 1978). When skeletal myofibrillar proteins are degraded under various catabolic 
conditions, 3-MH is not reutilized for protein synthesis but rather is excreted in a manner 
that is directly related to the rate of degradation (Young and Munro, 1978). Over the last 
30 years, urinary 3-MH normalized to creatinine (3-MH/creatinine), and representing the 
fractional excretion relative to muscle mass, has been used for the preclinical and clinical 
evaluation of myofibrillar protein degradation in various catabolic (atrophy) and anabolic 
(hypertrophy) skeletal muscle conditions (Agrawal et al., 2003; Asatoor and Armstrong, 
1967; Johnson et al., 1967, 1970; Kuhl et al., 1998; Li and Wasner, 1981; Long et al., 
1975; Young et al., 1972; Young and Munro, 1978). Accordingly, the observation that 3-
MH levels in urine and serum increase with cerivastatin-induced myopathy may further 
extend the utility of this metabolite as a potential biomarker of drug-induced skeletal 
muscle toxicity.  
 
There are several mechanisms which contribute to intracellular protein degradation, 
however the ubiquitin-proteasome pathway (UPP) is responsible for 80-90% of 
myofibrillar protein degradation which occurs in response to various catabolic conditions 
like fasting, sarcopenia, cachexia, denervation, and drugs like glucocorticoids, 
chloroquine and statins (Chapter 1.7.3., Buettner and Lecker, 2008; Goll et al., 2008; 
Kimura et al., 2009; Lecker et al., 2004; Mallinson et al., 2009; Mitch and Goldberg, 
1996; Murton et al., 2008; Solomon and Goldberg, 1996). In these conditions, there is a 
common and coordinated transcriptional and biochemical adaptation which mediates 
rapid catabolism of  myofibrillar proteins through the UPP (Cohen et al., 2009; Fielitz et 
al., 2007; Lecker et al., 2004). Within the UPP, there are two skeletal muscle specific 
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ubiquitin ligases, atrogin-1 and MuRF-1 which are transcriptionally induced and 
considered hallmark changes associated with increased myofibrillar protein degradation 
(Chapter 1.7.3.; Bodine et al., 2001; Buettner and Lecker, 2008; Cohen et al., 2009; 
Foletta et al., 2011; Kimura et al., 2009; Lecker et al., 2004; Mitch and Goldberg, 1996). 
In chapter 6 it was shown that both atrogin-1 and MuRF-1 are transcriptionally induced 
in fast-twitch muscles with cerivastatin-induced myopathy. Furthermore, in Chapter 7 it 
was demonstrated that urine and serum 3-MH were also increased with cerivastatin-
induced myopathy. Therefore, since transcriptional induction of the muscle specific 
ubiquitin ligases, and increased excretion of 3-MH are both indicators of myofibrillar 
protein degradation, it was hypothesized that upregulation of atrogin-1 and MuRF-1 
precedes an increase in urine and serum levels of 3-MH associated with skeletal muscle 
atrophy and necrosis.  
 
The goal of this work was to further investigate the potential utility of 3-MH as a 
preclinical urine and serum biomarker of drug-induced myopathy. An additional goal of 
this work was to determine the temporal relationship between transcriptional induction of 
the muscle specific ubiquitin ligases with changes in urine and serum levels of 3-MH. For 
this work, several different models known to induce skeletal muscle catabolism were 
employed, including necrosis and, atrophy, thereby providing a range of experimental 
conditions to assess changes in 3-MH compared to more traditional endpoints including 
CK, AST and histopathology. Specifically, a time course of cerivastatin-induced 
myotoxicity was conducted in non-fasted rats to further investigate the utility of 3-MH in 
this model. Additionally, since rats are typically fasted during routine preclinical studies, 
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and this experimental manipulation is associated with myofibrillar protein degradation, a 
fasting time course study was conducted to determine the effect on 3-MH. Moreover, a 
dosing paradigm, using the muscle toxicant BMS-600149 (p38 kinase inhibitor) was 
performed to determine whether 3-MH could detect a minimal drug-induced myotoxicity 
in fasted rats (Vassallo et al., 2009).  
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8.2. Methods 
Chemicals. Cerivastatin was prepared as previously described in Chapter 2.2. BMS-
600149 ((S)-2-(sec-butylamino)-N-(5-(cyclopropylcarbamoyl)-2-methylphenyl)thiazole-
5-carboxamide) was synthesized at Bristol-Myers Squibb (Princeton, NJ). Polyethylene 
glycol 400 was purchased from EMD Chemicals Inc. (Gibbstown, NJ).  
 
Animals. Female and male rats were used for this study as previously described in 
Chapter 2.2. 
 
Study design. Rats were randomized by weight and treated as outlined in Table 8.1. The 
cerivastatin time course was conducted as previously described in Chapter 2 (study 2). 
Evaluation of fasting in rats was conducted for up to 16 hours because this time is 
routinely used during the conduct of preclinical safety studies and has been previously 
demonstrated to increase 3-MH (Robertson et al., 2011). The BMS-600149 dosing 
paradigm was selected based on the literature indicating 100 mg/kg dosed for 3 days 
causes minimal skeletal muscle damage (Vassallo et al., 2009).  
 
After the last dose, rats treated with cerivastatin and BMS-600149 were placed in 
metabolism cages (Nalgene, Rochester, NY) and urine was collected at 4 C over a 24 
hour period. Fasted rats were placed in metabolism cages upon removal of food at 2, 4, 8, 
12 and 16 hours prior to necropsy. Animals treated with cerivastatin and BMS-600149 
were anesthetized with isoflurane prior to exsanguination (vena cava) approximately 24 
hours after the last dose. Fasted rats were anesthetized with isoflurane prior to 
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exsanguination (vena cava) between 6 and 8 am. Blood was collected for serum 
separation and tissues were harvested as described below.  
 
Skeletal muscle collection. For all studies, skeletal muscles, including representative 
fast-twitch (quadriceps femoris and gastrocnemius) and slow-twitch (soleus) fiber type 
composition were harvested from the right side of the animal along with the right coronal 
section of the heart and the right lobe of the liver and stored at -80˚C pending RNA 
isolation (Table 2.1).  
 
Histopathology. For all studies, skeletal muscles including representative fast-twitch 
(quadriceps femoris and gastrocnemius) and slow-twitch (soleus) fiber type composition 
were harvested from the left side of the animal along with the left coronal section of the 
heart and left lateral lobe of the liver were collected for histopathologic evaluation as 
described in Chapter 2.2 (Table 2.1; Armstrong and Phelps, 1984; Hamalainen and Pette, 
1993; Koerker et al., 1990).  
 
Clinical chemistry analysis. Serum and urine samples were stored at -80 C immediately 
after collection and analyzed for CK, AST and ALT on a Seimens Advia 1800 chemistry 
autoanalyzer (Seimens Healthcare Diagnostics, Tarrytown, NY). Creatinine (Roche 
Hitachi 917 instrument) was determined for each urine sample.  
 
Serum and urine methylhistidine. Quantitation of serum and urine 3-MH was 
determined by GC-MS as previously described in Chapter 7.2 (Aranibar et al., 2010; 
Rathmacher et al., 1992).  
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RNA isolation and RT-PCR. RNA was isolated from frozen skeletal muscles and 
quantitative RT-PCR was conducted as previously described in Chapter 5.2 with primers 
listed in Table 6.1.  
 
Data analysis. The mean ± SE concentration of 3-MH, CK, AST and ALT were 
determined for each treatment group. For quantitative RT-PCR, relative changes in gene 
expression were determined by the ΔΔCt method. The Ct values for each gene were 
normalized to 18S Ct values and the fold change in treated muscles was determined 
relative to control. Group means for all analyses were compared with a Student‟s t-test or 
ANOVA using StatView (SAS Institute, Cary, NC) at p<0.05. However, statistics for the 
RT-PCR results were conducted on the values following normalization to 18S.  
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8.3. Results 
To investigate the utility of 3-MH as a biomarker of drug-induced myotoxicity a time 
course with cerivastatin was conducted. Cerivastatin caused a time dependent, fast-twitch 
specific myofiber necrosis and degeneration whereas the slow-twitch muscle (soleus) was 
unaffected as previously described (Figure 2.2; Table 8.2). In the quadriceps, a minimal 
myopathy was first observed in 50% of the animals after 8 days of cerivastatin treatment 
(Figure 2.2; Table 8.2). At this time, serum 3-MH increased in conjunction with the 
muscle specific ubiquitin ligases in all rats, whereas all other markers were unchanged 
(Table 8.2). After 10 days of cerivastatin treatment, 75% of the animals had evidence of a 
mild myopathy in the quadriceps and urine and serum 3-MH increased in conjunction 
with transcriptional induction of the muscle specific ubiquitin ligases in all rats (Figure 
2.2; Table 8.2). An increase in the other serum biomarkers, including CK, AST and ALT 
was noted, however these changes were highly variable and not significant (Table 8.2). 
Following 14 days of cerivastatin treatment, 100% of the animals had evidence of 
myopathy in the quadriceps, generally characterized as moderate to severe, and all 
biomarkers were significantly increased along with the muscle specific ubiquitin ligases 
(Figure 2.2; Table 8.2). Although the muscle specific ubiquitin ligases were significantly 
increased relative to control, the magnitude of increase was significantly less compared to 
muscles from rats after 10 days of cerivastatin treatment which may reflect dissolution of 
the myofibers after 14 doses (Figure 2.2; Table 8.2). Together, these results suggest a 
temporal relationship between transcriptional induction of the muscle specific ubiquitin 
ligases and increases in serum 3-MH with cerivastatin-induced myopathy. Specifically, 
there was a correlation between an increase in the muscle specific ubiquitin ligases and 3-
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MH for individual animals. Furthermore, these results demonstrate that serum 3-MH was 
more sensitive than urine 3-MH, CK and AST for detecting cerivastatin-induced 
myopathy.  
 
Overnight (16 hours) fasting is commonly employed in routine rodent toxicological 
studies. However, the temporal effects on myofibrillar protein degradation associated 
with this experimental manipulation are unknown. Following 16 hours of fasting, there 
was no evidence of myopathy or atrophy by histopathology or clinical chemistry (Figure 
8.1; Table 8.3). However, serum 3-MH increased after 8 hours of fasting and continued to 
stay elevated at 16 hours whereas urine 3-MH was only elevated at the later time point 
(Table 8.3). Consistent with fasting-induced myofibrillar protein degradation, the muscle 
specific ubiquitin ligases were also transcriptionally induced in a time-dependent manner, 
with atrogin-1 preceding an increase in MuRF-1 (Table 8.3). Collectively, these results 
demonstrate that 16 hours of fasting causes a time-dependent transcriptional induction in 
the muscle specific ubiquitin ligases and increases in serum and urine 3-MH. 
Furthermore, these results demonstrate that serum was more sensitive than urine 3-MH 
for detecting fasting-induced myofibrillar protein degradation.  
  
Since both cerivastatin-induced myopathy as well as fasting-induced myofibrillar protein 
degradation resulted in a similar increase in 3-MH, a study was conducted to determine 
whether 3-MH was useful for detecting drug-induced myopathy in fasted rats (Tables 8.2 
and 8.3). For this study, BMS-600149 was used as a model compound because it has 
previously been shown to cause a consistent but minimal myotoxicity. Following 3 days 
272  
 
of dosing, BMS-600149 caused a minimal myopathy, with 100% incidence in the 
quadriceps characterized by necrosis, atrophy and cellular infiltration which was 
corroborated by a slight increase in AST but not CK (Figure 8.1; Table 8.4). As expected, 
an underlying myofibrillar protein degradation was likely present in control fasted rats as 
3-MH levels were similar to those observed in the 16 hour fasting time course study 
(Tables 8.3 and 8.4). However, serum but not urine 3-MH, was further increased in BMS-
600149 treated rats relative to control, suggesting a minimal drug-induced myopathy was 
detected in the presence of fasting-induced myofibrillar protein degradation. 
Furthermore, these results are consistent with a slight, but significant transcriptional 
induction of atrogin-1 and MuRF-1 which may represent an effect above fasting alone 
(Tables 8.3 and 8.4).  
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8.4. Discussion 
Skeletal muscle mass is determined by the balance between myofibrillar protein synthesis 
and degradation and these processes are highly regulated to meet the functional needs of 
this tissue as well as whole body energy metabolism (Murton et al., 2008). Despite this 
tight regulation, skeletal muscle rapidly adapts to catabolic and anabolic conditions by 
modulating the rates of myofibrillar protein synthesis and degradation (Figure 8.2). 
Although both of these processes are important, the focus of this work was on the 
evaluation of myofibrillar protein degradation. Specifically, this work was designed to 
further investigate the potential utility of 3-MH as a preclinical biomarker of myofibrillar 
protein degradation resulting from drug-induced myopathy, and to determine the 
temporal relationship between transcriptional induction of the muscle specific ubiquitin 
ligases with changes in urine and serum levels of 3-MH.  
 
For this work, several different models known to induce skeletal muscle catabolism were 
employed, including necrosis and atrophy, thereby providing a range of experimental 
conditions to assess changes in 3-MH compared to more traditional endpoints including 
CK, AST and histopathology. Specifically, a time course of cerivastatin-induced 
myotoxicity was conducted in non-fasted rats to further investigate the utility of 3-MH in 
this model. Additionally, since rats are typically fasted during routine preclinical studies, 
and this experimental manipulation is associated with myofibrillar protein degradation, a 
fasting time course was conducted to determine the effect on 3-MH. Moreover, a dosing 
paradigm, using the muscle toxicant BMS-600149 was performed to determine whether 
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3-MH could detect a minimal drug-induced myotoxicity in fasted rats (Vassallo et al., 
2009).  
 
Historically, urine 3-MH has been useful for monitoring skeletal muscle atrophy and the 
current work further confirms the utility of this biomarker for catabolic conditions 
(Figure 8.2). Additionally, the current work provides perspective on the utility of urine 3-
MH for evaluating drug-induced myopathy (Figure 8.2). Based on the current results, 
urine 3-MH showed similar utility as CK and AST for monitoring cerivastatin-induced 
myopathy in non-fasted rats. However, an important experimental variable needs to be 
considered when using this biomarker in the urine. Specifically, overnight fasting, which 
is typically employed in routine safety studies, increases myofibrillar protein degradation 
and urine 3-MH in the absence of myopathy. Accordingly, this urine biomarker may be 
most useful for monitoring drug-induced myopathy in non-fasted rats. 
 
In contrast to the urine, serum levels of 3-MH were more sensitive than the standard 
biomarkers of myopathy, and increases were generally correlated with evidence of 
myofibrillar protein catabolism, including histopathology and transcriptional induction of 
the muscle specific ubiquitin ligases (Figure 8.2). However, similar to the urine, fasting 
also increased serum 3-MH. Therefore, this biomarker may be most useful for monitoring 
drug-induced myopathy in non-fasted rats.  
 
It was hypothesized that transcriptional induction of the muscle specific ubiquitin ligases 
would precede an increase in 3-MH. In general, there was a correlation between 
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transcriptional induction of the muscle specific ubiquitin ligases and increases in 3-MH 
which is consistent with the notion that atrogin-1 and MuRF-1 are considered strong 
predictors of increased myofibrillar protein catabolism (Foletta et al., 2011). Despite this 
correlation, the temporal relationship and the magnitude of transcriptional induction for 
atrogin-1 and MuRF-1 were not always in absolute concordance with an increase in 
serum 3-MH, and this was particularly the case in the fasting time course. However, this 
pattern has also been observed by other investigators and may reflect the fact that atrogin-
1 and MuRF-1 are differentially regulated with separate targets in protein synthesis and 
degradation, respectively (Figure 8.2; Foletta et al., 2011; Mikura et al., 2009; Nakashima 
and Yakabe, 2007; Pruznak et al., 2008; Sachek et al., 2004; Vary et al., 2008). 
Furthermore, several other factors, including proteasome activity and enzymes like 
calpains, tripeptidyl-peptidase II and exopeptidases contribute to the rate of myofibrillar 
protein degradation (Figure 1.15; Taillandier et al., 2004). Despite the complex regulation 
involved with myofibrillar protein degradation, transcriptional induction of the muscle 
specific ubiquitin ligases was temporally correlated with an increase in serum 3-MH.    
 
The totality of these results confirms the utility of urine 3-MH as a useful preclinical 
biomarker for monitoring catabolic conditions in skeletal muscle, including cerivastatin-
induced myopathy in non-fasted rats. This work also provides additional perspective on 
the utility of serum 3-MH as a potential biomarker of drug-induced myopathy. 
Specifically, serum 3-MH was more sensitive than CK, AST and urine 3-MH for 
assessing drug-induced myopathy. Furthermore, the ability of 3-MH to monitor skeletal 
muscle atrophy provides an advantage over the standard biomarkers which are limited to 
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detecting necrosis (Table 1.5). Accordingly, this biomarker may be particularly useful for 
compounds which cause skeletal muscle atrophy in the absence of myopathy. Moreover, 
the sensitivity of serum 3-MH to changes in myofibrillar protein degradation which may 
indicate that this biomarker has potential utility in providing early evidence that an 
adverse skeletal muscle may develop. However, additional studies are needed to further 
investigate this hypothesis.  
 
One limitation of 3-MH is the dynamic range in both matrices. Therefore, both urine and 
serum 3-MH may be most useful as a qualitative, and not a quantitative biomarker of 
myofibrillar protein degradation in non-fasted rat studies. Although the current 
investigation was conducted in rats, 3-MH is highly conserved and these findings may 
translate across species including dogs, nonhuman primates and humans under conditions 
in which factors like diet, exercise, physiological or pathological changes which could 
affect skeletal muscle protein metabolism are controlled (Asatoor and Armstrong, 1967; 
Johnson et al., 1967). 
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Figure 8.1. Histopathology of quadriceps femoris muscle from fasted and BMS-
600149 treated rats. 
Skeletal muscles from control (A) and 16 hour fasted (B) rats demonstrates no evidence 
of myopathy or atrophy. Skeletal muscles from control (C) and BMS-600149-treated (D) 
rats illustrates myopathy (arrow) characterized by hyalinization, atrophy and cellular 
infiltration.  
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Figure 8.2. Regulation of myofibrillar protein turnover. A) Myofibrillar protein 
turnover is a constitutively active process involving de novo synthesis and degradation. 
Under normal physiological conditions, the rate of myofibrillar protein synthesis and 
degradation are tightly regulated to prevent changes in muscle mass. B) During catabolic 
conditions, transcriptional induction of atrogin-1 and MuRF-1 inhibits protein synthesis 
and increases protein degradation, respectively resulting in an increase in serum 3-MH 
and urine 3-MH/creatinine.  
Note: Black indicates constitutive protein turnover under normal physiological conditions 
whereas red and green indicates an increase or decrease, respectively in atrogin-1 or 
MuRF-1 transcription, protein synthesis, protein degradation and 3-MH.  
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a
Dosing paradigms and related effects were based on previously published literature.  
b
MC, 0.5% methylcellulose; PEG, polyethylene glycol 400.  
c
Oral, oral gavage. 
d
Dosing was conducted once daily before noon.
e
Necropsy was conducted before noon and 24 
hours after the last dose for all treated animals. 
f
Rats were fasted for 2, 4, 8, 12 and 16 hours with necropsy between 6-8 am. 
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a
Results represent the mean and SE of eight treated and four control rats per day. Results 
for all control rats (n = 20) were pooled together. Rats in this study were not fasted prior 
to necropsy. 
b
3-MH levels were measured in a 24 hour urine collection and total excretion was 
normalized to creatinine.  
c
Results represent the number of animals with skeletal or cardiac myofiber necrosis and 
degeneration / number of animals per group. The mean severity score in () is based on an 
arbitrary score of 1 to 4 (most severe). (-) Denotes no significant findings observed. No 
adverse histological effects were observed in the soleus or liver. 
d
Values represent the mean mRNA expression ± SE normalized to 18s and relative to 
control in the quadriceps femoris. (-) No values were entered because the transcriptional 
data are presented as fold change over control. 
*Significantly different from control (p<0.05). ^Significantly different from day 10 
(p<0.05). 
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a
Results represent the mean and SE of five rats per group.  
b
Control rats were given food ad libitum for 16 hours whereas all other rats were fasted 
for the time indicated prior to necropsy. All rats were necropsied between 6-8 am.  
c
3-MH levels were measured in urine collected for the respective fasting time and total 
excretion was normalized to a 24 hour collection and creatinine. CK, AST and ALT were 
unchanged and no adverse histological effects were observed in the muscles or liver. 
d
Values represent the mean mRNA expression ± SE normalized to 18s and relative to 
control in the quadriceps femoris. (-) No values were entered because the transcriptional 
data are presented as fold change over control.  
*Significantly different from control (p < 0.05). 
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a
Results represent the mean and SE of six rats per group. Rats in this study were fasted 
for 16 hours prior to necropsy.  
b
3-MH levels were measured in urine collected for 16 hours and total excretion was 
normalized to a 24 hour collection and creatinine. 
c
Results represent the number of animals with skeletal myofiber necrosis and 
degeneration / number of animals per group. The mean severity score in () is based on an 
arbitrary score of 1 to 4 (most severe). (-) Denotes no significant findings observed. No 
adverse histological effects were observed in the heart or liver. 
d
Values represent the mean mRNA expression ± SE relative to control and normalized to 
18s in the quadriceps. (-) No values were entered because the transcriptional data are 
presented as fold change over control. 
*Significantly different from control (p < 0.05). 
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Chapter 9 
 
 
Summary, conclusions and future research 
 
Despite extensive research efforts indicating statin-induced myotoxicity is an on-target 
effect mediated by HMG-CoA reductase inhibition, the underlying pathophysiology 
remains unknown. The purpose of this dissertation was to use transcriptomic and 
metabolomic profiling to identify potential mechanisms and biomarkers of statin-induced 
myopathy. To determine transcriptional and metabolite changes, global gene expression 
analysis and metabolomic profiling, respectively were conducted on skeletal muscles 
from naïve and cerivastatin treated rats. Integration of these results led to the 
development of specific hypotheses regarding potential mechanisms of toxicity which 
were further investigated in a time course of cerivastatin-induced myopathy, as well as in 
primary cultures of isolated fast-twitch rat myofibers. An additional objective of this 
work was to identify biomarkers of myopathy by conducting metabolomic profiling on 
urine collected from cerivastatin treated rats. These results led to the identification of new 
biomarkers of myopathy which were further investigated to determine their utility for 
detecting preclinical drug-induced myopathy. A brief summary of this work is described 
below. 
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Hypothesis 1: Cerivastatin-induced myopathy in rats occurs in a fiber- and sex-
dependent manner which is recapitulated in isolated rat fast-twitch differentiated 
myofibers (Chapter 2). 
The goal of this work was to determine the dose response and time course of cerivastatin-
induced myopathy in rats and isolated primary fast-twitch FDB myofibers. Cerivastatin-
induced myopathy occurred in a dose-, time-, fiber- and sex-dependent manner with 
female fast-twitch muscles showing the greatest sensitivity whereas slow-twitch muscles 
were resistant to myotoxicity. Furthermore, dose- and time-dependent cerivastatin-
induced myotoxicity was recapitulated in isolated primary fast-twitch myofibers and was 
prevented with mevalonate supplementation, confirming toxicity is an on-target effect. In 
contrast, sex-specific differences in cerivastatin-induced myopathy were not observed in 
vitro, suggesting in vivo factors may be important in mediating the pathophysiology.  
 
Hypothesis 2: Transcriptional profiles of skeletal muscles from rats are useful for 
identifying molecular targets causally related to the mechanism of cerivastatin-
induced myotoxicity (Chapter 3).   
The goal of this work was to determine the fiber- and sex specific transcriptional profiles 
of skeletal muscles from naïve and cerivastatin treated rats, and to identify potential 
molecular targets or pathways causally related to myopathy. Transcriptional profiling of 
skeletal muscles from naïve rats demonstrated genes involved with energy metabolism 
and the sarcomere were differentially expressed in a fiber- and sex-dependent manner 
consistent with the phenotype of these muscles. Furthermore, the gene expression 
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changes were most significant between muscle fiber types whereas fast-twitch muscles 
from female and male rats were similar.  
 
In fast-twitch muscles from cerivastatin (1 mg/kg) treated female rats approximately 50% 
of the probes were differentially expressed. Transcriptional changes of this magnitude are 
typically associated with pathology. Therefore, it was not possible to identify specific 
pathways causally related to the mechanism of statin-induced myopathy. However, an 
unexpected increase in a number of transcripts in the mevalonate pathway and cholesterol 
regulation was observed. Although this is a common response associated with 
hepatotoxicity, the pharmacology of hepatic HMG-CoA reductase inhibition with statin 
treatment in rats causes similar transcriptional effects in the absence of liver damage. 
Therefore, this skeletal muscle specific response may be mediated by pharmacology and 
causally related to the mechanism of statin-induced myopathy.   
 
In skeletal muscles from cerivastatin treated rats, with minimal to no myopathy, the 
transcriptional changes were typically subtle, and potentially more informative of 
molecular changes or pathways involved with myopathy. Specifically, a variety of fiber- 
and sex-specific transcriptional changes were observed which may be important. 
However, there was also a common gene expression response across skeletal muscles 
characterized by modulation of a stress response, nuclear receptors, including Nr1d1, 
Nr1d2, Nr4a1, Nr4a2 and Nr4a3 as well as transcripts involved with energy metabolism, 
including PDK4 which is considered a metabolic energy switch. Together, these results 
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suggest cellular stress and altered energy metabolism may be causally related to the 
mechanism of statin-induced myopathy.   
 
Hypothesis 3: Metabolomic profiles of skeletal muscles from rats are useful for 
identifying metabolite changes causally related to the mechanism of cerivastatin-
induced myotoxicity (Chapter 4).  
The goal of this work was to determine the fiber- and sex specific metabolomic profiles 
of skeletal muscles from naïve and cerivastatin treated rats, and to identify potential 
metabolites or pathways causally related to myopathy. Metabolomic profiling of skeletal 
muscles from naïve rats were similar with only a few changes noted. In aqueous and 
lipophilic extracts of skeletal muscles, lactate was higher in fast-twitch muscles, whereas 
taurine, fumarate and cholesterol were higher in slow-twitch muscles from female rats. 
Metabolomic profiles of aqueous and lipophilic extracts of fast-twitch muscles from 
female and male rats were similar, with creatine showing higher levels in male rats. 
Although metabolomic profiling did not reveal as many fiber- and sex-specific changes 
as transcriptomic profiling, these results were limited to highly concentrated metabolites 
with resolved resonances, in which the identification of the chemical structure could be 
confirmed with standard spectra. Furthermore, similar metabolomic profiles may also 
indicate that mRNA and protein expression are more important in defining the skeletal 
muscle phenotype.   
 
In cerivastatin (1 mg/kg) treated female rats, metabolic profiles of lipophilic extracts of 
fast-twitch muscles indicated cholesterol and phosphatidylcholine were increased in a 
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manner that was consistent the transcriptional changes. Furthermore, these changes 
occurred in dose-dependent manner whereas similar effects were not observed in skeletal 
muscles without myopathy. To further determine the effects on the cholesterol pathway, a 
panel of sterols was measured which indicated that the cholesterol biosynthesis 
precursors, desmosterol and 7-dehydrocholesterol were also increased in the fast-twitch 
muscles from female rats treated with cerivastatin. While the origin and implication of 
these changes was unknown, abnormal accumulation of cholesterol is toxic. Therefore, 
additional experiments were conducted in Chapter 5 to determine whether alterations in 
cholesterol homeostasis were causally related to the mechanism of cerivastatin-induced 
myopathy or whether these changes represent an effect associated with toxicity. 
 
In cerivastatin (1 mg/kg) treated female rats, metabolic profiles of aqueous extracts of 
fast-twitch muscles indicated a decrease in a variety of metabolites, including lactate, 
NAD
+
, creatine, phosphocreatine, carnosine and anserine which were likely associated 
with myopathy. Skeletal muscles from cerivastatin treated rats with minimal to no 
myopathy were also evaluated and the metabolomic changes were typically subtle, and 
potentially more informative of metabolites and pathways involved with myopathy. 
Specifically, in the aqueous extracts of skeletal muscles from cerivastatin treated rats, 
fiber- and sex-specific changes in NAD
+
, phosphocreatine and anserine were noted and 
consistent with the transcriptional changes indicating cellular stress and alterations in 
energy metabolism may be causally related to the mechanism of cerivastatin-induced 
myopathy. Additional experiments were conducted in Chapter 6 to further investigate the 
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role of altered energy metabolism as a potential mechanism of cerivastatin-induced 
myopathy. 
  
Hypothesis 4: Cerivastatin-induced myopathy is causally related to alterations in 
cholesterol homeostasis (Chapter 5). 
The goal of this work was to determine whether alterations in cholesterol homeostasis are 
causally related to the mechanism of cerivastatin-induced myopathy. To determine the 
temporal relationship between alterations in cholesterol homeostasis and the development 
of myopathy a cerivastatin (1 mg/kg) time course study was conducted in female rats. 
Alterations in cholesterol homeostasis were monitored in the sensitive fast-twitch muscle, 
the unaffected slow-twitch muscle and in the liver by measuring transcriptional and sterol 
changes. 
 
In the cerivastatin time course, transcriptional and sterol changes in the fast-twitch 
muscle demonstrated that altered cholesterol homeostasis was a manifestation of the 
myopathy and unrelated to the mechanism of toxicity. Importantly, these changes were 
different from the soleus in which there was no evidence of toxicity or changes in 
cholesterol homeostasis. Furthermore, the time course profile was also different from the 
liver, which showed an immediate and sustained compensatory transcriptional induction 
of HMG-CoA reductase consistent with the pharmacology of cerivastatin. Although the 
mechanism of altered cholesterol homeostasis was not directly probed in this work 
skeletal muscle regeneration requires activation of HMG-CoA reductase. However, in the 
face of ongoing toxicity, skeletal muscle is unable to regenerate, and this causes  
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cholesterol accumulation and activation of several pathways including, cholesterol 
esterification (acyl-CoA: cholesterol acyltransferase), efflux (ABCG1 and ABCA1) and 
conversion (cholesterol 25-hydroxylase) to 25-hydroxycholesterol. An important 
observation of this work was that the in vitro model did not recapitulate the in vivo 
changes in cholesterol suggesting in vivo factors are important in mediating this process. 
 
Activation of the 25-hydroxylation pathway has not been previously reported with 
skeletal muscle necrosis. Therefore, it is unknown whether this response is specific to 
statin myopathy or commonly associated with other muscle pathologies. However, 
various biological roles for 25-hydroxycholesterol have been previously identified. 
Specifically, this oxysterol is more hydrophilic than cholesterol and is able to passively 
diffuse across the membrane and is reverse transported to the liver where it is converted 
to bile acids. Moreover, 25-hydroxycholesterol is a ligand for LXR which activates the 
efflux transporters and further increases removal of cholesterol. Accordingly, the current 
results demonstrate that cholesterol 25-hydroxylation may be an important pathway in 
skeletal muscle which regulates cholesterol homeostasis with statin-induced myopathy. 
 
Hypothesis 5: Cerivastatin-induced myopathy is causally associated with alterations 
in energy metabolism (Chapter 6). 
Skeletal muscle energy metabolism relies on oxidative phosphorylation, and a critical 
step in this process is glucose oxidation followed by conversion of pyruvate to acetyl-
CoA, in a reaction catalyzed by PDC. This irreversible process plays a major role in 
energy metabolism, particularly in fast-twitch skeletal muscles, as it represents the only 
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entry point for glucose into the mitochondria for oxidation and ATP synthesis. PDK4 is 
transcriptionally upregulated in fast-twitch muscles prior to the onset of statin-induced 
myopathy and chronic induction can impair energy metabolism and lead to extensive 
myofibrillar protein degradation and myotoxicity. Therefore, a major goal of this work 
was to determine whether PDK4 inhibition in fast-twitch skeletal muscles is causally 
related to cerivastatin-induced myopathy. An additional goal of this work was to 
determine the temporal relationship in fast- and slow-twitch muscle fibers between 
transcriptional induction of PDK4, PGC-1α which increases mitochondrial content and 
oxidative capacity, and markers of myofibrillar protein degradation, including atrogin-1 
and MuRF1 indicating impaired energy metabolism.  
 
Results from this work demonstrated that cerivastatin triggers an early and sustained 
transcriptional induction of PDK4 in fast-twitch muscles which is consistent with a 
metabolic switch in energy metabolism to a more oxidative phenotype. However, 
inhibition of this metabolic switch by dichloroacetate was insufficient in protecting the 
fast-twitch muscle from cerivastatin-induced toxicity. Therefore, these results suggest 
that transcriptional induction of PDK4 may be necessary but insufficient to mediate 
cerivastatin-induced myopathy. Consistent with this observation, previous investigators 
have also demonstrated that statins reduce mitochondrial oxidative capacity resulting in 
impaired energy metabolism in fast-twitch muscles. Further evidence to support a 
deficiency in oxidative capacity is based on the observation that NAD
+
 is significantly 
decreased in the female rat fast-twitch muscles following cerivastatin (0.5 mg/kg) 
treatment which is associated with reduced oxidation capacity of substrates in glycolysis, 
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fatty acid oxidation and the citric acid cycle. Together, these results implicate a 
deficiency in both glycolytic and oxidative energy metabolism in mediating cerivastatin-
induced myopathy. Consistent with this hypothesis, transcriptional induction of PGC-1α 
expression was observed supporting a metabolic demand for a more oxidative phenotype. 
However, this metabolic adaptation was insufficient in protecting the muscle, as 
transcriptional markers of protein degradation, indicative of impaired energy metabolism, 
were transcriptionally induced in association with toxicity. In contrast to the current 
results, a recent in vivo study demonstrated that DCA treatment prevents simvastatin-
induced myopathy in rats. While the disparity in these results is unknown, it may be 
related to the in vitro model which also did not recapitulate alterations in cholesterol 
homeostasis observed in Chapter 5. 
 
Previous transcriptional and metabolomic results (Chapters 3 and 4) demonstrated that 
cerivastatin causes altered energy metabolism and a cell stress response in the slow-
twitch muscle. Similarly, in the current work, slow-twitch fibers showed a transcriptional 
response represented by upregulation of PDK4, atrogin-1 and MuRF1, indicating 
impaired energy metabolism, however this was a delayed response and only observed 
after 14 days of cerivastatin treatment. Unlike the fast-twitch muscle, PGC-1α was not 
transcriptionally induced in the slow-twitch muscle following cerivastatin treatment, 
however constitutive levels were 4-times higher in this fiber type. Together, these results 
implicate additional fiber specific factors in mediating impaired energy metabolism and 
toxicity.  
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Hypothesis 6: Metabolomic profiling of urine is useful for identifying biomarkers of 
cerivastatin-induced myopathy (Chapter 7). 
In Chapter 4, metabolomic profiling of skeletal muscles from cerivastatin treated rats 
indicated several metabolites which were decreased with myopathy. The goal of this 
work was to use metabolic profiling of urine to identify metabolites originating from 
skeletal muscle, which may represent potential biomarkers of cerivastatin-induced 
myopathy. The urinary excretion of two metabolites, 1- and 3-MH were identified and 
correlated with cerivastatin-induced myotoxicity. Further analysis indicated that these 
metabolites also increase in the serum with myopathy. Although this is the first report 
showing increased excretion of 1- and 3-MH in response to a muscle toxicant such as 
cerivastatin, these metabolites have been used for studying muscle protein turnover for 
more than 30 years. 1-MH is a component of anserine (β-alanyl-1-MH), which is found in 
the cytoplasm of skeletal muscles in millimolar concentrations, regardless of sex or 
muscle fiber type, with substantially lower concentrations detected in cardiac muscle or 
in organs that have abundant smooth muscle (i.e. gastrointestinal tract). In contrast, 3-MH 
is a post-translational modification of myofibrillar actin and fast-twitch myosin. 
Conditions that cause skeletal muscle atrophy result in degradation of these proteins and 
increased urinary excretion. In this work, constitutive concentrations of 3-MH were lower 
than 1-MH in skeletal muscles, whereas 3-MH was typically higher than 1-MH in cardiac 
and smooth muscle. 1-MH increased to a much greater extent than 3-MH following 
cerivastatin treatment, a result that is consistent with the relative levels of these 
metabolites in skeletal muscles. 
 
293  
 
A marked increase in excretion and serum levels of 1- and 3-MH in response to 
cerivastatin, coupled with their recognized relevance to skeletal muscle biology, suggests 
these metabolites may be useful biomarkers of skeletal muscle toxicity. However, 
anserine, which contains 1-MH, is most likely not present in human skeletal muscles and 
thus has the most potential utility in preclinical species such as rodents, dogs and non-
human primates. In contrast, 3-MH is highly conserved, and although its basal levels can 
be altered by diet, age or disease, it should translate across species such as rodents, dogs, 
non-human primates and humans under highly controlled experimental conditions. Given 
the need for more reliable biomarkers, additional investigative studies were conducted in 
Chapter 8 to determine the preclinical utility of 3-MH for the preclinical assessment of 
drug-induced myopathy. 
 
Hypothesis 7: 3-Methylhistidine is a preclinical biomarker of drug-induced 
myopathy (Chapter 8). 
The goal of this work was to further investigate the potential utility of 3-MH as a 
preclinical biomarker of drug-induced myopathy, and to determine the temporal 
relationship between transcriptional induction of the muscle specific ubiquitin ligases 
with changes in urine and serum levels of 3-MH. For this work, several different models 
known to induce skeletal muscle myofibrillar catabolism were employed, including a 
time course of cerivastatin-induced myopathy, fasting-induced atrophy, and BMS-
600149-induced myopathy, thereby providing a range of experimental conditions to 
assess changes in 3-MH compared to more traditional endpoints including CK, AST and 
histopathology.  
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This work confirmed the utility of urine 3-MH as a preclinical biomarker for monitoring 
skeletal muscle atrophy, an advantage not currently offered with the standard biomarkers 
of myopathy, including CK and AST. Furthermore, serum 3-MH was more sensitive than 
CK, AST and urine 3-MH for assessing drug-induced myopathy. However, overnight 
fasting, which is typically employed in routine preclinical safety studies increases 
myofibrillar protein degradation and 3-MH in the absence of myopathy. Accordingly, this 
biomarker would be most useful for monitoring drug-induced myopathy in non-fasted 
rats. Moreover, this biomarker may be particularly useful for providing early evidence 
that an adverse skeletal muscle effect may develop as transcriptional induction of the 
muscle specific ubiquitin ligases and an increase in myofibrillar degradation can occur 
prior to the onset of myopathy. However, additional studies are needed to further 
investigate this hypothesis. One limitation of 3-MH is the dynamic range in both 
matrices. Therefore, both urine and serum 3-MH may be most useful as a qualitative, and 
not a quantitative biomarker of myofibrillar protein degradation in non-fasted rat studies. 
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Conclusions  
This dissertation demonstrates the utility of transcriptomic and metabolomic profiling for 
identifying potential mechanisms and biomarkers of cerivastatin-induced myopathy. 
Specifically, integration of transcriptomic and metabolomic technologies was synergistic, 
enabling characterization of both molecular and biochemical changes in skeletal muscles, 
representing common pathways which were perturbed in conjunction with the 
development of myopathy. Importantly, the use of these platforms led to the development 
of specific hypotheses regarding modes of toxicity which were further investigated. 
Together, these technologies and follow up investigative studies enabled a more thorough 
understanding of the molecular and biochemical changes associated with statin-induced 
myopathy. Furthermore, the utility of urinary metabolomic profiling was highlighted by 
the identification of novel biomarkers of drug-induced myopathy.  
 
 
 
 
 
 
 
 
 
 
 
296  
 
Future research 
Future research should be directed towards determining the mechanism by which statins 
alter energy metabolism in skeletal muscle, and whether these changes are causally 
related to the mode of toxicity. Based on the current research, as well as the literature, 
several potential targets have been identified which play a significant role in skeletal 
muscle energy metabolism and are modulated with statin treatment. Specifically, PDK4, 
PGC-1α, the muscle specific ubiquitin ligases and several nuclear receptors identified in 
chapter 3 represent potential targets which may play a role in altering energy metabolism 
in skeletal muscle with statin therapy. Therefore, future research should be conducted to 
determine the relationship between mevalonate depletion, alterations in energy 
metabolism and the development of statin-induced myopathy.  
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